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ABSTRACT 
 
Synthesis of Haptens for the Marine Toxin, Gymnodimine; Synthesis of Beta-Lactone 
Fused Carbocycles and Nitrogen Heterocycles; Efforts toward the Synthesis of the 
Proposed Structure of Thiolyngbyan.  
(May 2010) 
Chang Suk Lee, B.S., Kwangwoon University, Seoul, Korea; M.S., Kwangwoon 
University, Seoul, Korea  
Chair of Advisory Committee: Dr. Daniel Romo 
 
Contamination of seafood by marine toxins has been a consistent public health 
problem. Gymnodimine (GYM) is a member of a family of spirocyclic imine containing 
marine natural products which was shown to be highly toxic (LD50 96 µg/kg, 
intraperitoneal injection); thus ensuring public safety requires stringent monitoring of 
gymnodimine. Current detection methods for GYM and spirolides include the mouse 
bioassay and LC-MS-based detection techniques which, however, have significant 
limitations. Therefore, more efficient and convenient detection methods are required. 
Building on our recently completed total synthesis of (-)-gymnodimine, the synthesis of 
two haptens were targeted for eventual production of monoclonal antibodies (mAb) to be 
used in an eventual Enzyme-Linked Immunosorbent Assay (ELISA) for gymnodimine.  
As an extension of the intramolecular nucleophilic catalyzed aldol lactonization 
(NCAL) process from aldehyde acid to keto acid substrates, carbocyclic and nitrogen 
heterocyclic β-lactones were synthesized. Demonstration of the utility of the NCAL 
process for keto acids was applied to the synthesis of dihydroplakevulin A and the core of 
tussilagine. In addition, although initial attempts to develop guanidine catalysts for the 
asymmetric NCAL process were unsuccessful, homobenzotetramisole (HBTM) was 
found to be a suitable asymmetric catalyst for keto acid substrates.  
  
iv 
Finally, synthetic studies toward the proposed structure of thiolyngbyan are 
described. Thiolyngbyan was isolated from a blue-green algae and it exhibited antifungal 
activity. 
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CHAPTER I 
 
INTRODUCTION: ANTIBODIES FROM SYNTHETIC HAPTENS FOR 
MARINE TOXINS DETECTION  
1.1 Methods for Detection of Marin Toxins 
 
Contamination of seafood by marine toxins has been a consistent public health 
problem. Significant shellfish poisoning cases occur worldwide and a great deal of these 
incidents is associated with microalgae-produced natural marine biotoxins. Most algal 
toxins cause human illness by disrupting electrical conductance, uncoupling 
communication between nerve and muscle, and impeding critical physiological 
processes. Thus, ensuring public safety requires stringent monitoring of shellfish. Various 
methods have been used for toxins detection. Most of these methods are modifications of 
the intraperitoneal mouse bioassay procedure but all have suffered from inaccuracy of the 
test methods, length of time required to prepare the samples and animal ethics associated 
with the 24 h duration of the animal testing.1 Analytical methods have also been 
developed using high-performance liquid chromatography (HPLC) or gas 
chromatography (GC) coupled with selective detection systems. However, they suffer 
from being laborious and expensive and unsuitable for monitoring a large number of 
samples. Antibody-based assays have been developed due to a better detection limit, fast 
analysis of numerous samples and lower cost.  They would be further classified by 
detection methods. Surface plasmon resonance (SPR) measured the difference of 
reflected intensity on the surface, which is caused by the complex between antibodies and 
analytes.2  Radioimmunoassay (RIA) is measured the concentration of labeled iodine, 
which was developed by Rosalyn Yalow and Solomon Aaron Bersin in the 1950s.3 To 
perform a radioimmunoassay, a known quantity of an antigen is labeling with gamma-
radioactive isotopes of iodine attached to tyrosine.  
 
____________ 
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This radiolabeled antigen is mixed with a known amount of antibody for that 
antigen. To this radiolabeled antigen-antibody complex is added an unknown amount of 
sample. If a sample of serum competes with radiolabeled antigen, the concentration of 
unbound radiolabeled antigen would be increased. Therefore radioactivity of the 
radiolabeled antigen is measured using known standard binding curves, which allows the 
amount of antigen in the sample of serum to be quantitated. Rosalyn Yalow developed 
the RIA for insulin, which allowed the precise quantification of minute amounts of such a 
hormone.2 RIA overcomes limitations of other methods in crude sample matrices by not 
requiring animals, a tissue culture facility or extensive sample preparation. While the RIA 
technique is extremely sensitive and specific, it necessitates specialized equipment and is 
costly. It commonly requires a licensed laboratory facility, and presents waste disposal 
problems. Therefore, today it has been largely supplanted by the Enzyme-Linked 
Immunosorbent Assay (ELISA) method, where the antigen-antibody reaction is measured 
using colorimetric signals instead of a radioactive signal.4  In order to replace the 
radioactive signal to colorimetric signal, the first antibody should be fixed to the surface 
of the container and secondary antibody need to link to an enzyme, which elicits a 
chromogenic signal. In 1966, Wide and coworkers developed the linking technique.3 
ELISA is a biochemical technique mainly used in immunology to detect the presence of 
an antibody in a sample. For its sensitivity, accuracy, portability and cost-affectivity, 
ELISA has found applications in the food industry and in the toxicology for drugs.  In a 
typical direct ELISA, an antigen is added to a solid surface, to which antibodies specific 
for the antigen and labeled with an enzyme such as a peroxidase or a lactase are added 
(Figure 1.1).5 The enzyme would then catalyze a reaction that emits light by adding 
chromogenic substrate such as tetramethylbenzidine (TMB) or 2,2’-azino-bis(3-
ethylbenzethiazoline-6-sulphonic acid) (ATBS), which serves as an in situ readout of the 
concentration of the antigen both qualitatively and quantitatively.  
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Figure 1.1 Working mechanism of ELISA.5 
 
Stewart and coworkers reported a rapid analytical optical biosensor-based 
immunoassay for the detection of okadaic acid (OA) and its structurally related toxins.6 
Although several antibody-based kits are commercially available for the detection of OA 
including ERFA biotech, DSP-Check (Sceti, Japan), Rougier Bio-Tech ELISA, issues 
exist regarding the cross-reactivity to congeners. Since ELISA detection is structural 
recognition and not toxicity, present ELISAs did not detect other members of the OA 
group of toxins. Therefore this technique could be useful in parallel in order to provide a 
full individual toxin determination and quantification. 
Botana and coworkers reported fluorescence polarization technique for the 
detection of gymnodimine (GYM) and 13-desmethyl C spirolide.7 Current detection 
methods for GYM and spirolides include mouse bioassay and LC-MS-based detection 
techniques. Although these toxins are not still regulated, efficient detection methods need 
to be developed. Recent studies have provided direct evidence that GYM and spirolides 
target muscular and nicotinic acetylcholine receptors (nAChR) subtypes with high 
affinity. Therefore these toxins inhibited the interaction of fluorescent-labled α-
bungarotoxin with nAChR. This analytical method allowed detection of these toxins up 
to 1µg/kg of shellfish meat and could be useful for detection of toxins, which showed the 
affinity to nAChR.  
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1.2 Derivatization of Natural Products to Produce Antibodies 
 
One of the first attempts to study antibodies from the viewpoint of chemistry was 
taken up by Arrhenius.8 Considerably more important work was done by Landsteiner 
who investigated many of the fundamental principles. One important observation that 
came out of Landsteiner’s investigations was that small molecules, by themselves, are not 
capable of inducing an immune response. Therefore small molecules, called “haptens”, 
could be covalently attached to a carrier protein to generate an immune response. In fact, 
a number of ELISAs were already developed and used to monitor the environment. Most 
haptens were derived from natural products. For example, saxitoxin,9  brevetoxin,10 
domoic acid,11 and yessotoxin12 are marine toxins and their antibodies were produced 
from their protein conjugates. The isolated antibodies showed high affinity to the natural 
product.   
The conjugation of saxitoxin to keyhole limpets hemocyanin (KLH) or bovine 
serum albumin (BSA) involve an one-step formaldehyde method (Figure 1.2). 13 
Polyclonal antibodies against saxitoxin antigen were collected from rabbits. The 
detection limit of saxitoxin, defined as the concentration of toxin standard equivalent to 
three standard deviation at A0 (no competition), was 10 pg mL-1 for the indirect assay and 
3 pg mL-1 for the direct format. 
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Figure 1.2 The conjugation reaction between STX and KLH or BSA. 
 
The conjugation of brevetoxin to BSA involved a three-step sequence.9 Reduction 
of brevetoxin with sodium borohydride followed by succinylating with succinic 
anhydride in pyridine at 85 oC. The free carboxyl group on the succinate derivative 1-5 
was covalently coupled to BSA using standard carbodiimide condensation (Figure 1.3). 
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 Baden and coworkers developed efficient ELISA-based tools to monitor 
brevetoxins and demonstrated that ELISA have quantitative resolving capabilities (0.04-
0.4 pM) which are higher than RIA (1.6-43 nM) due to secondary antibody enzyme 
conjugates which act as reporter molecules.  
 
O
O
O
O
O
O
O
O
O
O
O
HO
CH2O
H
O
1
3
5 6
8 10
13
18 22
25
27
28
36
37
41
42
43
O
O
O
O
O
O
O
O
O
O
O
HO
CH2O
H
1
3
5 6
8 10
13
18 22
25
27
28
36
37
41
42
43
OH
H
O
O
O
O
O
O
O
O
O
O
O
HO
CH2O
H
O
H OH
O
O
O
NH2
OH
NaBH4
O
OH
O
O
N
O
O
BSA
1-3
1-4
1-5
1-6
 
Figure 1.3 The conjugation reaction between brevetoxin and BSA. 
 
The conjugation of domoic acid to BSA was done using a modified carbodiimide 
method. Briefly, domoic acid and carbodiimide and N-hydroxysucinimide were dissolved 
in DMSO at room temperature. After stirring for 1.5 h, BSA solution in phosphate 
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buffered saline (PBS) was added to the mixture (Figure 1.4). The detection limit was 0.41 
ng well-1 in PBS. 
 
HO NRCOOH +
O
O
EDC
RCOO N
O
O
BSA-NH2
RCO NH BSA
HN
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H3C
CH3
COOH
HOOC
R =
1-7  
Figure 1.4 The conjugation reaction between domoic acid and BSA. 
 
The conjugation of yessotoxin to BSA was achieved using the olefinic moiety. 
Briefly, yessotoxin was readily oxidized by ozone and the resulting ozonized yessotoxin 
1-9 was conjugated with BSA via reductive amination by adding a solution of sodium 
cyanoborohydride in 1 mL PBS buffer. Yessotoxin was also readily oxidized with 
bromine, and examined by 1H NMR. The resulting bromo derivative 1-10 was conjugated 
via nucleophilic amination with ovalbumin (OVA) in carbonate buffer (Figure 1.5). 
Although the structure of both 1-11 and 1-12 were tentatively assigned, both of them 
elicited antibodies that showed high affinity to the yessotoxin.    
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Figure 1.5 Preparation of immunizing and coating conjugates by derivatization of 
yessotoxin by ozonolysis and by bromination.  
 
However, one important drawback of the use of natural product itself as a hapten 
is the loss of toxicity because the primary amine or carboxylic acid functional groups 
used for protein conjugation could be essential for its bioactivity. Indeed, Serum from 
rabbits immunized with a conjugate, in which palytoxin’s amino group was covalently 
bound to a carboxyl function of BSA in the presence of carbodiimide, neutralized the 
biological activities of palytoxin (Figure 1.6).14  
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Figure 1.6 Structure of palytoxin-BSA conjugation. 
 
1.3 Synthetic Haptens to Produce Antibodies 
1.3.1 Direct Sandwich Immunoassay for Ciguatoxin 1B and 3C  
 
Coupling of a nonnative functionality that can be chemically reacted with the 
carrier protein can be difficult to fulfill in the case of complex natural products. Therefore 
synthetic haptens are more readily accessible to antigens without losing its bioactivity. 
Although many marine toxins have been synthesized, only ciguatoxin 3C (CTX3C)15 and 
azaspiracid (AZA)16 were successfully demonstrated to have the advantage as synthetic 
haptens. 
Ciguatera fish poisoning is caused by the ingestion of a variety of reef fish, which 
have bioaccumulated ciguatoxins in their tissues. Ciguatoxins are produced by the marine 
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dinoflagellate gambieriscus toxicus.  Since over twenty thousand people in the tropics 
suffer from ciguatera poisoning, several methods have been developed to detect 
ciguatoxins.  Although Hokama and coworkers prepared a monoclonal antibody (mAb) 
using Ciguatoxin 1B (CTX1B) 14, this antibody showed a high cross reactivity to another 
marine toxin, okadaic acid (Figure 1.7).17  
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Figure 1.7 Structure of ciguatoxins and okadaic acid. 
 
The extremely low content of ciguatoxin 1B (CTX1B) 14 in fish has hampered 
the further development of ciguatoxin antibodies. As a solution to this problem, two 
groups have developed the synthetic haptens of CTX1B independently. Hirama and 
coworkers synthesized the ABC ring fragment as a haptenic group with a carboxylic acid 
linker. Although the antibodies elicited by the antigen bound strongly to the ABC ring 
fragment, they did not recognize CTX1B itself. They speculated that the size of the ABC 
ring hapten would be too small to get enough information of CTX1B (Figure 1.8). 
Therefore they synthesized bigger hapten to elucidate their questions. Tachibana and 
coworkers synthesized a hapten, a carboxylic derivative of the right hand tetracyclic 
terminus portion of CTX1B, which was conjugated to carrier proteins.18 Although the 
antibodies elicited by the JKLM ring antigen bound to CTX1B itself, they showed the 
cross reactivity to other natural products.  
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Figure 1.8 Synthetic haptens of ciguatoxin 1B. 
 
A direct sandwich ELISA method developed by Hirma, Fugii and coworkers 
solved the aforementioned cross-reactivity problem.19  This assay requires two distinct 
antibodies for detection. Since they synthesized the ABCDE ring fragment 1-19 and 
IJKLM ring fragment 1-20 to complete the total synthesis of CTX3C, both were used as 
haptens (Figure 1.9). Interestingly, antibodies (mAb 10C9) from an antigen (ABCDE ring 
hapten conjugated with protein) larger than ABC ring hapten conjugated with protein 
tightly bound to CTX3C itself. More importantly mAb 10C9 showed no cross reactivity 
with the IJKLM ring hapten. This result strongly suggested that mAb 10C9 recognized 
the pentacyclic ABCDE ring fragment of CTX3C. Similarly the other antibodies (mAb 
3D11) showed strongly bound to CTX3C itself and did not cross-react with ABCDE ring 
hapten. For this assay they used mAb 10C9 to capture CTX3C and mAb 3D11 as a 
detector. This protocol could detect CTX3C at ppb (part per billion) level. Importantly 
none of the other marine toxins gave any detectable signals at 20 µM concentration. 
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Figure 1.9 Synthetic haptens of ciguatoxin 3C. 
 
1.3.2 Congener Independent Immunoassay for Azaspiracids  
 
The azaspiracids are natural marine toxin witch have been proposed to originate 
from the dinoflagellate protoperidium crassipes.20 The Yasumoto and Satake group21 
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proposed a structure for azaspiracid-1 and Nicolaou and coworkers later revised the 
structure through degradative and synthetic efforts (Figure 1.10).22  
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Figure 1.10 Structures of azaspiracids and synthetic general hapten.  
 
In general, antibodies that are raised against specific congeners tend to be 
sensitive to a relatively narrow range of natural product analogues.  If detection and 
quantitation of numerous congeners including structurally similar other toxins are 
needed, congener dependent assays are not ideal for screening because of the possibility 
of false negatives in the presence of toxic congeners to which the assay is insensitive. 
Since all eleven azaspiracids shared the C28-C40 domain, Forsyth, Miles, and coworkers 
designed hapten 1-22, which would eventually provide congener independent ELISA.13 
The conjugation of carboxylic acid 1-22 to Bovine Serum Albumin (BSA) was prepared 
using a modified carbodiimide method. Briefly, carboxylic acid 1-22 and carbodiimide 
and N-hydroxysucinimide dissolved in DMF at room temperature. After stirring for 0.5 h, 
BSA solution in PBS was added to the mixture. Indeed, antibodies raised against this 
hapten 1-22 cross-reacted with AZA 1, AZA 2, AZA 3 and AZA 6 with similar affinity. 
Nicolaou and coworkers have published studies toward the development of a 
sandwich immunoassay for azaspiracids.17 As mention before, these assays require two 
distinct antibodies for detection. Although azaspiracids was of sufficient size to have one 
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antibody bind to some portion of the C1-C26 domain (ABCDE ring), antibodies raised 
against antigen (ABCDE ring conjugated with protein) showed weak or no binding to 
azaspiracids.   
  
1.4 Design of Synthetic Haptens of Gymnodimine  
 
 The advantages and success of synthetic haptens-based ELISA encouraged us 
to delvelop an antibody probe for the gymnodimine congeners detection. Our goal 
was to isolate antibody proteins that recognize gymnodimine congeners without 
cross-reactivity with other marine toxins. An ideal hapten should be a near perfect 
mimic of the target structure in size, shape (geometry) and  electronic properties. The 
hapten handle (required for conjugating the target mimic to a carrier protein) should 
in itself not elicit antibody recognition. Thus, an innocuous alkyl handle often is most 
appropriate, the length of which should be evaluated using one or more homologs. An 
appropriate functional group for covalent attachment of the hapten handle to the 
protein must be compatible with the chemistry of the functional groups on the protein. 
Building on our recently completed total synthesis of (-)-gymondimine, two haptens 
were proposed for eventual production of monoclonal antibodies (mAb). Toward a 
congener-independent immunoassay, an invariable sector of the toxin between all 
known congeners of the toxin of interest including degradation fragments must be 
identified. Careful examination of gymnodimines isolated to date and also of 
proposed and of potential degradation products lead to the analysis shown in Figure 
1-11. It should be noted that hydrolysis of the butenolide ring under basic and neutral 
conditions (t1/2 = 33 h at pH 7.6, 37oC) is known to occur readily, and thus a 
congener-independent hapten should exclude this portion of the molecule (Figure 
1.11, eastern green area). 23   Also, the recent isolation of toxic gymnodimine 
congeners B and C (see the figure on page 17) that only differs in bearing an 
additional allylic alcohol  suggests avoiding this sector. It should be noted that 
hydrolysis of the cyclic imine is expected to provide a mechanism of detoxification 
based on related studies of the spirolides and thus a congener-independent assay 
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should include this region.  
 
O
OH
Me
N
Me
Me
O
O
Me
H
H
Me
HH
Sites of hydrolytic
degradation
Site of congener 
structural differences
 
Figure 1.11 Proposed regions of gymnodimine suitable for congener specific (green) 
and congener-independent (blue) hapten synthesis. 
 
 Our target macrocyclic gymnodimine hapten M  will be prepared starting from 
known ketone M-1, an intermediate in our total synthesis (Figure 1.12). This hapten 
M retains most structural and streochemical information of the natural product. 
Therefore this hapten will ideally provide an antibody that recognizes gymnodimine. 
However, it would require more synthetic effort to prepare hapten M and antibodies 
raised from it might recognize only gymnodimine without recognition of its 
congeners. One example of a congener-independent hapten to be prepared is the 
spirocycle hapten S, and the synthesis makes use of an unfortunate (but useful for this 
purpose) by-product available during Nozaki-Hiyama-Kishi (NHK) couplings in the 
total synthesis, namely the deiodinated alkene S-1. Hapten S contains the imine 
moiety, which is the pharmacophore of gymnodimine. However, its size might not be 
sufficient to allow the preparation of specific antibody for gymnodimine. Although 
hapten T derived from the tetrahydrofuran fragment does not seem ideal, it is 
structurally complementary to the hapten S. If the antibodies elicited from antigen of 
hapten T binds to gymnodimine, it could have potentially valuable applications in 
development of a sandwich ELISA. Since antigen of hapten S has higher potential to 
elicite antibodies which recognize gymnodimine, we will have two sets of 
complimentary antibodies for a sandwich ELISA. Furthermore, these results could 
provide some insight into the structure-activity relationship of the toxicity of 
gymnodimine. 
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Figure 1.12 Designed haptens based on structures of gymnodimines. 
 
1.5 Previously Synthesized Hapten of Gymnodimine  
 
 The synthesis of the hapten T was achieved from the tetrahydrofuran 
intermediate in our total synthesis. Our collaborators Prof. Chris Elliott from 
university of Belfast, Ireland conjugated it to a carrier protein. Immunization with this 
antigen led to the production of antibodies (mAbs). Although the antibodies raised by 
antigen of  hapten T binds strongly to the hapten T, it did not recognize gymnodimine 
itself. We anticipate that haptens containing the spiroimine phamacophore and larger 
in size than the hapten T are required to induce mAbs that will recognize 
gymnodimine.  
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1.6 Summary and Outlook 
  
Food and water intoxications posing serious threats to public health and the food 
industry and ELISAs are one of the best methods that efficiently monitor massive 
samples. A lot of ELISAs for marine toxins were already developed and showed high 
sensitivity. The main component of ELISA, which is antibodies, was elicited by natural 
product antigen. However, it is difficult to control the affinity of antibodies toward target 
toxins if antibodies have a problem such as cross reactivity to another marine toxins. 
Therefore, synthetic haptens are ideal and efficient to develop ELISAs. In order to obtain 
successful synthetic haptens, synthetic methodologies to acess marine toxins should be 
achieved beforehand. Since we completed the first total synthesis of gymnodimine, 
taking advantage of this, we have developed synthetic haptens. Although first example 
hapten T did not give promising results, hapten S and hapten M will give us valuable 
information to achieve our goal.   
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CHAPTER II 
 
SYNTHESIS OF GYMNODIMINE IMMUNOGENS*  
 
2.1 Biological Studies of Gymnodimine 
 
 Numerous cases of shellfish poisoning occur worldwide each year and a 
significant number of these incidents are associated with natural marine biotoxins 
produced by microalgae. Seafood intoxications posing serious threats to public health 
and the shellfish industry. Shellfish can concentrate phycotoxins in their edible tissue 
and act as vectors for transferring toxic chemical compounds to crabs, fish, birds 
marine mammals and unltimately to humans. Three main species of dinoflagellates 
that produce the toxins are: Alexadrium sp., Gymnodinium and Pyrodinium.24 The 
marine biotoxin gymnodimine was first isolated in 1995 from oysters (Tiostrea 
chilensis) collected at Foveaux Strait in the South Island of New Zealand by 
Yasumoto and coworkers.25 Gymnodimine was later shown to be widely distributed 
around the New Zealand coastline and has recently been identified in shellfish from 
both Tunisia and Canada. The gross structure was assigned by detailed spectroscopic 
studies. In 1997, Munro and coworkers elucidated the relative and absolute 
stereochemistry through X-ray crystallographic analysis of a N-acylated derivative.26 
The structural features of gymnodimine include a trisubstituted tetrahydrofuran within 
a 16-membered carbocycle, a chiral butenolide, and an azaspiro[5.5]undecadiene 
moiety. Two additional analogs were isolated and named gymnodimine B and C, 
respectively, that appear to be allylic oxidation products of the C17-C18 olefin of 
gymnodimine (Figure 2.1).27 Gymnodimine toxicity was associated with a bloom of a 
gymnodinoid dinoflagellate within the Karenia selliforms.28  
 
____________ 
*Reprinted with permission from “Enantioselective Total Synthesis of the Marine Toxin 
(-)-Gymnodimine Employing a Barbier-Type Macrocyclization” by Kong, K.; Romo, D.; 
Lee, C. Angew. Chem., Int. Ed. 2009, 48, 7402-7405. Copyright 2009 Wiely-VCH.  
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Figure 2.1 Structures of gymnodimines. 
 
 Gymnodimine was first suggested to act on voltage-gated Na+ ion channels, 
but direct proof of this hypothesis was not provided. Gymnodimine 2-1 was highly 
toxic by intraperitioneal injection, LD50 96 µg/kg. However, much toxicity was lost 
LD50 755 µg/kg after oral administration by gavage.29 No signs of toxicity were seen 
in mice voluntarily ingesting food containing gymnodimine at sufficient level as to 
give a dose of 7500 µg/kg. One study  showed that gymnodine and its analogues had 
weak effects on Neuro2a cells alone, yet indeed tended to reduce Neuro2a cell 
number. 30  In contrast, gymnodimine and its analogues produced a strong and 
consistant sensitization to the toxic effects of another toxin, okadaic acid. Algal 
blooms possibly involve production of both okadaic acid-type molecules and 
gymnodimine thus enhencing toxicity and posing a greater public health problem. 
However, the direct combined effects presently remain ambigous. Interestingly, 
symtoms observed after intraperitoneal injection of gymnodimine were identical to 
those recorded with tubocurarine. Since the latter substance is a competitive non-
depolarizing neuromuscular blocking agent which binds reversibly with 
postjunctional nicotinic receptors, thereby blocking the acetylcholine transmitter. If 
gymnodimine acted reversibly at the nicotinic receptors, it would be expected that 
neostigmine and physostigmine would similarly protect against gymnodimine toxicity 
in the same manner. This was found to be true as pre-treatment with physostigmine or 
neostigmine protected against injected gymnodimine, suggesting that gymnodimine 
exerts its toxic effects via blockade of nicotinic receptors at the neuromuscular 
junction. More recently, this hypothesis was investigated to test whether 
gymnodimine induced nicotinic acetylcholine receptor (nAChR) blockade (Figure 
2.2).31 Current-voltage relationships were performed with ionophoretic acetylcholine 
receptor (ACh) because it is well known that the binding of ACh to nAChRs caused 
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inward nicotinic currents. The ACh-evoked current peaks and the membrane potential 
from -140 to -60 mV range under control conditions and after 10 nM gymnodimine 
treatment that blocked about 50-60 % of the nicotinic peak current amplitudes were 
block which indicated that gymnodimine shows high affinity with nAChRs.  
 
  
Figure 2.2 Representative current-voltage relationship obtained with AChRs under 
control conditions and after addition of 10 nM GYM.28 
 
2.2 Previous Synthetic Approaches to Gymnodimine  
 
 Several groups have disclosed their synthetic studies toward gymnodimine. 
Murai and coworkers synthesized the tetrahydrofuran segment 2-5 of gymnodimine in 
a highly stereoselective fashion (Scheme 2).32 The key intermolecular Diels-Alder 
reaction of the triene 2-6 with α-methylene Cbz-lactam 2-7 was conducted in the 
presence of a full equivalent of Ellman’s copper bis(sulfinyl)-imidoamidine (siam) 
complex 2-8.33 A double diastereoselective Diels-Alder reaction to construct the 
spirocyclic lactam provided the spirolactam 2-9 in good yield and remarkably high 
diastereoselectivity (dr > 20:1). 
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 White and coworkers employed a convergent coupling of the optically active 
spirolactam and tetrahydrofuran moiety through a B-alkyl Suzuki-Miyaura coupling 
(Scheme 3).34 Subsequent attempts to move alkyne 2-13 toward a substrate suitable 
for closing the macrocylic core met difficulties due to the relatively hindered 
enviroment of the alkyne 2-13. A variety of conditions such as silylcupration-
iodination, hydrozirconation-iodination, and palladium-catalyzed hydrostannylation-
iodination of alkyne 2-13 all returned starting material. 
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 In a manner related to his pinnatoxin studies, Kishi and coworkers utilized a 
Diels-Alder/ macrocyclization process for an approach to gymnodimine (Scheme 4).35 
Diels-Alder macrocyclization of this imine 2-14 occurred in water at pH 6.5 under 
dilute conditions to give the desired product 2-15 as a mixture of three diastereomers. 
The desired natural product derivative 2-16 was isolated after reduction of a mixture 
of three imines 2-15 followed by acylation. 
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 Brimble and Trzoss developed an alternative approach other than Diels-Alder 
reaction for synthesis of the spirolactam (Scheme 5).36 Their method involved a 
diastereoselective Birch reductive alkylation as the key step. The resulting 
cyclohexadienes 2-18 was  reduced under hydrogenation conditions followed by 
acidolysis to remove chiral auxiliary delivered amino acid 2-21. The final 
inramolecular stylization of the amino acids provided enatiopure spirolactams 2-22. 
However, the potential utility of this methodology for gymnodimine synthesis has not 
been demonstrated. 
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2.3 Large Scale Synthesis of Gymnodimine Precursors 
 
2.3.1 Retrosynthetic Strategy toward Gymnodimine  
 
 Our synthetic plan called for a convergent coupling of tetrahydrofuran 2-23 
the optically active spirolactam 2-24 (Figure 2.3). Nozaki–Hiyama–Kishi (NHK) 
macrocyclization, 37  which is well-established in both inter- and intramolecular 
settings, was initially envisioned for the proposed merging of C9 and C10. The 
formation of the C20–C21 bond through nucleophilic opening of a δ-lactam by an 
sp3carbanion is rare, especially in a complex setting.38 The fragile butenolide would 
be annulated at a late stage by a vinylogous Mukaiyama aldol reaction of a 
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hypothetical furanone anion 2-25 to a ketone at C5 after unmasking of the silylenol 
ether in spirolactam 2-24. 
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Figure 2.3 Retrosynthetic strategy toward gymnodimine. 
 
2.3.2 Synthesis of the Tetrahydrofuran  Fragment 
 
 The conditions were already optimized in our group.39 However, problemes 
were encountered in reproducing some of the reactions in terms of yields and 
diastereoselectivity. Optimized conditions were followed through the synthesis unless 
otherwise I mentioned. The synthesis of the tetrahydrofuran fragment began with 
monoprotection of 1,3-propanediol 2-26 followed by PCC oxidation to deliver the 
known aldehyde 2-28 (Scheme 6). Horner-Wadsworth-Emmons (HWE) reaction of 
aldehyde 2-28 gave the known trans α,β-unsaturated ester 2-29. Reduction followed 
by Swern oxidation afforded the known α,β-unsaturated aldehyde 2-30.40  
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 The chiral auxilary, (S,S)-5-phenyl-3-propionyl-2-oxzolidinone 2-31, was 
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synthesized according to the proceure of Evans.41  In order to obtain the anti-aldol 
adduct 2-32 between C15 and C16 (gynodimine numbering) our  synthesis 
commenced with the Heathcock’s typical procedure employing BBu2OTf followed by 
aldehyde 2-30 addition (Scheme 7).  
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 Previous studies by Yang, in the our group, indicated that reductive cleavage 
of the TES ether 2-33 from the chiral auxiliary with LiBH4 led to extensive 
epimerization 2-34 and endo-carbonyl reduction product 2-35 (Scheme 8). Whereas a 
reduction of unprotected alcohol 2-32 resulted in a retro-aldol product 2-37. However, 
the cleavage of the chiral auxiliary 2-32 with the Weinreb amide resulted in cleavage 
at the endo carbonyl group with either allylic alcohol protection present or absent due 
to the extremely hindered nature of the exo-carbonyl blocked by the substituents.  
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 After extensive studies, it was determined that methanolysis provided the best 
conditions for cleavage of the chiral auxiliary from the aldol adduct 2-32 (Scheme 9). 
Alcohol protection, DIBAL-H reduction, followed by Swern oxidation gave aldehye 
2-38. However, Swern oxidation conditions on large scale led to deprotection of 
triethyl silyl (TES) group. Therefore, the TES group was switched to the more robust 
triisopropyl silyl (TIPS) group. 
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 When alcohol protection have done prior to methanolysis low regioselectity 
and slow reactivity were observed due to the extremly hindered nature of the exo-
  25 
 
carbonyl group (Scheme 10).  
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 Therefore, removal of the chiral auxiliary 2-32 by methanolysis then allylic 
alcohol protection with TIPSOTf followed by a reduction-oxidation sequence 
provided aldehyde 2-44 (Scheme 11). After Wittig reaction, the TIPS group on 2-44 
in this sequence did not cleavege to cyclize onto the enol ether to provide furanose 2-
46, so one extra step requiring deprotection was necessary followed by subsequent 
acid catalyzed cyclization to provide epimeric methoxyfuranose 2-46.  
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 Previous studies by Yang in our group indicated that the allylation of furanose 
2-46 with allyl trimethylsilane in the presence of exogenous Lewis acid BF3•OEt2 led 
to moderate  diastereoselectivity and excellent yield (Scheme 12).   
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 Base on these results, Dr. Kong in our group explored these conditions to 
enhance the selectivity (Scheme 13).  Since the allylation to methoxyfuranose 2-46 
did not proceed at lower temperature, Dr. Kong synthesized the more reactive 
acetoxyfuranose, however reaction temperature and Lewis acids had no effect on the 
diastereoselectivity. Interestingly, toluene provided comparable diastereoselectivity 
with good reproducibility.  
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 These optimized conditions were difficult to reproduce on large scale. 
Interestingly, some of the primary alcohol 2-49  was observed resulting from cleavage 
of the PMB group under Lewis acid in Methanol (Scheme 14). Since the next step 
was PMB deprotection, this result was not a problem. However, low selectivity 
became a serious problem. Since Dr. Kong mentioned that solvent affected the 
allylation reaction, dichloromethane was switched to toluene providing similar 
diastereoselectivity.  
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 Reductive cleavage of the PMB ether 2-48 under dissolving metal conditions 
afforded the alcohol 2-49. The primary alcohol 2-49 was transformed to the alkyl 
chloride 2-50 which was then subjected to hydroboration and oxidation to the 
aldehyde 2-51 (Scheme 15).    
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2.3.3 Asymmetric Synthesis of the Spirolactam 
 
 Previous studies from the our group have resulted in concise synthesis of the 
chiral spirolactam moiety. In the racemic spirolactam synthesis, Yang found that 
geometry of diene did not effect reaction outcome since both E/Z olefin lead to the 
same diastereomer with high diastereoselectivity with a strong Lewis acid such as 
Et2AlCl. However, in the chiral spirolactam synthesis, Dr. Kong found that only the E 
olefin isomer promoted the Diels-Alder reaction with Evans’ copper-
bis(oxazoline)hexafluoroantimony complex.42 Synthesis of diene commenced with 
stannylcupration of the commercially available 2,4-hexadiyne 2-52 to provide high 
regioselectivity to give E vinyl stannane 2-53a. In order to obtain similar 
regioselctivity, slow addition of an external proton source over 30 min as well as slow 
warming of the reaction to room temperature over 1 hour was important. Fast addition 
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of methanol to quench the reaction provided mixture of 2-53a, 2-53b, and 2-53c 
(Scheme 16). The optimal conditions used required four equivalents of 
tributyltinhydride and a large exess of reagents which made it difficult to separate the 
desired product 2-53a because tin reagent has similar Rf value with desired compound 
2-53a (Rf = 0.65; hexanes). Although the stannylcupration yield was diminished by 
using less reagent quivalents, it is beneficial due to the toxicity of tributyltinhydride 
as well as its price. Tin-lithium exchange of stannane 2-53a followed by reaction with 
N-methoxy-N-methyl acetamide gave the corresponding ketone 2-54. Subsequent 
formation of silyenol ether led to the diene 2-55.  
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 The synthesis of the α-methylene lactam dienophile 2-59 began with reduction 
of commercially available 3-carbethoxy-2-piperidone 2-56 to alcohol 2-57 and 
elimination with dicyclohexylcarbodiimide (DCC) produced the α-methylene lactam 
dienophile 2-58 (Scheme 17). Subsequent protection of lactam 2-58 led to the 
dienophile 2-59.  
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 The asymmetric Diels-Alder reaction leading to spirolactam 2-60 proceeded 
with high enantioselectivity (Scheme 18). Due to the instability of the diene 2-55, 
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short basic Al2O3 was used for purification. The asymmetric Diels-Alder was also met 
with a reproducibility problem on large scale. When the Diels-Alder reaction was 
carried out on smaller scale it provide good yields and diastereoselectivity. However, 
when the diene 2-55 was used on a one gram or larger scale the reaction provided 
very low yields and enantioselectivity.  It was fixed simply by purifing the diene 2-55 
2-3 time with the short chromatographies with basic Al2O3. Since 10 mol % of Evans’ 
copper catalyst was used to promote the asymmetric Diels-Alder reaction, trace 
amounts of triethyl amine possibly deactivited the copper catalyst. 
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 A chemoselective deprotection and conversion to the N-tosyl lactam 2-62  
followed by hydrostannylation led to the vinyl stannane 2-63 (Scheme 19).43 The 
subsquent conversion of the stannane 2-63 to the corresponding iodide 2-64 required 
for the Nozaki-Hiyama-Kishi coupling proceeded smoothly. 
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 The smooth intermolecular coupling between vinyl iodide 2-64  and the 
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aldehyde 2-51  provided the allylic alcohols in excellent yield as a 1:1.3 mixture of 
epimers 2-65a and  2-65b (Scheme 20). The undesired α-epimer 2-65a could be 
converted to desired diastereomer 2-65b via an oxidation-reduction sequence using 
the Itsuno-Corey reduction protocol (dr, 6:1) enabling greater material throughput.44 
Allylic alcohol 2-65b  was protected as silyl ether and the C-13 epimer (derived from 
minor diastereomer from the allylation of the furanose 2-46, Scheme 14) could be 
separated at this stage thus allowing a clean pure spectrum to be obtained after seven 
steps from the allylation of the furanose 2-46, Scheme 14. Subsequent Finkelstein 
reaction furnished the requisite alkyl iodide 2-68.  
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2.3.4 Completion of the Synthesis of Gymnodimine 
 
 After some experimentation by Dr. Kong in our group, optimal conditions 
were found for an intramolecular Barbier-type coupling involving halogen-lithium 
exchange in the presence of the N-tosyl lactam electrophile which provided adduct 2-
69 in 56-61 % yields (Scheme 21). The robust tosyl group was switched to a more 
labile trifluoroacetamide by sequential treatment with base, trifluoroacetic anhydride 
and samarium diiodide.45 Both silyl groups in 2-69 were then removed under acidic 
conditions furnishing the hydroxyl ketone 2-70. The ketone 2-70 and silyloxyfuran 2-
71 was exposed to TiCl4 and provided the γ-hydroxy-α,β-unsaturated lactone as a 
mixture diastereomers 2-72.46 The two epimeric tertiary alcohols 2-72 were readily 
seperated after silyl protection. Dehydration of the tertiary alcohol 2-73b under 
SOCl2/NEt3 conditions delivered the tetrasubstituted olefin (Δ4,5) regioisomer 2-74 as 
the major product.47 However, tertiary alcohol 2-73a provided both regioisomers 
without preference. A variety of basic conditions such as; K2CO3/MeOH, 
NH3·H2O/MeOH, LiOH/THF/H2O, NaHCO3/MeOH were screened and all led to 
decomposition of this sensitive substrate, in agreement with Miles’ finding that 
gymnodimine is unstable under neutral and alkaline pH values.48 Attempted acid 
hydrolysis also proved unsuitable. Therefore, the trifluoroacetamide group was 
switched to a more acid labile group, t-butoxycarbonyl group. Hence, treatment of the 
trifluoroacetamide 2-74 with (Boc)2O followed by brief exposure to hydrazine 
provided the N-Boc amine 2-75.49 Careful treatment of the Boc amine 2-75 with 
trifluoroacetic acid led to both t-butylcarbamate and silylether cleavage. Finally, 
cyclization to the cyclic imine under vaccum led to (-)-gymnodimine.44 
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2.4 Synthesis of Gymnodimine Haptens 
2.4.1 Synthesis toward Hapten S  
 
 The principal objectives of this research were to develop ELISA, which 
selectively quantify one chemical compound in the presence of others in its class and 
to meet the demands of regulatory agencies for inexpensive, accurate and sensitive, 
routine and portable use. Since selectivity among classes depends on the immunogen, 
structural design of the hapten becomes increasingly important. Our goal was to 
develop antibodies recognized gymnodimine congeners without cross-reactivity with 
other marine toxins. An efficient hapten should be a near perfect mimic of the target 
structure in size, shape (geometry) and  electronic properties. The hapten handle 
(required for connecting the target mimic to a carrier protein) should not itself elicit 
antibody recognition. Building on our recently completed total synthesis of (-)-
gymnodimine,50 two haptens are proposed for eventual production of monoclonal 
antibodies (mAb). One example of a congener-independent hapten to be prepared is 
the spirocycle hapten S (Figure 1.12). Synthesis of hapten S began with spirolactam 
2-76, which is the by-product of the NHK reaction (Scheme 22). Treatment of lactam 
2-76 with the alkyl lithium reagent afforded the desired amino ketone 2-77 in good 
yield. Silyl deprotection gave the corresponding ketone 2-78 as 5:1 mixture of two 
diastereomers. The major diastereomer was α-methyl group of cyclohexanone 
occupied equatorial and cis configuration with β-alkene group. Since stereocenter at 
C2 will be lost during dehyratation reaction, no need to improve diastereoselectivity 
of this reaction.  
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 The relative stereochemistry of ketone 2-78 was determined via γ-hydroxy-
α,β-unsaturated lactone 2-80 which was derived from addition of siloxyfuran 2-71 to 
ketone 2-79 (Scheme 23).  
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 X-ray crystal structure of lactone 2-80 showed substituents on cyclohexane are 
syn to each other (Figure 2.4). 
 
 
Figure 2.4 ORTEP representation of X-ray crystal structure of 2-80. 
 
 Treatment of ketone 2-78 with alkyl bromide 2-81 and t-butyl lithium provided 
corresponding tertiary alcohol 2-82 (Scheme 24). Unexpectedly dehydration of 
tertiary alcohol 2-82 under thionyl chloride/triethylamine conditions, used 
successfully in the total synthesis of gymnodimine, led to cyclohexene 2-83a and 2-
83b as inseparable regioisomers (~1:1). It would be interesting to know weather 
olefin geometry of haptens is important to generate ideal antibodies which can 
recognize gymnodimine. In order to seperate two regioisomers, two olefin isomers 2-
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83a and 2-83b were further functionalized. However, they were not seperable at any 
stage.  
Scheme 24 
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Therefore, other dehydration conditions were reconsidered. In order to obtain the 
desired cyclohexene 2-84, higher reaction temperatures were tested. Extensive 
screening of dehydration protocols such as pyridine and SOCl2, I2 and PPh3 and CSA, 
under refluxing conditions each gave unsatisfactory results. 
 
2.4.2. Synthesis of Hapten M  
 
 Although dehydration conditions toward hapten S provided inseperable 
mixture of two regioisomers 2-83a and 2-83b, the macrocycle intermediate 2-85 
(Figure 2.5) toward synthesis of hapten M (Figure 1.12) would more likely yield 
separable isomers based on results toward gymnodimine synthesis. Since geometry of 
the macrocycle intermediate 2-85 could make conformation change more than acyclic 
olefin 2-83a and 2-83b, physical property of two regioisomers would be more 
different.   
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Figure 2.5. Dehydration results and desired intermediate of hapten M. 
 
 The macrocyclic hapten M started from known ketone 2-69 (Scheme 21). With 
macrocycle 2-69 in hand, the site selective deprotection of the silyl group was 
studied. The acidic conditions toward synthesis of gymnodimine did not differentiate 
two silyl group under various temperature. Therefore relatively strong acid conditions 
was switched to buffered PPTS conditions (Scheme 25). After stirring for 48h, 53 % 
of desired product 2-86, ~4% of allylic alcohol 2-87, and ~11 % of ketone 2-88 was 
obtained. Although desired product 2-85 was obtained in moderate yields, the rest of 
material could be recycled. Allylic alcohol 2-87 could be converted to ketone 2-88 
and allylic alcohol 2-87 could be protected with TBSCl, to provide the desired ketone 
2-86. After recycled undesired products, overall yield was good. Therefore, further 
optimization would not be necessary. 
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  As mentioned before, the butenolide moiety will be replaced with a linker, 
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which will connect with a carrier protein. It was known that addition of organoalkali 
reagents to the α-methyl group of cyclohexanone is attacked from equatorial position 
(Scheme 26). Since the α-methyl group introduces a pseudo-axial hydrogen into the 
molecule which increase hinderance of attack from the axial position.51 Unexpectely 
these conditions provided two diastereomers 2-89a and relative stereochemistry was 
tentativly assigned. 
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 Newly generated stereogenic center will be lost during dehydration. Therefore 
diastereomerically enriched tertiary alcohol 2-89a was subjected to dehydration 
conditions (Scheme 27). However, undesired trisubstituted olefin isomer 2-90a was 
found to be the sole product under thionyl chloride/triethylamine conditions. 
Diastereomer tertiary alcohol 2-89b also gave trisubstituted olefin isomer 2-90a but 
unexpectedly 1H NMR spectrum of 2-90a from 2-89a and 2-89b did not match.  
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If the assignment of tertiary alcohol 2-89a and 2-89b was correct, both diastereomers 
2-89a and 2-89b would give same product 2-90a. Therefore structure of tertiary 
alcool 2-89b would be more likely 2-89c (Scheme 28). 
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 In order to obtain the desired cyclohexene, higher reaction temperatures were 
tested. As I expected, extensive screening of dehydration protocols such as Pyridine 
and SOCl2, I2 and PPh3 and CSA, under refluxing conditions each did not change the 
regioselectivity. Since the main goal of this project is to produce an antibody, which 
could recognize gymnodimine congeners, the geometry of the cyclohexene 
component might not be important in this respect. Therefore, macrocycle haxene 2-
90a was carried on in future steps (Scheme 29). The robust tosyl group was switched 
to a more labile trifluoroacetamide by sequential treatment with base, trifluoroacetic 
anhydride ad samarium diiodie and desired product 2-91 was obtained. 
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 Deprotection of the PMB group was performed under DDQ and pH 7 buffer 
conditions.52 Although PMB deprotection conditions with DDQ and CAN required 
relatively higher concentration (0.1-0.05 M), the conditions used here were quite 
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dilute. In order to overcome lower substrate concentration, large excess amount of 
DDQ was employed. Although the PMB group was removed under these conditions, 
suprisingly furan ring also oxidized to the compound 2-92 (Scheme 30). During the 
synthesis of THF fragment toward gymnodimine, Birch conditions provided better 
yields than oxidative cleavage of PMB ether 2-49 (Scheme 15) using DDQ/H2O 
conditions. Since dissolving metal conditions reduced carbonyl group as well, 
oxidation of resulting alcohol 2-93 would be required. However, various oxidation 
conditions such as Dess-Martin periodinane (DMP), Swern and collins oxidation gave 
multiple products. Presumably oxidation was only occurred at primary alcohol to 
deliver the aldehyde 2-94. Since we have limited amount macrocycle intermediate 2-
69 (Scheme 25), this route was abandoned and a more productive strategy was 
pursued. 
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2.4.3 Second Generation Synthesis toward Hapten S  
 
 In order to obtain the desired olefin isomer, we reexamined the original 
approach with butenolide addition followed by dehydration. We envisioned a late-
stage opening of the butenolide with amino acid derivatives. This approach would 
also provide an acid tether suitable for further manipulation. The mukaiyama aldol 
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addition to ketone 2-95 in moderate yields with mixture of diastereomers 2-95a and 2-
95b (Scheme 31). Pure tertiary alcohols 2-95a was subjected to dehydration 
conditions and as expected, desired tetrasubstituted olefin 2-96 was obtained with 
good regioselctivity.  
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 Previously, Dr. Ziad, a former postdoc in our group found that the tosyl group 
was difficult to cleave under a variety of conditions. Specially, the unstable 
betenolide group caused many problems during the protecting group swich. Therefore 
the trifluoroacetyl group was installed at early stage due to the presumed instability of 
butenolide. However, for the hapten synthesis, butenolide 2-96 will be opened so the 
trifluoroacetyl group could be installed after amide bond formation. In addition, the 
opening of the butenolide 2-96 would be the biggest challenging step for hapten 
synthesis which was desired to carry out at the early state.  
 Wengel and coworkers reported interesting observations which piperazine 
added at C2 position of furanone 2-98 instead of C4 position (Scheme 32).53 The 
formation of 2-98 can be explained by a nucleophic attack at C2 and concomitant ring 
opening assisted by the acidity of the C5 proton. 
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  Inspired by these conditions, several nucleophiles were chosen instead of 
piperidine and explored at room temperature and no desired product was obtained 
(entry 1-6, Table 2.1). The reaction might require Lewis acid catalyst or higher 
temperature. Lewis acid catalyst showed no desired products and some of starting 
material was recovered (entry 5, 6). The butenolide 2-100 was mixed with excess 
aminoacid ester in triethylamine as a solvent at 40 oC (entry 7, 8). Interestingly, β-
alanine ethylester gave desired product 2-101 but t-butyl aminobutyrate did not gave 
desired product. Initially, I speculated that different solubility of amino esters in 
triethylamine caused different results, but using co-solvent with triethylamine did not 
improve the yields.  
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Table 2.1. Optimization of the opening of butenolide moiety 
2-100
O
O
2-101
Entry Nucleophile catalyst solvent Temperature product
N
H
O
O O
OR
1
2
3
4
5
6
H2N O
tBu
O
H2N OEt
O
H2N O
tBu
O
H2N
OtBu
O
H2N
OEt
O
H2N OEt
O
Et3N
23 oCTHF  SM
23 oCTHF  SM
Me2AlCl 23 oCCH2Cl2
No desired
Product
23 oCCH2Cl2
No desired
Product
Me2AlCl
40 oC
40 oC
No desired
Product
LiOH MeOH 23 oC
No desired
Product
N
O
O
HO
DMAP 23 oC
No desired
Product
7
8 46 %
Et3N
Et3N
n=1,2
 
 
 After developing a protocol for opening butenolide with aminoacids, this 
conditions applied to the butenolide 2-96 (Scheme 33). Interestingly, 1H NMR and 
MS supported intermolecular imine 2-102 as a major compound which was 
hydrolyzed under acid conditions to give mixture of ketone 2-103.  
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 The robust tosyl group was switched to a more labile trifluoroacetamide by 
sequential treatment with base, trifluoroacetic anhydride and samarium diiodide 
(Scheme 34). Interestingly mixture of two diastereomers 2-103 became a single 
product due to formation of furan 2-104.  
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 Priviously cleavage of the trifluoroacetamide 2-105 with warm ammonium 
hydroxide led to concomitant cyclization to provide imine 2-10639 but this condition 
led to many products (Scheme 35).  
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 Therefore mild protocol for imine formation of gymnodimine was employed.  
Hence, treatment of the trifluoroacetamide 2-104 with (Boc)2O followed by brief 
exposure to hydrazine provided the N-Boc amine 2-107. Careful treatment of the Boc 
amine 2-107 with trifluoroacetic acid led to both t-butylcarbamate and silylether 
cleavage (Scheme 36). Finally, cyclization to the cyclic imine under vaccum led to 
desired imine 2-108. 
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 In order to conjugate with carrier protein, hyderolysis of ethyl ester 108 was 
exposure to lithium hydroxide in aqueous tetrahydrofuran (Scheme 37). These 
conditions were utilized to synthesis of pinnatoxin A by Zakarian and coworkers.54 
However, imine 2-108 provided multiple products under these conditions.  
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2.4.4. Second Generation Synthesis toward Hapten M  
 
 In order to obtain the desired olefin isomer, we reexamined the original 
approach with butenolide addition followed by dehydration. We envisioned a late-
stage opening of the butenolide with aminoacid derivatives. The mukaiyama aldol 
addition to ketone 2-69 in moderate yields with mixture of diastereomers 2-112a and 
2-112b (Scheme 38). The two epimeric tertiary alcohols 2-112 were readily seperated 
after silyl protection. Dehydration of the tertiary alcohol 2-112b under SOCl2/NEt3 
conditions delivered the tetrasubstituted olefin (Δ4,5) regioisomer 2-113 as the major 
product. The butenolide 2-114 was mixed with excess aminoacid ester in 
triethylamine as a solvent at 40 oC. Although these conditions provided desired 
product 2-115, complex molecule 2-114  provided more compounds than 2-96 such as 
dehyderation of allylic alcohol and other substrate related compounds. Using same 
methods of gymnodimine synthesis required a lot of material input and the key step to 
generate linker on gymnodimine moiety needed to study more to find better 
conditions.  
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.  
2.5 Conclusions 
  
 Consumption of seafood contaminated by marine toxins has been a long-
standing public health problem. Gymnodimine is a member of the spirocyclic imine 
family of marine toxins initially isolated from oysters collected off the coast of New 
Zealand. Current detection methods for gymnodimines include mouse bioassay and 
LC-MS and recently Botana and coworkers developed fluoresence polarization 
mathods which used the high binding affinity of gymnodimine to nAChRs.6 This 
method is an inhibition assay so it will recognized any toxins which can interact with 
nAChRs. Since antibody immunoassay is structural recognition, ELISA will be 
complementary analytical techniques. Therefore, building on our recently completed 
  47 
 
total synthesis of (-)-gymondimine, haptens were designed and studied for eventual 
production of monoclonal antibodies (Mab). We have completed the synthesis of the 
cores of hapten S and hapten M. This will enable subsequent conjugation to carrier 
proteins. 
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CHAPTER III 
 
INTRAMOLECULAR NUCLEOPHILE CATALYZED, ALDOL-
LACTONIZATIONS (NCAL) OF KETO ACIDS* 
3.1 Previous Nucleophile Catalyzed Aldol-Lactonizations  
 
Although the first β -lactone synthesis was demonstrated by Einhorn in 1883, it 
was not until almost 100 years later that β-lactones have attracted much attention, 
primarily due to their versatility as synthetic intermediates.55 β-lactones have unique 
bielectrophilic character as a result of the strain present in their compact structures. As a 
result, soft nucleophiles such as Norman reagent (R2CuMgX) lead to alkyl C-O cleavage, 
whereas hard nucleophiles such as alkoxy or amino group lead to acylation.56 Our group 
synthesized two representative natural products such as Merck IND 57  and 
dihydroplakevulin A58 utilizing this dual electrophilic character of β-lactones (Scheme 
39).   
 
Scheme 39 
1) MeOH, NEt3
CO2Me
OH
(CH2)15CH3
HO
 (+)-dihydroplakevulin A
2) HF•py
(CH2)15CH3
TBSO
O
O
3-3
O
O
O
O
1) CuCl, THF
2) BH3•THF
3) 1N HCl, THF
F MgCl
O
OH
F
3-1 3-2 3-4
Merck IND
soft Nu
hard Nu
 
 
In addition, many β-lactone-containing natural products have been isolated and 
 
 
 
_______ 
*Reprinted with permission from “Bicyclic and Tricyclic-β-lactones via 
Organonucleophile Promoted Bis-Cyclization of Keto Acids: Enantioselective Synthesis 
of (+)-Dihydroplakevulin” by Henry-Riyad, H.; Lee, C.; Purohit, V. C.; Romo, D. Org. 
Lett. 2006, 8, 4363-4366. Copyright 2006 American Chemical Society.  
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synthesized including panclicin D, orlistat, valilactone, salinosporamide A, and 
oxazolomycin. Besides drug or drug-like biological properties of these natural products, 
we have elucidated important information regarding structure-activity relationships and 
enzyme inhibition. Classical routes to β-lactones have generally involved the cyclization 
of β-halocarboxylate salts and the related “deaminative cyclization” which occurs upon 
diazotization of β-amino acids.59 β-Hydroxy acids acids have been reported to undergo a 
similar cyclization under Mitsunobu60 conditions, and the halolactonization of α, β-
unsaturated acids61 is a related process of some interest. Ketene participation in Lewis 
acid catalyzed [2+2] cycloadditions involving carbonyl compounds, 62  and addition 
reactions involving alkynolate63 have been other utilized routes for generating β-lactone 
intermediates. Although these classical methods have been successfully employed for the 
preparation of a variety of β-lactones, it should be noted that their utility is often limited 
by undesired side reactions including β-elimination (to form α,β-unsaturated acids) and 
decarboxylative elimination (to generate alkenes). Few methods have been reported to 
permit the direct conversion of ketones and aldehdyes to β-lactones in a single step.  The 
most popular method for this transformation of ketones and aldehydes to β-lactones 
employs a two-stage protocol:  condensation of the carbonyl compound with a carboxylic 
acid dianion,64 followed by benzenesulfonyl chloride in pyridine induced cyclization.65 In 
1982, Wynberg and Staring,56a building on earlier work by Borrmann and Wegler,66 
reported an asymmetric route for construction of β-lactones where the stereochemical 
setting step was dictated by a chiral Lewis base (Scheme 40). 
 
Scheme 40 
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The mechanism proposed by Wynberg involves initial attack of ketene 3-6 by the 
chiral amine 3-8 to form the neutral ammonium enolate intermediate A (Figure 3.1). The 
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enolate A then undergoes an aldol reaction with aldehyde 3-5 to form aldolate B, 
followed by cyclization to give oxetane C. Subsequent elimination delivers the chiral β-
lactone 3-8, thus regenerating the catalyst.   
 
O
C
NR3
*
O
NR3
O
R2R1
NR3
O O
O
O
NH2R3
NR3*
3-6
3-5
3-7
R1
R2
*
R1
R2
*
O
R1
R2
*
O
3-8
A B
C  
Figure 3.1 Wynberg’s proposed catalytic cycle with quinidine catalyst. 
 
While the Wynberg process is an important method for generating β-lactones, this 
method requires use of activated aldehyde and a ketene generator. Therefore, several 
other research groups were prompted to expand upon and improve this promising 
advancement. In 1999, Nelson and coworkers reported this transformation by using chiral 
Al(III)[triamine] 3-9 catalyzed cyclo-condensations of acyl halides and non-activated 
aldehydes (Figure 3.2).67 Fu and co-workers have been exploring the use of planar-chiral, 
4-pyrrolidinopyridine derivatives such as 3-10 (PPY), now shown to provide 
disubstituted β-lactones from disubstituted ketenes.68 Most recently, the groups of Bode, 
Glorious, Nair, and Scheidt groups employed N-heterocyclic carbenes (NHC) 3-11 and 3-
12 as nucleophile to promote aldol-lactonizations leading to β- and γ-lactones and 
cyclopentens.69 
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Me
N
N
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Me
Me
Me
Me
O
N
N
N
Me
Me
Me
Cl
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N
Me
Me
Me
Cl
Me
3-11 3-12  
Figure 3.2 Chiral catalysts for aldol lactonization. 
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In most cases, these carbene catalysts resulted in the formation of cyclopentens by 
spontaneous decarboxylation of a β-lactone intermediate. In order to trap the products at 
the lactone stage, Bode and coworkers used α-hydroxy enones (Scheme 41). To capture 
the stereochemical and functional complexity of these transient intermediates. 70 
Furthermore, They disclosed that structurally identical triazolium and imidazolium 
carbene catalysts 3-11 and 3-12 provide routes to β- and γ-lactones respectively.  
 
Scheme 41 
R1 H
O
EtO OH
O
O
Me Me
+
O
N
N
N
Me
Me
Me
Cl
O
N
N
Me
Me
Me
Cl
Me
cat (10 mol%)
DBU (1 eq)
toluene, rt, 15 h
O
O
CO2Et
R1
Me
OH
Me
CO2Et
R1
O
OH
Me
Me
O
99% ee 99% ee
triazolium
precatalyst
imidazolium
precatalyst
3-11 3-12
3-13 3-14
3-15 3-16  
 
They proposed two intermediates, D and E, based on leaving group ability of 
catalysts 3-11 and 3-12 (Figure 3.3). Mechanistic studies provide evidence for invoking a 
reversible benzoin condensation to result in anionic species A, which undergoes an Oxy-
Cope rearrangement to produce C and further intramolecular aldol cyclization generating 
D. In the case of the triazolium catalyst 3-11, the catalyst seems s a good leaving group in 
the tetrahedral intermediate, forming the β-lactone products. In contrast, imidazolium 
catalyst 3-12 preferred to expel the alkoxide leading to acyl imidazolium E, which 
undergoes a retro-aldol/aldol sequence inverting the stereochemistry and leading to the 
formation of the more stable γ-lactone.  
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Figure 3.3 Proposed mechanism via benzoin-oxy-cope reaction through boatlike 
transition state. 
 
In 1992, our group also developed an intramolecular version of this nucleophilic 
catalyzed aldol-lactonization (NCAL) process building on work of Wynberg, which 
provided the first strategy to achieve the formation of β-lactones with non-activated 
aldehydes.71 After several unsuccessful attempts with various activating agents and 
conditions, we were pleased to find that addition of an aldehyde acid to a mixture of 
Mukaiyama’s reagent 3-19a, Hunig’s base and O-acetyl quinidine 3-18 in 
dichloromethane gave the bicyclic β-lactone 3-20 in high enantioselectivity in moderate 
yields (Scheme 42). Previous work in our group has shown that modified Mukaiyama 
reagent 3-19b led to greatly improved conversion and efficiency (70-82% yield) with 
shorter reaction times and no diminution of enantioselectivity (91-98 % ee).72 
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3.2 Optimization of the NCAL with Keto Acids 
 
In our earlier studies, we reported that use of 6-oxoheptanoic acid (3-21) as 
substrate led to only to a 3% isolated yield of the corresponding bicyclic-β-lactone while 
employing Et3N as both a base and a nucleophilic promoter.65b More recently, we have 
focused on applying this process to ketoacid substrates. Initial studies with p-
dimethylamino pyridine (DMAP) using previously described conditions led to more than 
a 5-fold increase in yield of β-lactone (19%).  Further conversion was observed with the 
more nucleophilic 4-pyrrolidinopyridine (PPY) (Table 3.1). However, under the same 
conditions, it was determined that other N-heterocyclic nucleophiles including pyridine, 
diazabicyclooctane (DABCO), diazabicycloundecane (DBU), and Phosphorous 
nucleophiles such as triphenyl phosphine and tributylphosphine showed similar results to 
those of N-heterocyclic nucleophilic promoters. Use of only Hünig’s base led to 
formation of no β-lactone, which is suggestive of a nucleophile-catalyzed process.  
 
Table 3.1. Screen of nucleophile catalysts for NCAL process 
3-21 3-22
OH
O
O
O
OH
CH2Cl2, 0.07 M, 12h
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i-Pr2NEt
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1 0
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33-19b(3 equiv)
Py (1 equiv)2 4 03-19b (3 equiv)
DMAP (1 equiv)3 4 193-19b (3 equiv)
PPY  (1 equiv)4 4 483-19b (3 equiv)
none5 4 03-19b (3 equiv)
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N N
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DABCODBU
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  Based on these results, we have concluded that more nucleophilic catalysts are 
essential for generation of a more nucleophilic ammonium enolate intermediate B and B’ 
(Figure 3.4), which serves to favor formation of the aldolate intermediate C, increasing 
the rate of the presumed rate-determining oxetanone (D) formation step. Ketene 
intermediate E, derived from elimination of activated acid A, can undergo nucleophilic 
attack by the catalyst to generate ammonium enolates B and B’. The same pair of 
ammonium enolates B and B’ can be generated by direct acylation of the catalyst leading 
to the acyl ammonium species, which can then undergo deprotonation. Regardless of 
which intermediates C and C’ were formed, only the cis aldolate C would cyclize to an 
oxetane species D due to ring strain considerations. 
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Figure 3.4 Possible mechanistic pathways for intramolecular nucleophile catalyzed 
bis-cyclization process of aldehyde acids and keto acids. 
 
 The scope of this cyclization process was explored using various keto acids. As 
expected, all examples provided only cis-cyclopentyl-fused β-lactones due to ring strain 
considerations (Table 3.2). Keto-acids bearing β but not γ or δ-stereocenters relative to 
the carboxylic acid provided excellent diastereoselectivities (cf. β-lactones 3-23f vs. 3-
23d, e).  
 
  55 
 
Table 3.2. Substrate scope of the NCAL process 
O
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4
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2:1
~1:1
>19:1
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O
O
CO2H
Ph
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CO2H
Me
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O
CO2H
MePh
O
CO2H
Me
TBSO
3-23b
3-23c
3-23d
3-23e
3-23f
3-24
 
iPr2NEt (2.5 equiv) 
CH2Cl2 
 23 oC, 12 h3-23 (n = 1, 2)
3-23b(1.5 equiv)
O
O
R1
R2
H
n
CO2H
R1
n O
R2
3-19b (1.5 equiv)
3-24b
3-24c
3-24d
3-24e
3-24f
 
 
aRelative stereochemistry is based on strain arguments (3-24a-b), and eventual 
conversion of 3-24f to dihydroplakevulin (3-34).  bYields refer to isolated (silica gel), 
purified product.  c0.7 equiv PPY, 1.0 equiv 2-19b, and 2.0 equiv Hünig’s base were 
employed and both β-lactones 3-24a and 3-24e were achieved by Dr Huda in our group. 
dRatios were determined by 500 MHz 1H NMR on crude reaction mixtures and a dr of 
>19:1 indicates that minor diastereomers could not be detected. 
 
Regarding the mechanism of this bis-cyclization process, we favor an aldol-
lactonization route over a [2+2] cycloaddition pathway. The high diastereoselectivity 
(>19:1, dr) observed with β-substituted acid substrates, strongly supports a NCAL 
process. Namely, only keto-acids bearing a β-constituent to the carboxylic acid give anti 
3-24f with high diastereoselectivities raised from intermediate A. This is consistent with 
A1,3 strain for an ammonium enolate intermediate B leading to β-lactone syn 3-24f 
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(Figure 3.5). Other possible envelope intermediates C and D would be disfavored due to 
developing 1,3-diaxial interactions. In the case of a [2+2] cycloaddition pathway, such 
strain would be absent and thus intermediates E and F would have no difference of 
enthalpy resulting in low to no diastereoselectivity. More recent studies in our group have 
identified conditions for a catalytic asymmetric synthesis of β-lactones using keto-acid 
substrates. The asymmetric intramolecular NCAL process will be discussed in the 
subsequent chapter. 
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Figure 3.5 Rationale for high diastereoselectivity with β-substituted acids. 
 
3.3 Application to the Synthesis of (−)-Dihydroplakevulin 
 
Having developed this NCAL route to β-lactones, we interested in applying this 
route in natural product synthesis. Untenone A, natural product structurally related to 
plakevulin A, was isolated from marine sponges of the genus plakortis. In 2003, 
Kobayashi and co-workers reported it role as an inhibitor of mammalian DNA 
polymerase α and β, and human terminal deoxynucleotidyl transferase.73 An approach by 
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Kobayashi and co-workers approach toward synthesis of plakevulin A began with 
untenone A (Scheme 43). In order to determine the relative stereochemistry for 
plakevulin A, three derivatives of plakevulin A were prepared. The latter derivative 
dihydroplakevulin A became a synthetic target for the bis-cyclization of keto acids 
because the core of dihydroplakevulin A was almost identical with 3-23f. The proposed 
route to the ketoacid 3-32 began with alkylation of the acetoacetate 3-27 with ally 
bromide, providing ketoester 3-28 in 92% yield.74  The keto group of 3-28 was subjected 
to Noyori hydrogenation conditions, in the presence of RuBr2[(S)-(Binap)]catalyst 
generated in situ from Ru(Cod)(2-methylallyl)2. 75  Known hydroxy ester 3-29 was 
obtained in > 80% yield and high enantioselectivity (97% ee).68  TBS protection of 
alcohol 3-30, followed by ozonolysis and reduction of the ozonide with 
triphenylphosphine provided the corresponding aldehyde. Reaction with alkylmagnesium 
bromide followed by oxidation afforded the ketoester 3-31.  Subsequent hydrolysis of the 
ester provided the corresponding carboxylic acid 3-32, which was then exposed to our 
NCAL conditions.  The desired bicyclic β-lactone 3-33 was obtained in moderate yield 
with high diastereoselectivity. Subsequent methanolysis and deprotection provided 
dihydroplakevulin A 3-34. 
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3.4 Design and Attempted Synthesis of a Cyclic Guanidine Catalyst 
 
Although extension of the NCAL process to ketoacid substrates was shown to be 
successful, stoichiometric amounts of nucleophile were required for obtaining 
synthetically useful yields. Use of stoichiometric nucleophile is undesirable in the 
asymmetric NCAL process due to the availability and expense of chiral catalysts. 
Therefore, our focus was shifted to synthesis and testing of several pyridine nucleophiles 
and other related nucleophiles, which possess greater nucleophilicity compared to 4-PPY 
3-23b. Highly planar nucleophiles minimize developing torsional strain with the alkyl 
group (R) of ketone substrates, and efficient syntheses of both achiral and chiral versions 
of the nucleophilic catalyst were pursued (Figure 3.6). If the catalyst was able to enhance 
the stability of the reactive acylammonium intermediate, the rate of NCAL process could 
be increased by perturbing the equilibrium in favor of the aldolate. Zipse and coworkers 
reported energy calculations of pyridine derivatives, which were ranked according to 
their relative acylation enthalpy.76 Based on their calculations, the synthesis of two 
guanidine derivatives, which would have greater -ΔHacylation than 4-PPY were developed. 
Commercially available tetramisole 3-40 and structurally related benzotetramisole 3-4177 
and homobenzotetramisole (HBTM) catalysts 3-4278 also showed promise (Figure 3.6). 
Tetramisole-derived catalysts have recently been explored as asymmetric acylation 
catalysts by Birman and can be easily synthesized from the corresponding 2-amino 
alcohols.79 
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Figure 3.6 Possible nucleophile catalyst candidates and criteria for catalyst selection. 
 
First, in order to determine the usefulness of guanidine nucleophiles in the 
process, synthesis of racemic 3-38 was first undertaken. The proposed achiral guanidine 
nucleophile 3-38 was generated from the guanidinylation of chloroimidazolinium 
chloride 3-44 with 4-amino pyridine 3-45 (Scheme 44). This highly reactive Vilsmeier 
salt 3-44 was prepared according to a known procedure.80  
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The second achiral guanidine nucleophile 3-39 began with N-Boc protection of 
aminopyridine 3-45 followed by formylation to give aminopyridine aldehyde 3-46 (Scheme 
45).81 Alkyllithium addition to aldehyde 3-46 followed by cleavage of the carbamate 
delivered secondary alcohol 3-47. Guanidinylation of amino alcohol 3-47 afforded the 
corresponding guanidine 3-48. Surprisingly only one benzyl group was cleavaged under 
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dissolving metal conditions.  In order to promote the crucial cyclization, the alcohol was 
activated and exposed to various temperatures and solvents, yet the desired tricyclic 
guanidine 3-50 was not generated, likely due to the large energy barrier present when the 
guanidine and the activated alcohol came in close proximity to each other.  
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Since the development of a new catalyst required extensive effort and promising 
results with commercially available tetramisole 3-40 were being observed, this project 
was halted. Related work in our group showed that a 5,6 carbocycle-fused β-lactone 3-52 
was obtained in greater than 90% yield under identical NCAL conditions with 1,3-
cycloalkanedione acid 3-51 (Scheme 46).82  Furthermore, the asymmetric syntheses of β-
lactones from 1,3-cycloalkanedione acid substrates were achieved with the chiral 
tetramisole catalyst 3-40 in 53% (97% ee). Even though the NCAL process is expected to 
remain the same with these substrates, the inherent reactivity of 1,3-cycloalkanedione 
acid substrates differs from non-dione keto acid substrates. For example, DBU 3-23c 
promoted the bis-cyclization process in 62% yield with 1,3-cycloalkanedione acid. 
However, no β-lactone product was observed with non-dione keto acid substrates. These 
results provided an important starting point for the development of a catalytic asymmetric 
process with keto acid substrates.  
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Very recently, this dione and non-dione NCAL process has been explored with 
chiral catalysts such as benzotetramisole 3-41 and homobenzotetramisole (HBTM) 3-42, 
which are structurally related to tetramisole 3-40. Results show that HBTM 3-42 catalyst 
promotes formation of asymmetric β-lactones with non-dione keto acid substrates. More 
importantly 20 mol% HBTM catalyst 3-42 delivered β-lactones in moderate yields with 
high enantioselectivity.   
 
3.5 Synthesis of β-lactone Fused Nitrogen Heterocycles 
 
Polyhydroxylated pyrrolidine and pyrrolizidine moieties are found in a wide 
variety of natural and synthetic compounds of biomedical significance.83  Alkaloids such 
as (2S, 3R)-3-hydroxyproline (3-53),84 tussilagine (3-54),85 hyacinthacine A2 (3-55),86 
and platynecine (3-56) 87 have received much attention by both synthetic chemists and 
biochemists due to their challenging structures and diverse biological activities (Figure 
3.7). Although many racemic and enantioselective routes toward these alkaloids have 
been published, the NCAL process would be a practical new route to access these 
alkaloids.  
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Figure 3.7 Examples of pyrrolidine and pyrrolizidine alkaloids. 
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Previously we have synthesized nitrogen containing bicyclic β-lactones 3-58 from 
the corresponding aldehyde acid substrates 3-57 by an intramolecular NCAL process 
(Scheme 47).88   Pyrrolidine fused β-lactones 3-58a and 3-58b were obtained in yields up 
to 80% in the racemic series and up to 60% yields in (88% ee) for the asymmetric series. 
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Construction of the pyrrolidine framework has also been widely reported using 
alternate methods. List and co-workers discovered the first catalytic asymmetric α-
alkylation of aldehyde 3-60 by an intramolecular pathway (Scheme 48).89  Their process 
furnished chiral substituted pyrrolidine 3-62 in moderate yield and enantioselectivity.  
  
Scheme 48 
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OHC I
TsN
OHCN
H
CO2H
3-61 (10 mol%)
TEA, CHCl3, 30 °C
3-60 3-62(52%, 91% ee)  
 
Hamada and coworkers reported the asymmetric synthesis of (2S,3R)-3-hydroxy-
3-methylproline (OHMePro) 3-64  via an intramolecular asymmetric aldol reaction 
(Scheme 49).90 Interestingly, final target molecule, OHMePro 3-64 is a better catalyst 
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over (S)-proline toward the synthesis of (2S,3R)-3-hydroxy-3-methylproline (OHMePro) 
3-65.  
 
Scheme 49 
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Pyrrolidines have also been obtained via the intramolecular iodo-aldol cyclization, 
which is part of the Morita-Baylis-Hillman (MBH) family of tandem aldol reactions. A 
current limitation of the iodo-aldol process is the inability to apply this method to the 
construction of quaternary centers. Greaney and coworkers have explored the scope of 
the iodo-aldol process (Scheme 50),91 and have shown that the reaction of enolate-
aldehyde or ketones 3-66 produces hindered γ-iodoalcohols 3-67 with excellent trans 
selectivity in moderate to good yields.  
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As mentioned previously, our group discovered that 4-pyrrolidinopyridine (PPY) 
3-23b, tetramisole 3-40, and homobenzotetramisole (HBTM) 3-42 catalysts promoted 
intramolecular NCAL reactions with keto acids for generating bicyclic β-lactones. The 
scope of substrates was extended to include nitrogen-containing keto acid substrates. 
Keto acid 3-72 was readily synthesized from tosyl protected β-alanine ester 3-68  
(Scheme 51). Alkylation of β-alanine 3-68, followed by ozonolysis and ester hydrolysis 
  64 
 
provided ketoacid 3-72.  The NCAL reaction was conducted using PPY as a promoter, 
and the desired nitrogen containing bicyclic β-lactone 3-73 was isolated in 75% yield.88  
Scheme 51 
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In order to determine the use of this substrate in an asymmetric NCAL process, 
ketoacid 3-72 was subjected to previously developed NCAL conditions using tetramisole 
3-40.82 The desired bicyclic β-lactone 3-73 was obtained in 35% yield (unoptimized) and 
91% ee (Scheme 52). The absolute configuration has not yet been determined. Bicyclic 
β-lactone 3-58b was previously obtained with lower enantiomeric excess than bicyclic β-
lactone 3-58a,88 but structurally similar β-lactone 3-73 was obtained with excellent 
enantiomeric excess. Therefore NCAL of ketoacid 3-74 was expected to give as similar 
results as ketoacid 3-72. However, tetramisole catalyst provided very low conversion (> 
5%) with excellent enantiomeric excess (93% ee) with ketoacid 3-74, while the 
homobenzotetramisole (HBTM) catalyst 3-42 provided better yield.  
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After determining the utility of the NCAL with nitrogen-containing keto-acid 
substrates, we are interested in applying this method to more complex nitrogen 
containing natural products such as tussilagine. Among hundreds of isolated 
pyrrolizidines, tussilagine is anomalous and non-toxic. It has been found to exist in 
Tussilago farara, Echinacea purpurea, and Arnica. angustifolia.92 In 1998, Ma and co-
workers reported an enantioselective protocol from 1,4-butanediol in an overall 8% yield 
in 9 steps.93  
Our synthesis of tussilagine commences with homoproline 3-77 and a key step is 
the NCAL reaction with ketoacid 3-80. Although homoproline is commercially available, 
it is rather expensive and instead is easily accessed from (s)-proline 3-76 via Arndt-
Eistert homologation in two steps (Scheme 53).94 The resulting carboxylic acid was then 
benzyl protected and the Boc group subsequently deprotected under acidic conditions. N-
alkylation followed by ozonolysis provided ketoester 3-79. In the future, after 
deprotection of the benzyl group, the corresponding ketoacid 3-80 is expected to deliver 
tricyclic β-lactone 3-81 via the NCAL process and further ring opening of β-lactone 3-81 
should generate tussilagine 3-55.  
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3.6 Conclusions 
 
In an effort to expand utility of the nucleophile promoted aldol lactonization 
process, we explored keto-acid substrates using established protocols previously proven 
highly useful with aldehyde-acids substrates. However, N-heterocyclic nucleophiles 
cinchona alkaloids, pyridine, diazabicyclooctane (DABCO), diazabicycloundecane 
(DBU), and phosphorous nucleophiles did not successfully promote the NCAL process. 
We were pleased to find that more nucleophilic catalysts such as 4-pyrrolidinopyridine 
(PPY) 3-23b, tetramisole 3-40, and homobenzotetramisole (HBTM) catalyst 3-42 
promoted intramolecular NCAL reactions with keto-acid substrates for bicyclic β-
lactones. This reaction produced β-lactones possessing up to three stereocenters, which 
include a masked tertiary carbinol center and a reactive β-lactone moiety. This protocol 
for keto-acids was applied toward asymmetric synthesis of polyhydroxylated pyrrolidine 
and pyrrolizidine alkaloids. In addition, the application of the NCAL process to the total 
synthesis of dihydroplakevulin A was achieved and synthesis of tussilagine is under 
study. Finally, we have developed a catalytic asymmetric NCAL reaction using 
homobenzotetramisole (HBTM) as a nucleophile and additional studies are underway in 
our laboratory. 
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CHAPTER IV 
 
SYNTHETIC STUDIES TOWARD THIOLYGBYAN 
4.1 Isolation and Background 
 
The role of thiols and disulfides in biological systems is well known such as the 
thiol-disulfide interchange reaction and the related formation and cleavage under 
physiological conditions. The most well known disulfide natural products is the lipoic 
acid 4-1, which plays a dual role in living organisms as acyl group transfer agent to 
coenzyme A in the metabolic process and as antioxidant against the free radical (Figure 
4.1). Other natural products such as epi-zeylaoxide B 4-2,95 somocystinamide A 4-3,96 
and rostratin C 4-4 97  possessing disulfide moiety have been isolated and showed 
interesting bioactivity. Epi-zeylaoxide B 4-2 completely inhibited root growth of rice 
seedlings at 3 mM and somocystinamide A 4-3 exhibited cytotoxicity against mouse 
neuro-2a neuroblastoma cells with IC50 values of 1.4 µg/mL, rostratins C 4-4 showed in 
vitro cytotoxicity against human colon carcinoma (HCT-116) with IC50 values of 0.76 
µg/mL.  
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Figure 4.1. Examples of disulfide moiety containing natural product. 
 
Marine organisms are known producers of compounds with novel chemical 
structures and interesting biological activities. The marine cyanobacteria (blue-green 
algae), Lyngbya majuscula are a rich source of novel bioactive natural products. Many 
structurally diverse metabolites have been isolated from this microoganism. Its 
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compounds have been classified into various families such as the lyngbyabelliums, the 
majuscamides, and the curacins based on structural and functional similarities.98  One 
such metabolite, thiolyngbyan, was first isolated and characterized by Dr. William 
Gerwick’s research group at the University of California San Diego in 2003.99 After 
HPLC purification of the crude extraction of Lyngbya majuscula (strain 19L), a blue-
green algae collected from the coastal waters of Curacão, an island located near 
Venezuela, the isolated 0.1 mg sample of thiolyngbyan exhibited a 35 mm zone of 
inhibition with the yeast Candida albicans in a 6 mm disk after 24 hours (Figure 4.2). 
Because of the biological activity, thiolyngbyan may function as a useful antifungal 
agent.  
 
 
Figure 4.2 Fraction of organic extract from L. majuscula.88  
 
The gross structure of thiolyngbyan was tentatively assigned by spectroscopic 
studies including, accurate mass measurements and 1D and 2D NMR correlation methods 
(Figure 4.3). The proposed structural features of thiolyngbyan include an exo vinyl 
bromide, one stereogenic center, and a cyclic disulfide moiety. Unit peak patterns of 
thiolyngbyan mass spectrum indicated the presence of bromine because a unit peak and a 
base peak were approximately equal in intensity. The mass fragment peak of 208.8 
indicated the present of an alcohol. The 1H NMR spectra, exhibited a signal at δ 6.37 
ppm consistent with the presence of vinyl bromine. Furthermore, the carbon signal at δ 
128 ppm was 15 ppm more down field than a typical external olefin signal. This likely 
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demonstrates that vinyl halogen is present. The proton signals at δ 3.00 ppm to δ 4.00 
ppm suggested the present of sulfur atoms. In addition, the signals at around δ 35 ppm 
indicated carbon atoms bearing sulfur. The 13C signal at δ 123 ppm is indicative of a 
quaternary olefin especially due to relatively small intensity.  
 
 
Figure 4.3 1D spectrum data of proposed thiolyngbyan. 
 
2D NMR studies were ambiguous so the geometry of the vinyl bromide and the 
stereochemical assignment still need to be verified. As its structure has not been 
confirmed, structural verification of thiolyngbyan is the main goal of this project. In 
addition, the simple structure of the molecule should facilitate pinpointing the 
functionality responsible for thiolyngbyan’s antifungal activity.  
 
4.2 Synthetic Studies toward the Proposed Structure of Thiolyngbyan 
 
We envisioned formation of the disulfide unit in thiolyngbyan 4-5 via oxidation of 
a 1,3-dithiol derivative, which in turn can arise by Mistunobu esterification of 1,3-diol 4-
6 (Figure 4.4).  The ketone 4-7 can be formed from known diol 4-8,100 via selective 
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hydroxyl group protection followed by Swern oxidation.  The diol 4-8 can be formed 
from D-glucose 4-9, via selective hydroxyl protection followed by oxidative cleavage.  
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Figure 4.4 Retrosynthetic analysis of thiolyngbyan. 
 
The selective protection of hydroxyl groups from D-glucose 4-9 was carried out 
according to the protocol developed by Barili et al (Scheme 54).101 The initial reaction 
was performed on seven grams scale that provided 4 g of desired product in 45% yield. 
The oxidative cleavage of triol 4-10 followed by reduction of the resulting aldehyde 4-11 
gave the 2,4-O-isopropylidene-D-erythritol 4-8. Problems were encountered on scale up 
of the oxidative cleavage and above two gram-scale, the yield of this reaction diminished. 
Since the desired product was very soluble in water, it was difficult to extract it back to 
the organic layer. Therefore, the solvent was switched to methanol and the reproducibility 
problem was resolved. Resulting intermediate aldehyde 4-11 was not isolated due to its 
instability and direct reduction of the crude material provided primary alcohol 4-8, which 
was selectively protected with TBDPSCl. Swern oxidation of alcohol 4-12 then provided 
ketone 4-7.  
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To install the vinyl bromide, Wittig conditions were initially employed, but most 
of the starting material (> 90 %) was recovered under various conditions (Table 4.1).102 
We reasoned that the Wittig procedure might be unsuitable to convert ketone 4-7 to vinyl 
bromide 4-13 because of the steric hindrance. 
 
Table 4.1. Optimization of the Wittig conditions 
O O
TBDPSO
Br
Base,THF
Ph3P
+CH2BrBr
-
25 oC
Entry
1
2
3
1.1
Phosponium bromide MajorTemp.
1.2 equiv. SM
Base equiv.
KHMDS
Base
4
4.0 110 oC4.0 equiv.
4.0 110 oC4.0 equiv.
4.0 110 oC4.0 equiv.
LiHMDS
LDA
NaH SM
4-13
SM
SM
SM = starting material
TBDPSO
O O
O
4-7
 
 
However, when the bulky silyl group was removed to minimize the steric 
hindrance of ketone 4-7, results did not improve. Among alternative olefination methods, 
only Petasis conditions provided the desired olefin 4-14 (Scheme 55),103 however the 
product was only obtained in low yield. As these conditions did not directly give vinyl 
bromide 4-13, bromination of the olefin 4-14 followed by elimination provided a vinyl 
bromide 4-15. nOe experiments was used to determine the stereochemistry of vinyl 
bromide 4-15. We assumed that we have the desired diastereomer, because nOe analysis 
of vinyl bromide 4-15 indicated only existing relationship between H2 and H4. 
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Cleavage of the acetonide group generated Mistunobu substrate diol 4-6 (Scheme 
56). 
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Previously, an undergraduate student Jennifer Foulke in our group explored 
Mistunobu condition104 with simplified diol 4-16 (Scheme 57) and obtained desired 
product 4-17. However, under similar conditions, the mono-substituted thioacetate 
derivative 4-18a was only observed due to the steric hindrance of the carbon atom 
bearing secondary hydroxyl group. Therefore, a relatively small activating reagent 
methanesulfonyl chloride or trifluoroacetic anhydride was employed. Subsequent 
replacement with a small nucleophile such as sodium sulfide or potassium thioacetate at 
various temperatures,105 gave only decomposition, as suggested by the disappearance of 
the vinyl proton signal by analysis of the crude reaction mixture by NMR.  
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4.3 Conclusions 
 
Thiolyngbyan, was first isolated from Lyngbya majuscula, a blue-green algae 
collected from the coastal waters of Curacão, an island located near Venezuela and 
characterized by Dr. William Gerwick’s research group. The proposed structural features 
of thiolyngbyan include an exo vinyl bromide, one stereogenic center, and a cyclic 
disulfide moiety and although its structure has not been verified, thiolyngbyan may 
function as a useful antifungal agent. In our approach to the proposed structure of 
thiolyngbyan from chiral pool D-glucose 4-9, the hydroxy groups of 1,3 diol 4-6 could 
not be replaced with several thiol reagents due to the inherent steric hindrance of the 
secondary hydroxyl group. Although several potential ways to solve this problem remain 
unexplored, this project was halted.  
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CHAPTER V 
 
CONCLUSIONS 
 
In order to develop efficient and convenient detection methods for the marine 
toxin gymnodimine and to study its mode of action, synthetic haptens of gymnodimine 
were proposed. Building on our recently completed total synthesis of (-)-gymnodimine, 
core intermediates were prepared and linkers were installed which will be used to 
conjugate the haptens with the carrier protein. Treatment of ketone 2-78 with alkyl 
bromide 2-81 and t-butyl lithium provided corresponding tertiary alcohol 2-82. 
Unexpectedly dehydration of tertiary alcohol 2-82 under thionyl chloride/triethylamine 
conditions, used successfully in the total synthesis of gymnodimine, led to cyclohexene 
2-83a and 2-83b as inseparable regioisomers (~1:1) and dehydration of the tertiary 
alcohol 2-89a led to exclusively undesired trisubstituted olefin isomer 2-90a under 
various conditions. Therefore more advanced intermediate, which bear the butenolide 
moiety was studied. Although developing a protocol to open the butenolide of hapten S 
with amino acids provided the desired product in moderate yield, much lower yield was 
observed with hapten M. Thus further optimization is currently under study.  
β-lactones continue to attract interest as versatile intermediates in synthesis, and 
these heterocycles are also integral to many biologically active natural products. Early 
work in the Romo group led to the discovery of a nucleophile-catalyzed aldol 
lactonization (NCAL) process, resulting in a one-pot formation of bicyclic β-lactones 
from linear aldehyde-acids in high yields and enantioselectivites. We greatly expanded 
the scope and utility of this process to keto acid substrates leading to highly versatile 
carbocycles or heterocycles possessing up to three stereocenters including a masked 
tertiary carbinol center. We have been able to apply this method to the synthesis of 
dihydroplakevulin A and the core of tussilagine. Although initial attempts to develop 
guanidine catalysts for the asymmetric NCAL process were unsuccessful, 
homobenzotetramisole (HBTM) was found to be a suitable asymmetric catalyst for keto 
acid substrates. Studies are currently underway in our laboratory to further explore 
  75 
 
asymmetric NCAL process, which will lead to highly versatile carbocyclic or 
heterocyclic bicyclic β-lactones. 
Thiolyngbyan was first isolated from Lyngbya majuscula, a blue-green algae and 
showed potential as a useful antifungal agent. The synthesis of the proposed structure of 
thiolyngbyan was starting from D-glucose 4-9, however, the hydroxy groups of 1,3 diol 
4-6 could not be replaced with several thiol reagents due to the inherent steric hindrance 
of the secondary hydroxyl group. In contrast, when reactions were carried in the present 
of sulfides, installation of the vinyl bromide was problematic. Although this project was 
halted, the potential antifungal activity of thiolyngbyan warrants further investigation. 
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EXPERIMENTAL 
 
General 
All reactions were carried out under nitrogen atmosphere in oven-dried (120 °C) 
glassware unless noted otherwise. All non aqueous reactions were carried out under 
nitrogen atmosphere in oven-dried (120 ºC) glassware. Acetonitrile, dichloromethane, 
tetrahydrofuran, diethyl ether, N,N-dimethylformamide, toluene were dried by an Mbraun 
solvent drying system. Methanol was distilled from magnesium prior to use. Triethyl 
amine was distilled from calcium hydride prior to use. The molarities indicated for 
organolithium reagents were established by titration with 2,6-di-tert-butyl-4-
methylphenol and 1,10-phenanthroline as indicator.  All other commercially obtained 
reagents were used as received. Optical rotations were measured with a JASCO DIP-360 
digital polarimeter.  All optical rotation measurements were made at 16-23 °C in a 10 
millimeter cell (length); concentration c is reported in g/100mL. Infrared spectra were 
recorded with a Nicolet Impact 410 FTIR spectromer. Enantiomeric excess (ee) was 
determined by HPLC (Rainin SD-200) analysis using a chiralcell OD column. Flash 
column chromatography was performed using 60Å Silica Gel (Baker, 230-400 mesh) as a 
stationary phase. Sometimes basic Al2O3 (Brochmann, 150 mesh) was used for 
purification of acid labile compounds. Mass spectra were obtained on a VG analytical 
70S high resolution, double focusing, sectored (EB) mass spectrometer at the center for 
Chemical Characterization and Analysis. Thin layer chromatography (TLC) was 
performed using glass-backed silica gel 60F254 (Merck, 250 µm thickness). 1H NMR 
and 13C NMR spectra were recorded on a Varian Unity-500, VXR-300 spectrometer. 1H 
NMR chemical shifts are reported as δ values in ppm relative to tetramethylsilane (TMS, 
0.00 ppm). 1H NMR coupling constants (J) are reported in Hertz (Hz) and multiplicity is 
indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), sep (septet), m 
(multiplet), bs (broad singlet), dd (doublet of doublet), dt (doublet of triplet), dq (doublet 
of quartets), tt (triplet of triplet), ddd (doublet of doublet of doublet). Unless indicated 
otherwise, deuterochloroform (CDCl3) served as an internal standard (77.0 ppm) for all 
13C spectra.  
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Procedure 
 
Ts
N
H
O
OTBS
 
Olefin 2-76: By-product obtained during Nozaki-Hiyama-Kishi (NHK) coupling. 
m.p.122-126 ºC; Rf = 0.57 (20% EtOAc/hexanes); [α]D21 +95.5 (c 1.0, CHCl3); 1H NMR 
(500 MHz, CDCl3) δ 7.85 (d, J = 8.5 Hz, 2H), 7.28 (d, J = 8.5 Hz, 2H), 5.41 (dq, J = 
11.0, 7.0 Hz, 1H), 5.07 (ddq, J = 11.0, 11.0, 1.5 Hz, 1H), 3.83 (ddd, J = 12.0, 6.0, 6.0 Hz, 
1H), 3.60 (ddd, J = 12.0, 7.5, 5.0 Hz, 1H), 3.60 (d, J = 11.0 Hz, 1H), , 2.44 (s, 3H), 2.06-
2.00 (m, 2H), 1.94-1.87 (m, 3H), 1.87-1.80 (m, 1H), 1.69 (ddd, J = 13.0, 5.0, 5.0 Hz, 1H), 
1.67-1.61 (m, 1H), 1.41 (s, 3H), 1.28 (dd, J = 7.0, 1.5 Hz, 3H), 0.94 (s, 9H), 0.10 (s, 3H), 
0.09 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 175.3, 144.2, 142.1, 140.1, 136.5, 129.1, 
128.9, 128.5, 127.0, 111.9, 47.3, 46.9, 42.8, 31.4, 26.8, 26.7, 25.8, 21.6, 20.7, 18.1, 14.1, 
12.7, -3.9, -4.0; IR (thin film): 1686 cm-1; HRMS (ESI) Calcd. for C27H42NO4SSi [M+H]: 
504.2598. Found: 504.2626. 
O
NHTs
OTBS
 
Amino ketone 2-77: To a solution of 5-bromo-1-pentene (355 mg, 2.382 mmol) in Et2O 
(10 mL) at -78 ºC was added t-BuLi (1.5 M in pentane, 3.17 ml, 4.764 mmol) dropwise. 
After stirring for 30 min, a solution of olefin 2-76  (200 mg, 0.397 mmol) in THF (3 mL) 
was added. The reaction mixture was stirred at 0 ºC for 30 min, warmed to room 
temperature and the reaction was quenched by pH 7 buffer. The aqueous layer was 
extracted with Et2O, and the combined organic layers were dried (MgSO4), concentrated 
in vacuo and purified by flash chromatography (15% → 20% EtOAc/Hexanes) to afford 
172 mg (75%) of the desired product 2-77 as a colorless oil. Rf = 0.28 (20% 
EtOAc/hexanes); [α]17D + 188.9 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.71 (d, J 
= 8.0 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 5,72-5.80 (m, 1H), 5.69 (dq, J = 11.0, 6.5 Hz, 
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1H). 4.96-5.03 (m, 2H), 4.50 (dd, J = 6.0, 6.0 Hz, 1H), 3.43 (d, J = 10.5 Hz, 1H), 2.79 
(ddd, J = 6.5, 6.5, 6.5 Hz, 2H), 2.43 (s, 3H), 2.41 (dd, J = 7.5, 7.5 Hz, 2H), 1.91-2.06 (m, 
4H), 1.70 (dd, J = 7.0, 2.0 Hz, 3H), 1.53-1.62 (m, 3H), 1.51 (s, 3H), 1.31-1.35 (m, 3H), 
1.12-1.15 (m, 2H), 0.90 (s, 3H), 0.80-0.95 (m, 2H), 0.034 (s, 3H), 0.026 (s, 3H); 13C 
NMR (125 MHz, CDCl3) δ 212.9, 143.6, 143.4, 138.1, 136.8, 129.7, 127.0, 125.3, 115.1, 
113.7, 53.0, 43.4, 41.0, 35.9, 33.7, 33.1, 27.6, 26.2, 25.8, 24.0, 22.6, 21.5, 18.1, 15.0, 
13.5, -3.8, -4.1; IR (thin film): 3280, 1691 cm-1; HRMS (ESI) calcd for C32H52NO4SSi 
[M+H]:574.33863. Found: 574.3336. 
O
NHTs
O
 
Ketone 2-78: To a solution of the silyl ether 2-77 (349 mg, 0.608 mmol) in 
THF/CH2Cl2/MeOH (1:1:1, 15 mL) at 21 oC was added p-toluenesulfonic acid 
monohydrate (306 mg, 1.216 mmol). The reaction mixture was stirred at room 
temperature for 7 h and quenched by saturated NaHCO3 solution. The aqueous layer was 
extracted with Et2O and the combined organic layers were concentrated in vacuo. The 
residue was purified by flash chromatography (20%→30% EtOAc/hexanes) to afford 239 
mg (85%) of the desired product as a white foam. Rf = 0.26 (30% EtOAc/hexanes); [α]21D 
–54.7 (c 2.47, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.71 (d, J = 8.5 Hz, 2H), 7.31 (d, J 
= 8.5 Hz, 2H), 5,75-5.83 (m, 2H), 5.02-5.09 (m, 2H), 4.90 (dd, J = 11.5, 11.5 Hz, 1H), 
4.25 (dd, J = 6.0, 6.0 Hz, 1H), 3.43 (dd, J = 11.5, 4.5 Hz, 1H), 2.89 (dd, J = 13.5, 7.0 Hz, 
2H),  2.52-2.67 (m, 2H), 2.44 (s, 3H), 2.27-2.44 (m, 4H), 2.12 (dd, J = 14.5, 8.0 Hz, 2H), 
1.74 (dt, J = 7.0, 1.5 Hz, 2H), 1.65 (dd, J = 7.0, 1.5 Hz, 3H), 1.40-1.53 (m, 3H), 1.03-1.21 
(m, 2H), 0.87 (d, J =  7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 213.3, 212.0, 143.4, 
137.8, 136.7, 130.0, 130.0, 126.9, 124.5, 115.3, 55.2, 45.4, 45.1, 43.2, 38.6, 35.2, 34.1, 
32.9, 29.6, 24.1, 22.7, 21.4, 13.5, 12.0; IR (thin film): 3284, 1703, 1638 cm-1; HRMS 
(ESI) calcd for C26H38NO4S [M+H]:460.25215. Found: 460.2681. 
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Ketone 2-79: To a solution of the silyl ether (81 mg, 0.144 mmol) in THF/CH2Cl2/MeOH 
(1:1:1, 6.0 mL) at room temperature was added p-toluenesulfonic acid monohydrate (109 
mg, 0.58 mmol). The reaction mixture was stirred at 21 oC for 2.5 h and quenched by 
saturated NaHCO3 solution. The aqueous layer was extracted with Et2O and the 
combined organic layers were concentrated in vacuo. The residue was purified by flash 
chromatography 20%→30% EtOAc/hexanes) to afford 63 mg (98%) of the desired 
product as a white foam. Rf = 0.24 (30% EtOAc/hexanes); 1H NMR (500 MHz, CDCl3) δ 
7.70 (d, J = 7.5 Hz, 2H), 7.32 (d, J = 7.5 Hz, 2H), 5,77 (dq, J = 11.5, 7.5 Hz, 1H), 4.90 
(ddq, J = 11.5, 11.5, 2.0 Hz, 1H), 4.18 (dd, J = 6.5, 6.5 Hz, 1H), 3.43 (dd, J = 11.5, 2.5 
Hz, 1H), 2.80-2.88 (m, 2H), 2.50-2.64 (m, 2H), 2.44 (s, 3H), 2.27-2.42 (m, 4H), 1.60 (dd, 
J = 7.0, 1.5 Hz, 3H), 1.45-1.64 (m, 5H), 1.35-1.39 (m, 2H), 1.08-1.22 (m, 2H), 0.95, (t, J 
= 7.5 Hz, 3H), 0.87 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 213.5, 212.0, 
143.5, 136.7, 130.1, 129.7, 127.0, 124.6, 55.3, 45.5, 45.1, 43.3, 38.7, 36.0, 34.1, 29.3, 
26.0, 24.2, 22.5, 21.5, 14.0, 13.6, 12.0; IR (thin film): 3287, 1706 cm-1; HRMS (ESI) 
Calcd. for C25H38NO4S [M+H]: 448.25215. Found: 448.2437. 
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Butenolide 2-80: A mixture of the racemic ketone 2-79 (14.5 mg, 0.0334 mmol) and 
silyloxyfuran 2-71 (85 mg, 0.334 mmol) was azeotropically dried with PhMe and 
dissolved in CH2Cl2 (1.5 mL). To this vigorously stirred solution was added TiCl4 (1.0 M 
in CH2Cl2, 130 µL) dropwise at 21 oC. The cloudy yellow reaction mixture was stirred at 
21 oC for 30 s and quenched by saturated NH4Cl solution. The mixture was extracted 
with CH2Cl2 and the combined organic layers were concentrated in vacuo. The residue 
was purified by flash chromatography (10%→20%→30%→40% EtOAc/hexanes) to 
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afford two diastereomers 2-80a (less polar, 6.2 mg, 34% yield) and 2-80b (more polar, 
5.9 mg, 32% yield), respectively. 2-80a: Rf = 0.24 (40% EtOAc/hexanes); 1H NMR (500 
MHz, CDCl3) δ 7.69 (d, J = 7.5 Hz, 2H), 7.29 (d, J = 7.5 Hz, 2H), 6.88 (s, 1H), 5,58-5.59 
(m, 2H), 4.93 (s, 1H), 4.23 (t, J = 6.5 Hz, 1H), 3.17 (dd, J = 11.0, 4.5 Hz, 1H), 2.78 (dd, J 
= 13.5, 6.5 Hz, 2H), 2.42 (s, 3H), 2.32-2.42 (m, 2H), 1.80-1.91 (m, 1H), 1.74 (dt, J = 
12.0, 7.0 Hz, 1H), 1.62 (d, J = 5.5, 3H) 1.60 (s, 3H), 1.32-1.56 (m, 4H), 1.23-1.31 (m, 
4H), 1.06-1.16 (m, 2H), 0.97 (d, J = 4.5 Hz, 3H), 0.88-0.96 (m, 2H), 0.92 (t, J = 7.5 Hz, 
3H); 13C NMR (125 MHz, CDCl3) δ 214.5, 173.7, 144.6, 143.5, 131.5, 129.7, 128.1, 
127.0, 126.5, 86.3, 75.2, 54.6, 43.2, 39.2, 37.0, 35.9, 34.6, 29.7, 29.3, 26.0, 25.4, 23.3, 
22.5, 21.5, 14.0, 13.5, 13.4, 10.8; IR (thin film): 3500, 3281, 1756, 1694 cm-1; HRMS 
(ESI) Calcd. for C30H44NO6S [M+H]: 546.28893. Found: 546.3023. Recrystallization 
from CH2Cl2 provided colorless crystals suitable for X-ray analysis. 
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2-80b: Rf = 0.17 (40% EtOAc/hexanes); 1H NMR (500 MHz, CDCl3) δ 7.68 (d, J = 8.5 
Hz, 2H), 7.29 (d, J = 8.5 Hz, 2H), 7.09 (s, 1H), 5,69 (dq, J = 11.5, 7.0 Hz, 1H), 5.52 (dd, 
J = 11.0, 11.5 Hz, 1H), 4.73 (s, 1H), 4.21 (t, J = 6.0 Hz, 1H), 3.19 (dd, J = 11.5, 4.0 Hz, 
1H), 2.75 (dd, J = 11.5, 6.0 Hz, 2H), 2.42 (s, 3H), 2.28-2.46 (m, 2H), 1.71-1.91 (m, 2H), 
1.64 (d, J = 5.5 Hz, 3H), 1.60 (s, 3H), 1.41-1.58 (m, 2H), 1.20-1.41 (m, 6H), 1.06-1.16 
(m, 2H), 0.97 (d, J = 7.0 Hz, 3H), 0.81-0.96 (m, 2H), 0.90 (t, J = 7.5 Hz, 3H); ); 13C 
NMR (125 MHz, CDCl3) δ 213.1, 173.9, 147.2, 136.7, 130.8, 129.7,128.1, 127.5, 127.0, 
83.1, 75.0, 54.3, 43.3, 39.3, 36.4, 34.7, 28.7, 25.8, 25.0, 25.4, 23.2, 22.4, 21.5, 14.0, 13.7, 
12.7, 10.7; IR (thin film): 3496, 3284, 1762, 1699 cm-1; HRMS (ESI) Calcd. for 
C30H44NO6S [M+H]: 546.28893. Found: 546.3026.   
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Tertiary alcohol 2-82: To a solution of alkyl bromide (531 mg, 0.0571 mmol) in Et2O 
(30 mL) at -78 ºC was added t-BuLi (1.5 M in pentane, 2.8 mL, 4.2 mmol) dropwise. 
After stirring for 10 min, a solution of olefin 2-82  (173 mg, 0.376 mmol) in THF (9 mL) 
was added. The reaction mixture was stirred at -78 ºC for 1 h, warmed to room 
temperature. The reaction was quenched by pH 7 buffer. The aqueous layer was extracted 
with Et2O, and the combined organic layers were dried (MgSO4), concentrated in vacuo 
and purified by flash chromatography (10% → 30% EtOAc/Hexanes) to afford two 
diastereomers 2-82a (less polar, ~118 mg, 50% yield) and 2-82b (more polar, 75 mg, 
31% yield), respectively. 2-82a: Rf = 0.50 (30% EtOAc/hexanes); 1H NMR (500 MHz, 
CDCl3) δ 7.69 (d, J = 8.0 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 5,70-5.80 (m, 1H), 5.54-5.65 
(m, 2H), 4.89-5.09 (m, 2H), 4.46 (t, J = 6.0 Hz, 1H), 3.51-3.64 (m, 2H), 3.11 (dd, J = 
11.0, 4.5 Hz, 1H), 2.75 (dd, J = 13.0, 6.5 Hz, 2H), 2.35-2.49 (m, 2H), 2.42 (s, 3H), 1.91-
2.16 (m, 2H), 1.71-1.86 (m, 3H), 1.60 (d, J = 6.5 Hz, 3H), 1.50-1.66 (m, 2H), 1.39-1.49 
(m, 4H), 1.26-1.39 (m, 4H), 1.09-1.25 (m, 3H), 0.87 (s, 9H), 0.81 (d, J = 7.0 Hz, 3H), 
0.068 (s, 3H), 0.025 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 214.3, 143.4, 138.1, 136.7, 
129.6, 128.9, 127.1, 125.8, 115.1, 72.8, 63.6, 54.7, 43.3, 39.2, 38.6, 38.4, 35.4, 34.9, 33.9, 
33.1, 26.8, 26.1, 25.9, 23.2, 22.8, 21.5, 18.2, 13.4, 12.6, -5.4; IR (thin film): 3532, 3284, 
1697 cm-1; HRMS (ESI) calcd for C35H60NO5SSi [M+H]:634.39615 Found: 634.3571. 
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2-82b: Rf = 0.47 (30% EtOAc/hexanes); 1H NMR (500 MHz, CDCl3) δ 7.76 (d, J = 8.0 
Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 5,71-5.79 (m, 1H), 5.46 (dq, J = 13.5, 6.0 Hz, 2H), 
4.96-5.02 (m, 3H), 4.88 (t, J = 7.5 Hz, 1H), 3.66-3.76 (m, 2H), 2.93 (dd, J = 13.5, 6.5 Hz, 
2H), 2.91 (dd, J = 4.0, 4.0 Hz, 2H), 2.43 (s, 3H), 2.31-2.42 (m, 2H), 2.01 (dd, J = 14.0, 
7.0 Hz, 2H), 1.78-1.93 (m, 2H), 1.55-1.78 (m, 2H), 1.56-1.65 (m, 4H), 1.42-1.53 (m, 2H), 
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1.45 (d, J = 7.0 Hz, 3H), 0.92 (s, 9H), 0.77 (d, J = 6.5 Hz, 3H), 0.092 (s, 6H); 13C NMR 
(125 MHz, CDCl3) δ 213.7, 143.2, 138.1, 136.8, 129.6, 128.8, 127.1, 125.6, 115.0, 72.9, 
63.8, 55.0, 44.5, 43.6, 42.4, 37.0, 33.0, 31.4, 26.3, 25.9, 25.6, 24.4, 23.0, 21.4, 18.2, 13.3, 
12.2, -5.393, -5.419; LRMS (ESI) calcd for C35H60NO5SSi [M+H]:634.39615 Found: 
634.3789. 
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Olefin 2-83: To a solution of the alcohol 2-82 (63 mg, 0.00265 mmol, azeotropically 
dried with PhMe) in CH2Cl2 (10 mL) at -78 ºC was added 140 µL of Et3N and 140 µL of 
a solution of SOCl2 (36 µL) in CH2Cl2 (1 mL). The reaction mixture was stirred at -78 ºC 
for 30 min and quenched by pH 7 buffer. The aqueous layer was extracted with CH2Cl2 
and the combined organic layers were concentrated in vacuo. The residue was purified by 
flash chromatography (10% EtOAc/hexanes) to afford 46 mg (75%) of the inseparable 
mixture of olefin 2-83a and its regioisomer 2-83b (Δ5,6 : Δ5,24 = ~1:1). Rf = 0.61 (10% 
EtOAc/hexanes); IR (thin film): 3289, 1700 cm-1; HRMS (ESI) calcd for C35H58NO4SSi 
[M+H]:616.38558 Found: 616.3706. 
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Olefin 2-96: To a solution of the alcohol 2-95a (19 mg, 0.034 mmol, azeotropically dried 
with PhMe) in CH2Cl2 (2 mL) at -78 ºC was added 140 µL of a solution of SOCl2 
followed by 24 µL of Et3N. The reaction mixture was stirred at -78 ºC for 10 min and 
quenched by pH 7 buffer. The aqueous layer was extracted with CH2Cl2 and the 
combined organic layers were concentrated in vacuo. The residue was purified by flash 
chromatography (20% EtOAc/hexanes) to afford 11 mg (60%) of the desired product 2-
96 as a colorless oil. Rf = 0.23 (30% EtOAc/hexanes); 1H NMR (500 MHz, CDCl3) δ 
7.71 (d, J = 8.0 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 6.72 (s, 1H), 5,70-5.78 (m, 1H), 5.72 
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(s, 1H), 5.63 (dq, J = 11.0, 6.5 Hz, 1H), 5.06 (dt, J = 11.0, 1.5 Hz, 1H), 5.01-4.96 (m, 
2H), 4.81 (t, J = 6.0 Hz, 1H), 3.39 (d, J = 12.0 Hz, 1H), 2.77 (dd, J = 13.5, 6.5 Hz, 2H), 
2.41 (s, 3H), 2.30-2.42 (m, 2H), 2.00 (dd, J = 11.5, 6.5 Hz, 2H), 1.88 (s, 3H), 1.86 (dt, J = 
19.5, 6.0 Hz, 2H), 1.75 (s, 3H), 1.73 (dd, J = 7.0, 1.5 Hz, 3H), 1.54-1.60 (m, 3H), 1.33-
1.46 (m, 2H), 1.15-1.22 (m, 1H), 1.01-1.14 (m, 1H), 0.81-0.91 (m, 1H); 13C NMR (125 
MHz, CDCl3) δ 212.8, 174.6, 147.6, 143.5, 137.9, 136.7, 136.4, 129.7, 128.3, 127.0, 
126.8, 123.1, 115.2, 79.6, 53.2, 43.3, 41.4, 35.1, 33.8, 33.0, 26.5, 23.8, 22.7, 21.5, 20.6, 
17.7, 13.8, 10.6; HRMS (ESI) Calcd. for C31H42NO5S [M+H]: 540.27837. Found: 
540.2450. 
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Olefin 2-96b: To a solution of the alcohol 2-95b (38 mg, 0.068 mmol, azeotropically 
dried with PhMe) in CH2Cl2 (6 mL) at -78 ºC was added 140 µL of a solution of SOCl2 
followed by 48 µL of Et3N. The reaction mixture was stirred at -78 ºC for 30 min and 
quenched by pH 7 buffer. The aqueous layer was extracted with CH2Cl2 and the 
combined organic layers were concentrated in vacuo. The residue was purified by flash 
chromatography (20% EtOAc/hexanes) to afford 20 mg (68%) of the desired product 2-
96b as a colorless oil. Rf = 0.21 (30% EtOAc/hexanes); 1H NMR (500 MHz, CDCl3) δ 
7.70 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 6.79 (s, 1H), 5,72-5.80 (m, 1H), 5.72 
(s, 1H), 5.63 (dq, J = 11.0, 7.0 Hz, 1H), 4.97-5.06 (m, 3H), 4.31 (t, J = 6.0 Hz, 1H), 3.46 
(d, J = 11.0 Hz, 1H), 2.79 (dd, J = 13.0, 6.0 Hz, 2H), 2.43 (s, 3H), 2.38 (t, J = 6.0 Hz, 
2H), 2.03 (dd, J = 14.0, 7.0 Hz, 2H), 1.92 (s, 3H), 1.88-1.96 (m, 1H), 1.74 (s, 3H), 1.50-
1.66 (m, 5H), 1.34-1.44 (m, 2H), 1.16-1.24 (m, 1H), 0.61-1.06 (m, 1H); 13C NMR (125 
MHz, CDCl3) δ 212.4, 174.7, 147.3, 143.5, 138.1, 136.8, 135.0, 129.9, 129.7, 127.0, 
126.5, 123.3, 115.2, 79.9, 53.1, 43.3, 41.3, 35.4, 33.9, 33.0, 26.6, 23.7, 22.6, 21.7, 17.7, 
13.8, 10.6; HRMS (ESI) Calcd. for C31H42NO5S [M+H]: 540.27837. Found: 540.2133. 
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Amide 2-101: A mixture of the Butenolide 2-100 (15.0 mg, 0.078 mmol) and β-alanine 
ethylester (120 mg, 0.78 mmol) was dissolved in Et3N (0.3 mL). The reaction mixture 
was stirring for 12h at 40 oC. The volatiles were evaporated and the residue was purified 
by flash chromatography (20%→30%→40% EtOAc/hexanes) to afford 11 mg (46%) of 
the desired product as a colorless oil. Rf = 0.45 (40% EtOAc/hexanes); 1H NMR (500 
MHz, CDCl3) δ 6.29 (s, 1H), 4.16 (q, J = 8.0 Hz, 2H), 3.49 (dd, J = 12.0, 6.0 Hz, 2H), 
3.00 (dd, J = 18.0, 8.5 Hz, 1H), 2.74-2.82 (m, 1H), 2.48 (ddd, J = 8.0 6.0, 4.0 Hz, 2H), 
2.44 (d, J = 4.5 Hz, 1H), 2.14-2.28 (m, 2H), 2.07 (br s, 2H), 1.81 (s, 3H), 1.56-1.62 (m, 
4H), 1.46 (s, 3H), 1.27 (s, 3H), 1.47 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 
205.0, 175.9, 172.5, 141.0, 132.6, 45.5, 35.9, 34.8, 34.1, 33.0, 28.0, 26.4, 21.6, 17.8, 14.2, 
9.7; HRMS (ESI) Calcd. for C17H28NO4 [M+H]: 310.20183. Found: 310.1960. 
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Amide 2-103: A mixture of the Butenolide 2-100 (11.0 mg, 0.0204 mmol) and β-alanine 
ethylester (31 mg, 0.202 mmol) was dissolved in Et3N (0.3 mL). The reaction mixture 
was stirring for 12h at 40 oC. The volatiles were evaporated and the residue was passed 
through a short pad of SiO2 flushing with EtOAc. The crude was dissolved in acetic 
acid/H2O (1:1, 0.6 mL) at room temperature and the reaction mixture was stirred at room 
temperature for 18 h and the aqueous layer was extracted with EtOAc and the combined 
organic layers were concentrated in vacuo. The residue was purified by flash 
chromatography (40%→70%→100% EtOAc/hexanes) to afford the inseparable mixture 
of amide 2-103 6 mg (45%) as a colorless oil. Rf = 0.28 (40% EtOAc/hexanes); Key 1H 
NMR signals; 1H NMR (500 MHz, CDCl3) δ 7.70 (d, J = 14.0 Hz, 2H), 7.29 (d, J = 13.5 
Hz, 2H), 6.25 (t, J = 6.0 Hz, 1H), 5,73-5.79 (m, 1H), 5.60-5.70 (m, 1H), 4.98-5.08 (m, 
3H), 4.26 (t, J = 6.5 Hz, 1H), 4.15 (q, J = 7.5 Hz, 1H), 3.49 (dd, J = 12.0, 6.0 Hz, 1H), 
3.44 (d, J = 10.5 Hz, 1H), 2.96 (dd, J = 18.0, 9.0 Hz, 1H), 2.81 (dd, J = 13.0, 6.5 Hz, 2H), 
2.66-2.71 (m, 1H), 2.50 (t, J = 6.5 Hz, 2H), 2.34-2.48 (m, 4H), 2.45 (s, 3H), 2.18-2.28 
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(m, 1H), 1.96-2.16 (m, 3H), 1.77 (s, 3H), 1.74 (d, J = 7.0 Hz, 3H), 1.59-1.64 (m, 4H), 
1.36-1.48 (m, 3H), 1.27 (t, J = 7.5 Hz, 3H), 1.11 (d, J = 7.0 Hz, 3H); Key 13C NMR 
signals; 13C NMR (125 MHz, CDCl3) δ 212.6, 205.2, 175.7, 172.5, 143.4, 141.3, 138.0, 
136.8, 131.6, 129.7, 128.1, 127.2, 127.0, 115.2, 60.6, 53.0, 45.8, 43.3, 35.9, 35.4, 34.8, 
34.0, 33.6, 33.0, 26.3, 24.4, 23,7, 22.7, 21.5, 20.2, 17.9, 14.1, 13.8; HaRMS (ESI) Calcd. 
for C36H53N2O7S [M+H]: 657.35735. Found: 657.3439. 
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Furan 2-104: To a solution of Tosylamine 2-103 (28 mg, 0.0426 mmol) in THF (4 mL) 
was added triethylamine (0.12 mL, 0.852 mmol) and trifluoroacetic anhydride (0.072 mL, 
0.512 mmol) at 0 oC. After stirring for 15 min, samarium iodide (0.1 M in THF) was 
added until the mixture stayed blue (totally about 5 mL, 0.5 mmol). The mixture was 
stirred for 5 min, diluted with CH2Cl2, and quenched with 10% sodium thiosulfate 
solution. The aqueous layer was extracted with Et2O, and the combined organic layers 
were dried (MgSO4), concentrated in vacuo and purified by flash chromatography (10% 
→ 30% EtOAc/Hexanes) to afford 21 mg (73%) of the desired product as a slightly 
yellow oil. Rf = 0.53 (30% EtOAc/hexanes); [α]19D + 196.4 (c 0.6, CHCl3);  1H NMR 
(500 MHz, CDCl3) δ 6.25 (s, 1H), 6.03 (s, 1H), 5.71-5.80 (m,1H), 5.70 (dq, J = 11.0, 7.0 
Hz 1H), 5.17 (ddq, J = 11.0, 11.0, 2.0 Hz, 1H), 4.96-5.02 (m, 2H), 4.10 (q, J = 7.0 Hz, 
2H), 3.96 (t, J = 7.0 Hz, 2H), 3.58 (d, J = 10.5 Hz, 1H), 3.21-3.32 (m, 2H), 2.61 (t, J = 
7.5 Hz, 2H), 2.43-2.54 (m, 3H), 2.31-2.41 (m, 1H), 2.00-2.19 (m, 3H), 2.19-2.01 (m, 3H), 
1.90 (s, 3H), 1.88 (s, 3H), 1.72-1.81 (m, 1H), 1.82 (dd, J = 7.0, 1.5 Hz, 3H) 1.52-1.68 (m, 
1H), 1.48- 1.52 (m, 2H), 1.16,-1.41 (m, 1H), 1.24 (t, J = 7.0 Hz, 3H); 13C NMR (125 
MHz, CDCl3) δ 212.9, 170.5, 158.2 (q, J = 36.0 Hz), 157.2 (q, J = 36.6 Hz), 152.5, 138.0, 
137.6, 135.2, 128.6, 126.7, 120.0, 117.5,  115.8 (q, J = 286.1 Hz), 115.2, 115.7 (q, J = 
286.5 Hz), 111.0, 60.9, 53.1, 45.9, 42.2, 40.0, 35.6, 34.0, 33.0, 32.3, 26.5, 24.8, 23.3, 
22.6, 20.4, 14.1, 13.9, 9.5; HRMS calcd for C33H42F6N2NaO6 [M+Na]: 699.28448. 
Found: 699.2344. 
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Boc amine 2-107: To a solution of the trifluoroacetamide 2-104 (18 mg, 0.0228 mmol) 
was added Et3N (110 µL), DMAP (10 mg) and a solution of (Boc)2O (50 mg, 0.228 
mmol) in CH2Cl2 (1.2 mL) at room temperature. After 25 min, TLC indicated the starting 
material was completely converted to a new intermediate (Rf = 0.63, 30% 
EtOAc/hexanes). Hydrazine hydrate (50 µL) was added and the cloudy reaction mixture 
was stirred at room temperature for 5 min (TLC indicated the complete hydrolysis of this 
intermediate). The mixture was then quenched with saturated NH4Cl solution. The 
aqueous layer was extracted with EtOAc and the combined organic layers were 
concentrated in vacuo and purified by flash chromatography (10%→20%→30% 
EtOAc/hexanes) to provide 13 mg (84%) of the desired Boc amine 2-107 as a colorless 
oil. Rf = 0.53 (30% EtOAc/hexanes); [α]19D + 161.5 (c 1.2, CHCl3);  1H NMR (500 MHz, 
CDCl3) δ  6.02 (s, 1H), 5.70-5.81 (m,1H), 5.67 (dq, J = 11.0, 7.0 Hz 1H), 5.15 (t, J = 11.0 
Hz, 1H), 4.96-5.02 (m, 2H), 4.10 (q, J = 7.5 Hz, 2H), 3.96 (t, J = 7.5 Hz, 2H), 3.70 (d, J = 
10.5 Hz, 1H), 2.84-3.15 (m, 2H), 2.60 (t, J = 7.5 Hz, 2H), 2.40-2.54 (m, 3H), 2.28-2.38 
(m, 1H), 2.00-2.18 (m, 4H), 1.90 (s, 3H), 1.72-1.84 (m, 3H), 1.88 (s, 3H), 1.82 (dd, J = 
7.0, 1.5 Hz, 3H), 1.42- 1.52 (m, 2H), 1.44 (s, 9H), 1.16,-1.31 (m, 1H), 1.23 (t, J = 7.5 Hz, 
3H); 13C NMR (125 MHz, CDCl3) δ 213.0, 170.4, 158.2 (q, J = 36.1 Hz), 155..8, 152.7, 
138.1, 137.5, 135.5, 128.6, 126.6, 119.8, 117.4, 116.8 (q, J = 287.0 Hz), 110.9, 79.1, 
60.9, 53.3, 45.9, 42.4, 40.7, 35.5, 34.3, 33.1, 32.3, 29.7, 28.4, 28.3, 28.1, 26.5, 24.9, 24.4, 
22.7, 20.4, 14.1, 13.9, 9.5; HRMS (MALDI) calcd for C36H51F3N2NaO7 [M+Na]: 
703.35461. Found: 703.3273. 
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Spirocyclic imine 2-108: To a solution of the Boc amine 26 (13.0 mg) in CH2Cl2 (0.8 
mL) was added trifluoroacetic acid (200 µL). After 30 min, the reaction was quenched by 
careful addition of solid NaHCO3 (320 mg). After stirring for 5 min, saturated NaHCO3 
(1 mL) was added. The mixture was extracted with EtOAc/CH2Cl2 (5:1, 1.5 mL) for 6 
times. The combined organic layers were concentrated in vacuo and purified by flash 
chromatography (basic Al2O3, CH2Cl2→10% MeOH/CH2Cl2) to provide a primary amine 
(Rf = 0.13, 7% MeOH/CH2Cl2). Upon standing under high vacuum for 10 h, this amine 
cyclized to provide 7.1 mg (66%) of the free base of gymnodimine as a colorless oil. Rf = 
0.32 (7% MeOH/CH2Cl2); [α]19D + 59.0 (c 0.71, CHCl3); 1H NMR (500 MHz, CDCl3) δ 
6.10 (s, 1H), 5.76-5.82 (m,1H), 5.69 (dq, J = 11.0, 7.0 Hz 1H), 5.30 (ddq, J = 11.0, 11.0, 
1.5 Hz, 1H), 5.03 (dd, J = 12.0, 1.5 Hz 1H), 4.96 (dd, J = 11.5, 2.0 Hz 1H), 4.12 (q, J = 
7.5 Hz 1H), 3.99 (t, J = 7.5 Hz, 2H), 3.51-3.61 (m, 2H), 3.54 (d, J = 11.0 Hz, 1H), 2.64 (t, 
J = 7.5 Hz, 2H), 2.36-2.49 (m, 1H), 2.26-2.36 (m, 3H), 2.18-2.24 (m, 1H), 1.99-2.11 (m, 
2H),1.84-1.98 (m, 2H), 1.95 (s, 3H), 1.72-1.84 (m, 2H), 1.80 (s, 3H), 1.69 (dd, J = 7.0, 
1.5 Hz, 3H), 1.51-1.71 (m, 2H), 1.21-1.39 (m, 1H), 1.26 (t, J = 7.5 Hz, 3H); 13C NMR 
(125 MHz, CDCl3) δ 174.7, 170.5, 158.2 (q, J = 36.3 Hz), 152.7, 138.8, 137.7, 134.5, 
129.2, 127.0, 121.1, 117.5, 115.7 (q, J = 287.1 Hz), 114.6, 111.0, 60.9, 49.4, 45.9, 45.0, 
41.3, 33.9, 33.4, 32.3, 31.2, 29.7, 26.8, 26.5, 24.0, 19.9, 19.8, 14.1, 13.6; IR (thin film): 
1738, 1720, 1643 cm-1; HRMS (ESI) Calcd. for C31H42F3N2NaO4 [M+H]: 563.30967. 
Found: 563.3093. 
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N-Tosyl amine 2-69: Known macro cyclic amine 2-69 was prepared via Barbier-type 
coupling protocol, which was developed in our laboratory as colorless foam. Rf = 0.30 
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(20% EtOAc/hexanes); [α]20D + 20.2 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.76 
(d, J = 8.0 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 5.01 (br t, J = 5.0 Hz, 1H), 4.94 (dd, J = 
11.5 Hz, 1.5 Hz, 1H), 4.86 (t, J = 5.5 Hz, 1H, NH), 4.09 (m, 1H), 3.99 (br s, 1H), 3.84 
(dd, J = 3.5 Hz, 11.5 Hz, 1H), 3.68 (d, J = 11.5 Hz, 1H), 2.94 (m, 2H), 2.74 (ddd, J = 3.0 
Hz, 12.5 Hz, 19.0 Hz, 1H), 2.61 (ddd, J = 3.0 Hz, 3.0 Hz, 19.0 Hz, 1H), 2.44 (s, 3H), 2.21 
(m, 2H), 2.10-1.96 (m, 5H), 1.82 (m, 1H), 1.73 (m, 2H), 1.69 (d, J = 1.5 Hz, 3H), 1.66-
1.56 (m, 2H), 1.53 (s, 3H), 1.50 (m, 3H), 1.46 (s, 3H), 1.41 (m, 2H), 1.11 (d, J = 7.0 Hz, 
3H), 0.96 (s, 9H), 0.86 (s, 9H), 0.142 (s, 3H), 0.135 (s, 3H), 0.05 (s, 3H), 0.01 (s, 3H); 
13C NMR (125 MHz, CDCl3) δ 213.1, 143.1, 143.0, 140.5, 136.8, 135.5, 129.5, 127.2, 
123.8, 122.6, 111.9, 89.1, 79.4, 78.1, 53.3, 45.4, 43.7, 37.6, 36.9, 34.6, 32.9, 32.1, 28.8, 
27.3, 25.8, 25.6, 24.6, 23.4, 21.5, 20.6, 20.0, 18.1, 18.0, 14.2, 13.8, 10.7, -3.6, -3.8, -4.76, 
-4.82; IR (thin film): 3281, 1701, 1683 cm-1; HRMS (ESI) Calcd. for C46H77NO6SSi2Li 
[M+Li]: 834.5170. Found: 834.5163. 
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Macrocyclic ketone 2-86: To a solution of macrocycle 2-69 (37 mg, 0.0447 mmol) in 
THF/EtOH (1:1, 4 mL) at 23 oC was added pyridinium p-toluenesulfonate (23 mg, 0.0893 
mg). The reaction mixture was stirred at 23 oC for 48 h and quenched by saturated 
NaHCO3 solution. The aqueous layer was extracted with Et2O and the combined organic 
layers were concentrated in vacuo. The residue was purified by flash chromatography 
(40%→70%→100% EtOAc/hexanes) to afford 17 mg (53%) of the ketone 2-86 as a 
colorless oil, 14 mg (~34%) of the silyl enolether 2-87 and the recovered starting material 
of 2-86. Rf = 0.25 (30% EtOAc/hexanes); [α]21D –47.4 (c 0.75, CHCl3); 1H NMR (500 
MHz, CDCl3) δ 7.76 (d, J = 8.5 Hz, 2H), 7.31 (d, J = 8.5 Hz, 2H), 4.97-4.99 (m, 2H), 
4.86 (br t, J = 5.5 Hz, 1H), 4.06-4.11 (m, 1H), 3.97 (br s, 1H), 3.81 (dd, J = 11.5 Hz, 3.0 
Hz, 1H), 3.02 (dd, J = 13.0 Hz, 1.5 Hz, 1H), 3.02 (dd, J = 11.0 Hz, 11.0 Hz, 1H), 2.56-
2.68 (m, 2H), 2.44 (s, 3H), 2.41 (dt, J = 14.5 Hz, 3.5 Hz, 1H), 2.17-2.37 (m, 2H), 2.15-
2.19 (m, 3H), 1.92-2.15 (m, 6H), 1.65-1.72 (m, 3H), 1.63 (s, 3H), 1.51 (s, 3H), 1.28-1.56 
(m, 3H), 1.11 (d, J = 7.0 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 0.92-1.06 (m, 1H), 0.85 (s, 
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9H), 0.04 (s, 3H), -0.01 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 211.4, 210.1, 143.4, 
141.2, 136.9, 129.7, 127.1, 123.0, 122.2, 89.1, 79.5, 78.0, 54.4, 50.4, 46.1, 43.6, 37.6, 
37.3, 37.0, 34.7, 32.8, 32.4, 31.3, 25.6, 24.5, 23.2, 21.5, 20.6, 20.0, 18.0, 14.2, 11.7, 11.1, 
-4.7, -4.8; IR (thin film): 3278, 1738, 1706 cm-1; HRMS (ESI) Calcd. for C40H63LiNO6 
[M+Li]: 720.43054. Found: 720.4333. 
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Tertiary alcohol 2-89a: To a solution of alkyl bromide (102 mg, 0.392 mmol) in Et2O 
(2.5 mL) at -78 ºC was added t-BuLi (1.68 M in pentane, 0.45 mL, 0.784 mmol) 
dropwise. After stirring for 10 min, a solution of olefin 2-86  (35 mg, 0.376 mmol) in 
THF (3 x 0.8 mL) was added. The reaction mixture was stirred at -78 ºC for 1 h, warmed 
to room temperature. The reaction was quenched by pH 7 buffer. The aqueous layer was 
extracted with Et2O, and the combined organic layers were dried (MgSO4), concentrated 
in vacuo and purified by flash chromatography (20% → 30% EtOAc/Hexanes) to afford 
two diastereomers 2-89a (less polar, ~22 mg, 50% yield) and 2-89c (more polar, ~9 mg, 
15% yield), respectively. 2-89a: Rf = 0.22 (40% EtOAc/hexanes); 1H NMR (500 MHz, 
CDCl3) δ 7.75 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 7.27 (d, J = 8.0 Hz, 2H), 6.88 
(d, J = 8.0 Hz, 2H), 5.0 (br s, 1H), 4.87 (t, J = 5.5 Hz, 1H), 4.86 (d, J = 11.5 Hz, 1H), 
4.49 (dd, J = 11.5, 6.5 Hz, 2H), 4.06-4.11 (m, 1H), 3.97 (br s, 1H), 3.80 (dd, J = 12.5 Hz, 
3.0 Hz, 1H), 3.80 (s, 3H), 3.50-3.58 (m, 2H), 2.88-3.00 (m, 2H), 2.71 (dd, J = 11.0, 11.0 
Hz, 1H), 2.62 (dd, J = 5.0 Hz, 5.0 Hz, 1H), 2.43 (s, 3H), 2.16-2.26 (m, 2H), 1.96-2.05 (m, 
2H), 1.78-1.94 (m, 3H), 1.44-1.78 (m, 9H), 1.65 (s, 3H), 1.52 (s, 3H), 1.17-1.48 (m, 8H), 
1.10 (d, J = 7.5 Hz, 3H), 0.85 (s, 9H), 0.83 (d, J = 6.5 Hz, 3H), 0.043 (s, 3H), -0.004 (s, 
3H); 13C NMR (125 MHz, CDCl3) δ 213.1, 159.2, 143.2, 139.6, 136.9, 135.5, 129.6, 
129.3, 127.2, 124.0, 122.6, 113.8, 113.8, 89.1, 79.8, 78.1, 72.8, 71.6, 70.4, 59.3, 54.6, 
43.6, 43.6, 43.4, 39.1, 38.6, 37.6, 37.1, 34.5, 32.8, 32.5, 31.7, 26.0, 25.6, 24.2, 24.1, 22.5, 
21.5, 20.7, 20.0, 18.0, 14.2, 11.2, 11.0, -4.65, -4.80; IR (thin film): 3520, 3275, 1700, 
1614 cm-1; HRMS (MALDI) Calcd. for C51H79NNaO8SSi [M+Na]: 916.51934. Found: 
916.6692. 
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2-89c: Rf = 0.20 (40% EtOAc/hexanes); 1H NMR (500 MHz, CDCl3) δ 7.75 (d, J = 8.0 
Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 7.27 (d, J = 8.5 Hz, 2H), 6.89 (d, J = 8.5 Hz, 2H), 5.01 
(br s, 1H), 4.88 (t, J = 5.5 Hz, 1H), 4.83 (d, J = 12.0 Hz, 1H), 4.46 (br s, 2H), 4.06-4.12 
(m, 1H), 3.98 (br s, 1H), 3.77-3.84 (m, 1H), 3.82 (s, 3H), 3.41-3.51 (m, 2H), 2.87-2.98 
(m, 2H), 2.74 (dd, J = 9.0, 3.0 Hz, 1H), 2.58-2.78 (m, 1H), 2.43 (s, 3H), 2.14-2.26 (m, 
3H), 1.94-2.06 (m, 2H), 1.66-1.88 (m, 2H), 1.65 (s, 3H), 1.60 (s, 3H), 1.49-1.65 (m, 3H), 
1.52 (s 3H), 1.36-1.48 (m, 4H), 1.28-1.36 (m, 2H), 1.16-1.23 (m, 1H), 1.10 (d, J = 6.5 
Hz, 3H), 0.85 (s, 9H), 0.84 (d, J = 7.0 Hz, 3H), 0.042 (s, 3H), -0.005 (s, 3H); 13C NMR 
(125 MHz, CDCl3) δ 213.9, 159.2, 143.1, 139.9, 136.9, 135.3, 130.2, 129.6, 129.3, 127.2, 
124.8, 122.9, 113.8, 89.1, 79.9, 78.1, 73.1, 72.8, 71.6, 70.4, 59.3, 54.6, 45.8, 43.6, 43.2, 
37.5, 37.1, 34.4, 32.9, 32.4, 31.7, 28.3, 28.2, 25.7, 24.2, 23.4, 23.0, 21.5, 20.6, 20.0, 18.0, 
14.2, 11.5, 11.3, -4.7, -4.8. 
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Olefin 2-90a: To a solution of Tertiary alcohol 2-89a (9.8 mg, 0.0011 mmol, 
azeotropically dried with PhMe) in CH2Cl2 (1 mL) at -78 ºC was added 15 µL of Et3N 
followed by 25 µL of a solution of SOCl2 (16 µL) in CH2Cl2 (0.1 mL). The reaction 
mixture was stirred at -78 ºC for 1 h and quenched by pH 7 buffer. The aqueous layer was 
extracted with CH2Cl2 and the combined organic layers were concentrated in vacuo. The 
residue was purified by flash chromatography (20% EtOAc/hexanes) to afford 7.9 mg 
(82%) of olefin 2-90a as a colorless oil; Rf = 0.58 (40% EtOAc/hexanes); [α]21D –77.4 (c 
0.59, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.75 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 8.0 
Hz, 2H), 7.28 (d, J = 8.0 Hz, 2H), 6.88 (d, J = 8.0 Hz, 2H), 5.21 (t, J = 7.0 Hz, 1H), 4.99 
(br s, 1H), 4.94 (d, J = 11.0 Hz, 1H), 4.85 (t, J = 5.5 Hz, 1H), 4.47 (s, 2H), 4.06-4.12 (m, 
1H), 3.97 (br s, 1H), 3.77-3.85 (m, 1H), 3.81 (s, 3H), 3.42-3.50 (m, 2H), 2.93-3.00 (m, 
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2H), 2.55-2.64 (m, 2H), 2.51 (t, J = 11.0 Hz, 1H), 2.43 (s, 3H), 2.30-2.42 (m, 2H), 2.15-
2.23 (m, 2H), 1.90-2.03 (m, 2H), 1.56-1.75 (m, 4H), 1.62 (s, 3H), 1.60 (s, 3H), 1.42-1.55 
(m, 3H), 1.51 (s, 3H), 1.34-1.42 (m, 2H),1.16-1.28 (m, 1H), 1.10 (d, J = 7.0 Hz, 3H), 
0.97 (s, 3H), 0.86 (s, 9H), 0.05 (s, 3H), 0.01 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 
213.1, 159.1, 143.2, 142.5, 139.9, 136.9, 135.4, 130.6, 130.6, 129.6, 129.6, 129.2, 127.2, 
125.0, 122.8, 116.7, 113.7, 89.1, 79.9, 78.1, 72.6, 69.9, 55.3, 55.2, 50.4, 43.7, 37.9, 37.6, 
37.1, 34.4, 32.9, 32.7, 32.5, 28.2, 25.7, 24.6, 24.3, 23.4, 21.5, 20.6, 20.0, 18.0, 15.0, 14.2,  
11.2, -4.65, -4.80; IR (thin film): 3520, 3275, 1700, 1614 cm-1; LRMS (MALDI) Calcd. 
for C51H77NNaO7SSi [M+Na]: 898.50877. Found: 898.7725. 
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Trifluoroacetamide 2-91: To a solution of the tosylamine 2-90a (10.2 mg, 0.0116 
mmol) in CH2Cl2 (2 mL) at 0 ºC was added triethylamine (33 µL, 0.233 mmol) and 
trifluoroacetic anhydride (20 µL, 0.139 mml). After stirring at 0 ºC for 15 min, SmI2 (0.1 
M in THF) was added until the intermediate disappeared as monitored by TLC (ca. 1.2 
ml of SmI2 solution was added). The reaction mixture was stirred for additional 5 min 
and quenched by half saturated Na2S2O3 solution (0.3 mL). The aqueous layer was 
extracted with Et2O and the organic layers were concentrated in vacuo and purified by 
flash chromatography (5%→10%→15% EtOAc/hexanes) to afford 7 mg (74%) of the 
desired product as a colorless oil. Rf = 0.35 (20% EtOAc/hexanes); [α]21D –95.4 (c 0.79, 
CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.43 (br s, 1H), 7.28 (d, J = 8.5 Hz, 2H), 6.89 (d, 
J = 8.5 Hz, 2H), 5.24 (t, J = 7.0 Hz, 1H), 4.98 (d, J = 11.0 Hz, 1H), 3.81 (br s, 1H), 3.45-
3.50 (m, 2H), 3.34-3.40 (m, 2H), 2.62-2.69 (m, 2H), 2.56 (t, J = 11.0 Hz, 1H), 2.33-2.46 
(m, 2H), 2.12-2.24 (m, 3H), 1.94-2.06 (m, 4H), 1.74-1.82 (m, 3H), 1.62-1.73 (m, 4H), 
1.64 (s, 3H), 1.51 (s, 3H), 1.38-1.49 (m, 3H), 1.25-1.36 (m, 4H), 1.26 (s, 3H), 1.10 (d, J = 
7.0 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 0.86 (s, 9H), 0.04 (s, 3H), 0.004 (s, 3H); 13C NMR 
(125 MHz, CDCl3) δ 214.3, 162.4 (COCF3, q, J = 37 Hz), 159.2, 142.4, 140.2, 135.6, 
130.6,129.7, 12.8, 122.7, 120.8 (CF3, q, J = 287 Hz), 116.9, 113.7, 89.1, 79.8, 78.1, 72.6, 
69.9, 55.7, 50.4, 40.5, 38.0, 37.5, 36.7, 34.5, 32.8, 32.7, 32.2, 29.7, 28.2, 25.7, 24.7, 23.3, 
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23.1, 20.6, 19.9, 18.0, 15.0, 14.2, 11.2, -4.68, -4.84; IR (thin film): 3313, 1726, 1614 cm-
1; HRMS (MALDI) Calcd. for C46H70F3NNaO7SSi [M+Na]: 840.48222. Found: 
840.6652. 
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Enone 2-92: To a mixture of the PMB ether 2-91 (8.1 mg, 0.010 mmol) in CH2Cl2/H2O 
(3:1 0.4 mL) at 0 ºC was added dichloro-dicyanbenzoquione (DDQ) (36 mg, 0.16 mmol) 
in four portions. The mixture was stirred room temperature for 10 h and diluted with 
saturated NaHCO3. The aqueous layer was extracted with CH2Cl2 and the organic layers 
were concentrated in vacuo and purified by flash chromatography (10%→30% 
EtOAc/hexanes) to afford 5.5 mg (80%) of the desired product as a colorless oil. Rf = 
0.11 (25% EtOAc/hexanes); δ 7.30 (s, 1H), 7.09 (t, J = 7.5 Hz, 2H), 5.25 (t, J = 7.5 Hz, 
1H), 4.99 (d, J = 11.0 Hz, 1H), 3.84 (dd, J = 9.0, 5.5 Hz, 1H), 3.64-3.71 (m, 2H), 3.36-
3.48 (m, 2H), 3.03 (dt, J = 19.0, 4.0 Hz, 1H), 2.71 (d, J = 11.0 Hz, 1H), 2.45-2.52 (m, 
1H), 2.28-2.42 (m, 6H), 2.12-2.18 (m, 1H), 1.88-2.11 (m, 3H), 1.72-1.84 (m, 3H), 1.75 
(s, 3H), 1.54-1.72 (m, 2H), 1.36-1.48 (m, 3H), 1.39 (s, 3H), 1.21-1.35 (m, 3H), 1.06 (d, J 
= 6.5 Hz, 1H), 0.96-1.04 (m, 1H), 0.99 (d, J = 6.5 Hz, 3H), 0.84 (s, 9H), 0.025 (s, 3H), -
0.019 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 214.9, 207.4, missed (COCF3), 143.3, 
141.7, 140.6, 137.7, 124.9, 116.8, missed (CF3), 80.0, 69.6, 62.6, 55.6, 49.5, 41.8, 40.5, 
38.3, 35.4, 35.0, 32.7,31.4, 31.0, 30.8, 25.7, 24.5, 23.8, 23.4, 22.8, 19.0, 18.0, 15.3, 11.4, 
11.2, -4.56, -4.84; IR (thin film): 3313, 1726, 1614 cm-1; HRMS (MALDI) Calcd. for 
C38H62F3NNaO6Si [M+Na]: 736.41962. Found: 736.6912. 
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Macrocyclic ketone 2-111: To a solution of macrocycle 2-69 (82 mg, 0.0995 mmol) in 
THF/CH2Cl2/MeOH (1:1:1, 9.0 mL) at 23 oC was added p-toluenesulfonic acid 
monohydrate (38 mg, 0.199 mL). The reaction mixture was stirred at 23 oC for 2.5 h and 
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quenched by saturated NaHCO3 solution. The aqueous layer was extracted with CH2Cl2 
and the combined organic layers were concentrated in vacuo. The residue was purified by 
flash chromatography (30%→40%→50% EtOAc/hexanes) to afford 44 mg (74%) of the 
ketone 2-111 as a white foam. Rf = 0.42 (70% EtOAc/hexanes); [α]20D –42.9 (c 1.4, 
CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.75 (d, J = 8.0 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 
5.12 (d, J = 11.0 Hz, 1H), 4.96 (t, J = 5.5 Hz, 1H), 4.94 (t, J = 5.5 Hz, 1H), 4.06-4.11 (m, 
1H), 3.97 (br s, 1H), 2.96-3.08 (m, 2H), 2.93 (dd, J = 11.5 Hz, 11.5 Hz, 1H), 2.58-2.65 
(m, 2H), 2.43 (s, 3H), 2.38-2.42 (m, 2H), 2.35-2.37 (m, 1H), 2.26-2.34 (m, 1H), 2.14, 
2.24 (m, 2H), 2.09-2.14 (m, 2H), 2.02-2.08 (m, 1H), 1.94-2.00 (m, 3H), 1.66 (s, 3H), 1.51 
(s, 3H), 1.35-1.43 (m, 1H), 1.29-1.39 (m, 1H), 1.10 (d, J = 7.0 Hz, 3H), 0.94-1.10 (m, 
1H), 0.99 (d, J = 6.5 Hz, 1H); IR (thin film): 3414, 1732, 1643 cm-1; HRMS (MALDI) 
Calcd. for C34H49NNaO6S [M+Na]: 622.31783. Found: 622.1585. 
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TES ether butenolides 2-113: A mixture of the ketone 2-111 (44 mg, 0.073 mmol) and 
silyloxyfuran 2-71 (187 mg, 0.73 mmol) was azeotropically dried with PhMe and 
dissolved in CH2Cl2 (4 mL). To this vigorously stirred solution was added TiCl4 (1.0 M 
in CH2Cl2, 183 µL) at 23 oC dropwise over 60 s. The cloudy yellow reaction mixture was 
stirred for an additional 30 s and quickly quenched by saturated NH4Cl solution. The 
mixture was extracted with Et2O and the combined organic layers were concentrated in 
vacuo. The residue was purified by flash chromatography (40→70→100% 
EtOAc/hexanes) to afford 24 mg (47%) of the hydroxy butenolides 2-112a/b as a white 
foam and as a mixture of two inseparable diastereomers (dr = 1:1, epimeric at C4). Rf = 
0.16 (70% EtOAc/hexanes). 
Butenolides 2-112a and 2-112b (24 mg, 0.0344 mmol) as a mixture of diastereomers, 
imidazole (47 mg, 0.688 mmol) and DMAP (10 mg, 0.082 mmol) were azeotropically 
dried with PhMe. The mixture was dissolved in CH2Cl2 (3 mL) and at 23 oC was treated 
with TESCl (58 µL, 0.344 mmol). A white precipitate formed immediately. The reaction 
mixture was stirred at 23 oC for 5 min and then quenched by saturated NaHCO3 solution. 
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The aqueous layer was extracted with Et2O and the combined organic layers were 
concentrated and purified by flash chromatography (10→20→30% EtOAc/hexanes) to 
afford 11 mg (39%) of TES ether butenolide 2-113a and 10 mg (36%) of the C-4 epimer 
2-113b, respectively. 
Me
Me
OTES
O
Me
Me
O
NHTs
OH
O
O
Me
H
 
butenolide 2-113a: Rf = 0.15 (40% EtOAc/hexanes); 1H NMR (500 MHz, CDCl3) δ 7.75 
(d, J = 8.0 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 7.21 (s, 1H), 5.01 (t, J = 5.0, 1H), 4.93 (s, 
1H), 4.83 (d, J = 11.0 Hz, 1H), 4.07-4.12 (m, 1H), 3.98 (br s, 1H), 3.82 (dd, J = 11.5, 3.0 
Hz, 1H), 2.91-2.98 (m, 2H), 2.90 (dd, J = 11.0, 11.0 Hz, 1H), 2.82-2.90 (m, 1H), 2.63-
2.75 (m, 2H), 2.45 (s, 3H), 2.17-2.26 (m, 2H), 2.07-2.15 (m, 2H), 1.89-2.04 (m, 3H), 1.97 
(s, 3H), 1.69-1.79 (m, 2H), 1.67 (s, 3H), 1.54-1.65 (m, 3H), 1.52 (s, 3H), 1.42-1.50 (m, 
3H), 1.22-1.37 (m, 4H), 1.27 (d, J = 7.5 Hz, 3H), 1.10 (d, J = 7.5 Hz, 3H), 0.96 (t, J = 8.0 
Hz, 9H), 0.52-0.62 (m, 6H); 13C NMR (125 MHz, CDCl3) δ 212.8, 173.9, 147.0, 143.2, 
141.0, 136.7, 135.5, 131.1, 129.6, 127.2, 124.2, 122.6, 89.2, 83.2, 79.8, 78.1, 73.8, 54.5, 
43.3, 37.6, 37.1, 36.6, 34.6, 32.0, 32.6, 31.6, 26.5, 24.1, 22.6, 22.3, 20.7, 20.0, 14.2, 11.3, 
11.0, 10.8, 6.9, 5.0.  
Me
Me
OTES
O
Me
Me
O
NHTs
OH
O
O
Me
H
 
Diastereomeric butenolide 2-113b: Rf = 0.3 (40% EtOAc/hexanes); 1H NMR (500 
MHz, CDCl3) δ 7.73 (d, J = 8.0 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 7.08 (s, 1H), 5.15 (s, 
1H), 5.01 (s, 1H), 4.86 (d, J = 11.0 Hz, 1H), 4.76 (t, J = 5.5 Hz, 1H), 4.04-4.12 (m, 1H), 
3.97 (s, 1H), 3.82 (dd, J = 11.5, 3.0 Hz, 1H), 3.09 (dd, J = 11.0, 11.0 Hz, 1H), 2.91-2.98 
(m, 2H), 2.90 (dd, J = 11.0, 11.0 Hz, 1H), 2.87-2.98 (m, 2H), 2.67-2.79 (m, 2H), 2.44 (s, 
3H), 2.17-2.24 (m, 3H), 2.17-2.24 (m, 3H), 1.96-2.04 (m, 2H), 2.00 (s, 3H), 1.86-1.92 
(m, 2H), 1.69 (s, 3H), 1.58- 1.74 (m, 4H), 1.69 (s, 3H), 1.60-1.67 (m, 3H), 1.51 (s, 3H), 
1.45-1.54 (m, 1H), 1.36-1.44 (m, 3H), 1.19-1.32 (m, 3H), 1.03 (d, J = 7.0 Hz, 3H), 0.94 
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(t, J = 7.5 Hz, 9H), 0.52-0.65 (m, 6H); 13C NMR (125 MHz, CDCl3) δ 212.8, 173.9, 
147.0, 143.2, 141.0, 136.7, 135.5, 131.1, 129.6, 127.2, 124.2, 122.6, 89.2, 83.2, 79.8, 
78.1, 73.8, 54.5, 43.3, 37.6, 37.1, 36.6, 34.6, 32.0, 32.6, 31.6, 26.5, 24.1, 22.6, 22.3, 20.7, 
20.0, 14.2, 11.3, 11.0, 10.8, 6.9, 5.0. 
Me
Me
OTES
O
Me
Me
O
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Me  
Olefin 2-114: To a solution of alcohol 2-113b (10 mg, 0.00265 mmol, azeotropically 
dried with PhMe) in CH2Cl2 (1 mL) at -78 ºC was added 25 µL of a solution of SOCl2 (18 
µL) in CH2Cl2 (0.1 mL) followed by 9 µl of Et3N. The reaction mixture was stirred at -78 
ºC for 5 min and quenched by pH 7 buffer. The aqueous layer was extracted with CH2Cl2 
and the combined organic layers were concentrated in vacuo. The residue was purified by 
flash chromatography (10→20% EtOAc/hexanes) to afford 7.8 mg (80%) of the desired 
product 2-114 as a colorless oil. Rf = 0.58 (40% EtOAc/hexanes); [α]19D +36.2 (c 0.75, 
CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.73 (d, J = 8.0 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 
7.01 (s, 1H), 5.85 (s, 1H), 4.98 (d, J = 8.0 Hz, 2H),  4.64 (t, J = 6.0 Hz, 1H), 4.06-4.11 
(m, 1H), 3.98 (s, 1H), 3.87 (dd, J = 12.5, 2.5 Hz, 1H), 3.65 (d, J = 10.5 Hz, 1H ), 2.88-
2.95 (m, 2H), 2.58-2.74 (m, 2H), 2.44 (s, 3H), 2.16-2.28 (m, 2H), 1.97-2.08 (m, 2H), 1.99 
(s, 3H), 1.82-1.97 (m, 4H), 1.66- 1.74 (m, 4H), 1.74 (s, 3H), 1.66-1.78 (m, 4H), 1.59 (s, 
3H), 1.52 (s, 3H), 1.46-1.48 (m, 2H), 1.26-1.38 (m, 3H), 1.10 (d, J = 7.0 Hz, 3H), 0.94 (t, 
J = 7.5 Hz, 9H), 0.52-0.62 (m, 6H); 13C NMR (125 MHz, CDCl3) δ 212.6, 174.6, 147.7, 
143.4, 142.3, 136.8, 135.6, 135.5, 131.0, 129.7, 127.1, 124.9, 122.8, 122.6, 89.1, 79.6, 
79.4, 78.1, 52.8, 47.0, 43.7, 37.6, 37.0, 34.6, 33.1, 32.3, 28.2, 24.4, 23.6, 22.5, 20.6, 20.3, 
20.0, 16.9, 14.2, 11.0, 10.8, 6.9, 5.0. IR (thin film): 3271, 1759, 1700 cm-1; HRMS 
(MALDI) Calcd. for C45H67KNO7SSi [M+K]: 832.40446. Found: 832.4055. 
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Amide 2-115: A mixture of the Butenolide 2-114a (7.0 mg, 0.0088 mmol) and β-alanine 
ethylester (14 mg, 0.088 mmol) was dissolved in Et3N (0.3 ml). The reaction mixture was 
stirring for 12h at 40 oC. The volatiles were evaporated and the residue was purified by 
flash chromatography (20%→30%→40% EtOAc/hexanes) to afford the inseparable 
mixture of amide 2-115 1.4 mg (17%) as a colorless oil. Rf = 0.20 (40% EtOAc/hexanes); 
Key 1H NMR signals; 1H NMR (500 MHz, CDCl3) δ 7.75 (d, J = 8.0 Hz, 2H), 7.31 (d, J 
= 8.0 Hz, 2H), 6.31 (m, 1H), 5,44-5.24 (m, 2H), 5.00 (t, J = 3.5 Hz, 1H), 4.96 (d, J = 11.0 
Hz, 1H), 4.16-4.16 (m, 2H), 4.06-4.14 (m, 1H), 3.98 (s, 1H), 3.87 (dd, J = 11.5, 2.5 Hz, 
1H), 3.05-3.14 (m, 1H), 2.90-3.01 (m, 2H).  
 
Representative Procedure (Method A) as Described for 5-methyl-6-
oxaspiro[bicyclo[3.2.0]heptane-3,2'-[1,3]dioxolan]-7-one (±)-3-24b:  
O
O
Me
H
O
O
 
Pyridinium salt 19b (250 mg, 0.5 mmol, 1.0 equiv) was dissolved in 3 mL of CH2Cl2 and 
4-pyrrolidinopyridine (30 mg, 0.4 mmol, 0.7 equiv) was dissolved in 2 mL of CH2Cl2.  
These solutions were separately transferred to a flame-dried 25 mL round-bottomed flask 
resulting in a white slurry.  Hünig’s base (0.17 mL, 1.0 mmol, 2.0 equiv) was added 
dropwise to the reaction mixture by microliter syringe causing the reaction mixture to 
become a yellowish color.  The reaction mixture was left stirring for 10 minutes to ensure 
a uniform milky slurry and then a solution of keto-acid 23b1 (100 mg, 0.5 mmol, 1.0 
                                                
1 ) Keto acids 3-23b, 3-23c, 3-23d, 3-23e were prepared by (a) alkylation of 
cyclohexanone (Michel, P.; Ivan, J.; Gilbert, R. J. Chem. Soc. Perkin Trans. I. 1993, 
1935-1936.) (b) formation of the corresponding thermodynamic silyl enol ether (Krafft, 
M. E.; Holton, R. A. J. Org. Chem. 1984, 49, 3669-3670.; Behenna, D. C.;  Stoltz, B. 
M. J. Am. Chem. Soc. 2004, 126, 15044-15045.)  and (c) ozonolysis by our previously 
described procedure.  
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equiv) dissolved in 5 mL of CH2Cl2 was added via syringe pump over 1 h.  After 1-2 h, 
the reaction mixture became a homogeneous red solution.  After stirring for a total of 12 
h at 23 oC, the volatiles were removed under reduced pressure to give a dark red residue.  
The crude reaction mixture was then partitioned between aq. NH4Cl and diethyl ether (10 
mL each).  The biphasic mixture was transferred to a 125 mL separatory funnel and the 
organic phase was washed with 10% HCl (1 x 10 mL), aq. NaCl (1 x 10 mL), dried over 
MgSO4, filtered, and concentrated to afford a light red residue that was purified by flash 
chromatography on SiO2 (1:1, hexanes:EtOAc)  to provide cis-β-lactone (±)-24b (71 mg, 
78 %) as a pale yellow oil: Rf 0.68 (1:1, hexanes:EtOAc); IR (thin film) 1815 cm-1; 1H 
NMR (300 MHz, CDCl3) δ 4.01-4.08 (m, 2H), 3.89-3.99 (m, 2H), 3.56 (app d, J = 8.7 
Hz, 1H), 2.03-2.45 (m, 4H), 1.73 (s, 3H).  13C NMR (75 MHz, CDCl3) δ 170.5, 115.8, 
83.7, 65.2, 65.1, 57.2, 44.9, 37.8, 22.8; LRMS (APCI) Calcd for C9H13O4 [M+H]: 185. 
Found: 185.  
Representative Procedure (Method B) as Described for 2-(tert-
butyldimethylsilyloxy)-5-methyl-6-oxabicyclo[3.2.0]heptan-7-one ((±)-3-24f):  
O
O
Me
H
TBSO
 
The pyridinium salt 3-19b (191 mg, 0.55 mmol, 1.5 equiv) and 4-pyrrolidinopyridine (81 
mg, 0.55 mmol, 1.5 equiv) are weighed out and transferred to a flame-dried 25 mL 
round-bottomed flask and dissolved in 6 mL of CH2Cl2.  Hünig’s base (0.16 mL, 0.91 
mmol, 2.5 equiv) was transferred via syringe and then keto-acid 3-23f2 (100 mg, 0.36 
mmol, 1.0 equiv) in 2 mL CH2Cl2 was added via syringe pump over 1 h. The resulting 
dark solution was stirred for another 12 h, at which point the volatiles were removed 
under reduced pressure to give a dark red residue. The crude reaction mixture was diluted 
with CH2Cl2 (10 mL) and washed with aqueous NH4Cl solution (10 mL each).  After 
                                                
2) Keto acids 3-23f were prepared by alkylation of methyl acetoacetate, reduction of the 
resulting β-ketoester with NaBH4, protection of the resulting alcohol as the TBS silyl 
ether, ozonolysis by the previously described procedure and hydrolysis of the methyl 
ester. 
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separating phases, the aqueous phase was back extracted with CH2Cl2 (2 x 10 mL).  The 
combined organics were washed with brine (10 mL), dried over MgSO4, filtered, and 
concentrated to afford a light red residue.  Alternatively, the crude residue could also be 
loaded directly on a silica gel column with minimal loss in yield.  Analysis of the crude 
reaction mixture indicated a diastereomeric ratio of >19:1 (based on unidentified minor 
impurities in the spectrum).  Purification by flash chromatography on SiO2 (9:1, 
hexanes:EtOAc) to give β-lactone (±)-3-24f (63 mg, 68%) as a colorless oil and as a 
single diastereomer (1H NMR): Rf 0.22 (9:1, hexanes:EtOAc); IR (thin film) 1820 cm-1, 
1H NMR (500 MHz, CDCl3) δ 4.47 (d, J = 3.0  Hz, 1H), 3.33 (d, J = 2.0 Hz, 1H), 2.13 
(dd, J = 5.5, 12.0 Hz, 1H), 2.00-2.07 (m, 2H), 1.90 (ddd, J = 1.5, 5.5, 12.0 Hz, 1H), 1.73 
(s, 3H), 0.86 (s, 9H), 0.074 (s, 3H), 0.070 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 168.5, 
87.7, 73.1, 67.7, 33.8, 33.5, 25.6 (3), 21.9, 17.8, −4.9, −5.0; LRMS (ESI) Calcd for 
C13H24LiO3Si [M+Li]: 263. Found: 263.   
O
O
H
Ph  
5-benzyl-6-oxabicyclo[3.2.0]heptan-7-one ((±)-3-24c): Prepared according to the 
representative procedure (Method B) using pyridinium salt 3-19b (240 mg, 0.68 mmol, 
1.5 equiv), 4-pyrrolidinopyridine (100 mg, 0.68 mmol, 1.5 equiv), and Hünig’s base (0.16 
mL, 0.91 mmol, 2.0 equiv) in 6 mL of CH2Cl2.  Keto-acid 3-23c (100 mg, 0.5 mmol, 0.45 
equiv) was dissolved in 2 mL of CH2Cl2. Purification by flash chromatography on SiO2 
(9:1, hexanes:EtOAc) to give cis-bicyclic β-lactone (±)-3-24c  (53 mg, 58 %) as a 
colorless oil and as a single diastereomer: Rf 0.12 (9:1, hexanes:EtOAc); IR (CDCl3) 
1824 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.23-7.34 (m, 5H), 3.51 (app d, J = 8.0 Hz, 
1H), 3.24 (app t, J = 15.0 Hz, 2H), 2.08 (app dt, J = 6.0, 12.0, 2H), 1.78-1.94 (m, 2H), 
1.54-1.65 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 171.3, 136.0, 123.0 (2), 128.8 (2), 
127.4, 89.9, 57.8, 41.5, 34.3, 27.2, 23.8.  LRMS (ESI) Calcd for C13H14NaO2 [M+Na]: 
225. Found: 225.   
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Trans and cis-3-(tert-butyldimethylsilyloxy)-5-methyl-6-oxabicyclo[3.2.0]heptan-7-
one  ((±)3-24d): Prepared according to the representative procedure (Method B) using 
pyridinium salt 3-19b (155 mg, 0.44 mmol, 1.5 equiv), 4-pyrrolidinopyridine (65 mg, 
0.44 mmol, 1.5 equiv), Hünig’s base (0.13 mL, 0.74 mmol, 2.5 equiv), and keto-acid 3-
23d (80 mg, 0.29 mmol, 1.0 equiv) in 7 mL of CH2Cl2.  Purification by flash 
chromatography on SiO2  (9:1, hexanes:EtOAc) gave a 2:1 ratio of trans and cis-bicyclic 
β-lactone (±)-3-24d  (42 mg, ~56%) as a colorless oil contaminated with N-propyl-2-
pyridone.  A second purification allowed separation of trans- and cis-β-lactone (±)-3-
24d. 
Trans-β-lactone (±)-3-24d (28 mg, 37 %):  Rf 0.30 (9:1, hexanes:EtOAc); IR (thin film) 
1820 cm-1; 1H NMR (500 MHz, CDCl3) δ 4.43-4.49 (m, 1H), 3.46 (d, J = 8.5 Hz, 1H), 
2.48 (dd, J = 6.0, 14.5 Hz, 1H), 2.34 (dd, J = 6.0, 13.0 Hz, 1H), 1.75 (ddd, J = 8.5, 13.0, 
17.5 Hz, 1H), 1.67 (s, 3H), 1.60 (dd, J = 9.5, 17.5 Hz, 1H), 0.88 (s, 9H), 0.64 (s, 6H); 13C 
NMR (125 MHz, CDCl3) δ 170.8, 85.2, 71.5, 56.5, 44.6, 35.5, 25.7(3), 22.3, 18.0, −4.89, 
−4.92; HRMS (ESI) Calcd for C13H24LiO3Si [M+Li]: 263. Found: 263.  
Cis-β-lactone (±)-3-24d (10 mg, 13 %): Rf 0.20 (9:1, hexanes:EtOAc) ; IR (thin film) 
1824 cm-1; 1H NMR (500 MHz, CDCl3) δ 4.50 (app t, J = 4.5 Hz, 1H), 3.46 (d, J = 8.0 
Hz, 1H), 2.27 (dd, J = 2.0, 15.5 Hz, 1H), 2.21 (dd, J = 2.0, 14.0 Hz, 1H), 1.94 (ddd, J = 
4.0, 8.0, 14.0 Hz, 1H), 1.74 (dd, J = 5.0, 15.5 Hz, 1H), 1.66 (s, 3H), 1.60 (dd, J = 9.5, 
17.5 Hz, 1H), 0.87 (s, 9H), 0.050 (s, 3H), 0.043 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 
171.3, 86.4, 74.2, 58.3, 44.7, 37.9, 25.5(3), 22.2, 17.7, −4.99, −5.06; LRMS (ESI) Calcd 
for C13H24LiO3Si [M+Li]: 263. Found: 263. 
O
Me
O
H
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4-benzyl-5-methyl-6-oxabicyclo[3.2.0]heptan-7-one ((±)-3-24e): Prepared according to 
the representative procedure (Method A) using pyridinium salt 3-19b (145 mg, 0.4 mmol, 
1 equiv), 4-pyrrolidinopyridine (40 mg, 0.3 mmol, 0.7 equiv), Hünig’s base (0.14 mL, 0.8 
mmol, 2 equiv), and keto acid keto-acid 3-23e  (100 mg, 0.4 mmol, 1 equiv) in 10 mL of 
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CH2Cl2. The crude residue was purified by flash chromatography on SiO2 (CH2Cl2) to 
give β-lactone (±)-3-24e  (54 mg, 60 %) as yellow oil of inseparable mixture of 
diastereomers (~1:1) based on 1H NMR integration: Rf 0.75 (CH2Cl2); IR (thin film) 1807 
cm-1; 1H NMR (500 MHz, CDCl3) δ 7.14-7.33 (m, 10H), 3.50 (app t, J = 7.0 Hz, 2H), 
2.97 (dd, J = 5.0, 13.5 Hz, 1H), 2.82 (dd, J = 4.5, 13.0, 1H), 2.64 (dd, J = 10.0, 13.5, 1H), 
2.59 (dd, J = 5.0, 11.5 Hz, 1H), 2.16 (t, J = 13.5, 1H), 1.82-2.05 (m, 7H), 1.61-1.68 (m, 
2H), 1.59 (s, 3H), 1.56 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 171.4, 171.3, 140.4, 
139.4, 128.83 (2), 128.75 (2) 128.61 (2), 128.48 (2), 126.4, 126.2, 89.1, 87.5, 60.2, 59.2, 
49.9, 46.2, 34.5, 34.3, 30.0, 26.7, 24.9, 24.6, 20.4, 19.1; LRMS (ESI) Calcd for 
C14H16LiO2Si [M+Li]: 223. Found: 223. 
OMe
TBSO O
O
15
2
(+)-3-30 TBSO
OMe
O  
(S)-methyl 3-(tert-butyldimethylsilyloxy)-6-oxodocosanoate 3-31: (+)-Ester 3-30 3 
(1.23 g, 4.1 mmol) was dissolved in 30 mL of dichloromethane, cooled to –78 °C, and a 
stream of ozone was bubbled through the solution for 15 min. Ozone addition was 
stopped, and excess ozone was removed by bubbling nitrogen through the solution for 
30 min. The ozonide was quenched by addition of triphenylphosphine (1.2 g, 4.7 mmol). 
The reaction mixture was allowed to warm to 25 °C, and the solvent was removed under 
reduced pressure. The resulting residue was purified by flash chromatography on SiO2 
(9:1, hexanes:EtOAc) to afford the intermediate aldehyde (900 mg, 82 %) as a colorless 
oil: Rf 0.16 (9:1, hexanes:EtOAc); 1H NMR (500 MHz, CDCl3) δ 9.72 (t, J= 1.5 Hz, 
1H), 4.15 (dq, J= 5.0, 6.0 Hz, 1H), 3.60 (s, 3H), 2.46 (dt, J= 1.5, 7.5 Hz, 1H), 2.43 (dd, 
J= 6.5, 14.5 Hz, 1H), 2.34 (dd, J= 6.0, 15.0 Hz, 1H),1.81-1.88 (m, 1H),  1.70-1.77 (m, 
1H), 0.80 (s, 9H), 0.002 (s, 3H), -0.018 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 201.7, 
171.4, 68.0, 51.4, 42.0, 39.1, 29.2, 25.6 (3), 17.8, −4.82, −5.01.  
                                                
3) Optically active silylether ester (+)-10 was obtained by silyl protection of hydroxy 
ester 10’ (not shown) by standard conditions.  Hydroxy ester 10’ has been reported 
previously in the literarture (Hirama, M.; Shimizu, M.; Iwashita, M.  J. Chem. Soc., 
Chem. Commun.  1983, 599).  Lit. [α]25D -15.9  (c 1.0, CHCl3), >99% ee.  This study: 
[α]25D +15.78  (c 1.0, CHCl3), >98% ee. 
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To a stirred solution of aldehyde (600 mg, 2.0 mmol) in 20 mL of THF at –78 °C was 
added 1 M solution of hexadecyl magnesium bromide4 (3 mL, 3.0 mmol) in THF. After 
stirring at –78 °C for 4 h, the reaction mixture was poured into 10% HCl solution and 
extracted with EtOAc (3 x 20 mL).  The combined organic layers were washed with 
brine (20 mL), dried over MgSO4, filtered, and concentrated to afford a light yellow 
residue that was used passed quickly through a SiO2 plug to remove polar and non-polar 
impurities.  This material was then used directly in the oxidation step.  To a solution of 
crude alcohol in 10 mL of CH2Cl2 was added PCC (260 mg, 1.2 mmol) at 0 °C. After 20 
min, the reaction mixture was warmed to 25 °C and then stirred for 8 h. The solution was 
passed through a pad of celite and concentrated to afford a light yellow residue.  The 
resulting residue was purified by flash chromatography on SiO2 (9:1, hexanes:EtOAc) to 
afford the intermediate keto ester 3-31 (330 mg, 0.661 mmol, 33%, 2 steps) as a pale 
yellow oil: Rf 0.35 (9:1, hexanes:EtOAc); [α]25D +7.5° (c 1.0, CHCl3); IR (thin film) 
1745, 1717 cm-1; 1H NMR (300 MHz, CDCl3) δ 4.18 (app quintet, J = 6 Hz, 1H), 3.66 
(s, 3H), 2.35-2.50 (m, 6H), 1.67-1.87 (m, 2H), 1.55 (t, J = 7.2 Hz, 2H), 1.25 (br s, 26H), 
0.87 (br t, J = 11 Hz, 2H), 0.86 (s, 9H), 0.05 (s, 3H), 0.03 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 210.8, 171.8, 68.3, 51.5, 42.9, 42.3, 37.3, 31.9, 30.8, 29.7 (3), 29.6, 29.64 (3), 
29.59, 29.5, 29.4, 29.3, 29.2, 25.7 (3), 23.9, 17.9, 14.1, −4.6, −4.9; LRMS (ESI) Calcd 
for C29H59O4Si [M+H]: 499. Found: 499. 
O
15
TBSO
OH
O  
(S)-methyl 3-(tert-butyldimethylsilyloxy)-6-oxodocosanoic acid (3-32): A solution of 
keto ester 3-31 (330 mg, 0.662 mmol) in 10 mL of THF was cooled to 0 °C and treated 
with 1N LiOH (1.0 mL, 10.0 mmol). After 20 min, the reaction mixture was warmed to 
25 °C and then stirred 12 h. The volatiles were removed under reduced pressure to give a 
residue that was dissolved in 10 mL of H2O and subsequently washed with 10 mL of 
hexanes and the aqueous layer was acidified with 1% HCl solution. Extraction with 
                                                
4)  This Grignard reagent was prepared by standard conditions from hexadecyl bromide 
and activated Mgο turnings. 
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EtOAc (3 x 10 mL) was followed by combination of the organic layers, drying over 
MgSO4, filtration, and concentration to afford a white solid that was purified by flash 
chromatography on SiO2 (8:2, hexanes:EtOAc)  to afford acid 3-22 (200 mg, 67%) as a 
colorless oil: Rf 0.23 (8:2, hexanes:EtOAc); [α]25D -2.3° (c 1.0, CHCl3); IR (thin film) 
2928, 1713 cm-1; 1H NMR (300 MHz, CDCl3) δ 4.19 (app quintet, J= 5.5 Hz, 1H), 
2.47-2.50 (m, 4H), 2.40 (t, J= 7.5 Hz, 2H), 1.76-1.88 (m, 2H), 1.56 (t, J= 7.0 Hz, 2H), 
1.26 (br s, 27H), 0.89 (br s, 12H), 0.09 (s, 3H), 0.08 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 210.6, 175.8, 68.2, 42.8, 41.7, 37.7, 31.9, 30.6, 29.68 (3), 29.67, 29.64 (3), 
29.60, 29.5, 29.4, 29.35, 29.2, 25.7 (3), 23.9, 22.7, 17.9, 14.1, −4.7, −4.9. 
O
O
CH3(CH2)15
H
TBSO
 
(1R,2S,5S)-2-(tert-butyldimethylsilyloxy)-5-hexyadecyl-6-oxabicyclo[3,2,0]heptan-7-
one (3-33): Prepared according to the general procedure using pyridinium salt 3-19b 
(152 mg, 0.43 mmol, 1.5 equiv), 4-pyrrolidinopyridine (64 mg, 0.43 mmol, 1.5 equiv), 
Hünig’s base (0.12 mL, 0.72 mmol, 2.5 equiv), and keto-acid 3-32 (140 mg, 0.29 mmol, 
1.0 equiv) in 8 mL of CH2Cl2. The crude residue was purified by flash chromatography 
on SiO2 (95:5, hexanes:EtOAc) to give β-lactone (-)-3-33 (65 mg, 48%) as a white waxy 
solid: Rf 0.42 (95:5, hexanes:EtOAc); [α]25D –9.02° (c 1.0, CHCl3); IR (thin film) 2921, 
1824cm-1; 1H NMR (500 MHz, CDCl3) δ 4.46 (d, J = 2.0 Hz, 1H), 3.34 (d, J = 2.0 Hz, 
1H), 1.96-2.06 (m, 4H), 1.87-1.93 (m, 2H), 1.40-1.45 (m, 2H), 1.33-1.35 (m, 2H), 1.26 
(br s, 24H), 0.87 (t, J = 8.0,  Hz, 3H), 0.865 (s, 9H), 0.067 (s, 3H), 0.062 (s, 3H); 13C 
NMR (125 MHz, CDCl3) δ 168.9, 90.8, 72.7, 66.3, 35.2, 33.5, 31.9, 31.1, 29.69 29.68 
(3), 29.67, 29.65 (2), 29.62, 29.5, 29.44, 29.35 25.6 (3), 24.8, 22.7, 17.8, 14.1, −4.88, 
−4.94; LRMS (ESI) Calcd for C13H24LiO3Si [M+Li]+: 473. Found: 473. 
CO2Me
OH
(CH2)15CH3
HO
 
Synthesis of Dihydroplakevulin A 3-34: To a stirred solution of β-lactone 3-33 (15.0 
mg, 0.032mmol) in 1.5 mL of MeOH at 25 °C was added triethylamine (18 µL, 0.128 
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mmol). After stirring at 50 °C for 8 h, the volatilies were removed under reduced 
pressure to give a white foam that was used directly in the following step. To a solution 
of the crude hydroxy ester in 4 mL of CH3CN was added a 1M solution of HF/Pyridine 
(0.52 mL, 0.52 mmol) at 0 °C. After 1 h, the reaction mixture was washed with brine (5 
mL), dried over MgSO4, filtered, and concentrated to afford a white solid. The resulting 
residue was purified by flash chromatography on SiO2 (7:3, hexanes:EtOAc) to afford 
dihydroplakevulin A 3-34 (4 mg, 0.01 mmol, 32% over two steps) as a white solid: Rf 
0.30 (4:6, hexanes:EtOAc); [α]25D  +7.13 (c 1.0, CHCl3); IR (thin film) 3422, 1729 cm-1; 
1H NMR (500 MHz, CDCl3) δ 4.65 (q, J = 8.0 Hz, 1H), 3.79 (s, 1H), 2.99 (br s, 1H), 
2.56 (d, J = 8.0 Hz, 1H), 2.27-2.34 (m, 1H), 2.07 (s, 1H), 1.89 (ddd, J= 7.0, 10.0, 17.5 
Hz, 1H), 1.78 (dd, J= 5.0, 10.5 Hz, 1H), 1.75 (dd, J= 5.0, 10.5 Hz, 1H), 1.54-1.64 (m, 
4H),  1.26 (br s, 26H), 0.89 (t, J = 7.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 174.6, 
82.0, 75.8, 61.1, 52.3, 41.2, 35.9, 32.2, 31.7, 30.3, 29.94 (4), 29.92, 29.90 (2), 29.83, 
29.82, 29.6, 24.4, 22.9, 14.4; LRMS (ESI) Calcd for C23H44LiO4[M+Li]: 391.3 Found 
C29H58O4Si: 391.3 
O
HO
H5
15
OMe23
OH
O
HO
H5
15
OMe23
OH
O
HO
H5
15
OMe23
OH
H1
H1 H1
O
Me23
2.55 (m) 2.49 (d, J =  8.3 Hz)
4.65 (ddd ,J = 7.9, 3.7, 2.0 Hz) 4.47 (br d, J =  8.3 Hz)
3.33* 3.26*
4.65 (app q, J =8.0 Hz)
2.56 (d, J =8.0 Hz)
3.79 s
Kobayashi, J. et. al. Tetrahedron 2003, 59, 1137
(600 MHz 1H NMR)
O
H1
H5
15
OMe23
OH
(+)-plakevulin
Mizutani, H. et. al.
 Synlett 2005, 793.
2.83 (d, J =  5.3 Hz)
5.84 (dd, J = 5.7, 1.5 Hz)
3.79 (3.78†)
HO
H1
H5
This study (500 MHz 1H NMR).
†Data from Kobayashi, J. et. al. Tetrahedron 2003, 59, 1137.
*Chemical shifts for methyl ester in red appear to be anomalous based on expected chemical shifts for methyl ester protons, data from Mizutani, 
and may be due to typographical errors in Kobayashi, et. al.  We had no response to several inquiries regarding this spurious data.
(+)-Dihydroplakevulin
(+)-Dihydroplakevulin
Comparison of Selected 1H NMR Chemical Shifts and Couplings for Dihydroplakevullin and Derivatives.
Me
O
HO
H5 OMe
OH
H1
4.68 (app dt, J = 13.5, 6.0 Hz)
2.57 (d, J =13.5 Hz)
3.83 s
 
N
O
O
Ts
Me  
(±)-β-Lactone 3-73: To a solution of pyridinium salt 3-19b (117 mg, 0.334 mmol), 4-
PPY 3-23b (50 mg, 0.33 mmol) and Hunig’s base (118 µL, 0.676 mmol) in 8 mL of 
CH2Cl2 at ambient temperature was added via syringe pump a solution of keto acid 3-72 
(100 mg, 0.334 mmol) in 4 mL of CH2Cl2 over 1 h.  After the addition was complete, the 
reaction was stirred for an additional 11 h.  The solvent was then removed in vacuo and 
the orange residue was partitioned between ethyl acetate (10 mL) and water (8 mL). The 
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phases were separated, and the aqueous layer was extracted with ethyl acetate (2 x 5 mL). 
The combined organic phases were washed with saturated NH4Cl solution (6 mL), dried 
over MgSO4, and concentrated in vacuo. Purification of the residue by flash 
chromatography on SiO2 (1:1, hexanes:ethyl acetate) gave 3-73 (70 mg, 75%) as a white 
amorphous solid: Rf 0.35 (1:1, hexanes:ethyl aceatae). IR (CHCl3) 1845 cm-1; 1H NMR 
(500 MHz, CDCl3) δ 7.73 (d, J = 8.0, 2H), 7.36 (d, J = 8.0 Hz, 2H), 3.95 (d, J = 11.0 Hz, 
1H), 3.90 (d, J = 12.0 Hz, 1H), 3.60 (d, J = 6.5 Hz, 1H), 2.99 (dd, J = 10.5, 6.5 Hz, 1H), 
2.78 (d, J = 12.0 Hz, 1H), 2.46 (s, 3H), 1.67 (s, 3H); 13C NMR (125 MHz, CDCl3) 
δ 166.7, 144.2, 132.4, 130.0 (2), 128.0 (2), 81.9, 59.2, 54.6, 48.0, 21.9, 19.7; HRMS 
(ESI) Calcd for C13H16NO4S [M+H]: 282.0800. Found: 282.0791. 
(−)-β-Lactone 3-73: To a 10 mL round-bottomed flask containing pyridinium salt 3-19b 
(126 mg, 1.5 equiv, 0.241 mmol) and levamisole•HCl 3-40 (58 mg, 1.0 equiv, 0.241 
mmol) was added 2.5 mL CH2Cl2 and the reaction was cooled to 0°C. 
Diisopropylethylamine (307 µL, 5.0 equiv, 1.77 mmol) was added by syringe, followed 
by a solution of ketoacid 3-72 (72 mg, 1.0 equiv, 0.241 mmol) in 1.0 mL CH2Cl2 via 
syringe pump over 1 h. After 20 h, the reaction was concentrated in vacuo. Purification of 
the residue by flash chromatography on SiO2 (1:1, hexanes:ethyl acetate) gave (−)-β-
lactone 3-73 (24 mg, 35%) as a white amorphous solide. [α]16D −9.13 (c 1.0, CHCl3); 
Enantiomeric excess was determined to be 91% ee by chiral HPLC (Chiral OD, 250 x 4.5 
mm (L x I.D.), solvent (isocratic) 85:15 hexanes/2-propanol), flow rate 1.0 
mL/min,wavelength λ = 230 nm). Retention times: 31.13 min and 39.08 min.  
 
(±)-β-Lactone 3-73 
(−)-β-Lactone 3-73 
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N
O
O
Ts
CH3  
(±)-β-Lactone 3-75: To a solution of pyridinium salt 3-19b (84 mg, 0.24 mmol), 4-PPY 
3-23b (36 mg, 0.24 mmol) and Hunig’s base (84 µL, 0.48 mmol) in 3 mL of CH2Cl2 at 
ambient temperature was added via syringe pump a solution of keto acid 3-74 (72 mg, 
0.24 mmol) in 1 mL of CH2Cl2 over 1 h.  After the addition was complete, the reaction 
was stirred for an additional 24 h. The volatiles were evaporated and the residue was 
purified by flash chromatography (20%→30% EtOAc/hexanes) to afford the 3-75 (49 
mg, 72%) as a white solid: Rf 0.37 (30% EtOAc/hexanes). IR (CHCl3) 1833 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 7.79 (d, J = 8.0, 2H), 7.34 (d, J = 8.0 Hz, 2H), 5.08 (s, 1H), 
3.99 (dd, J = 11.0, 9.0 Hz, 1H), 3.15 (dt, J = 11.0, 6.0 Hz, 1H), 2.44 (s, 3H), 2.22 (dd, J = 
14.5, 6.0 Hz, 1H), 1.81 (ddd, J = 14.5, 11.5, 8.0 Hz, 1H), f1.67 (s, 3H); 13C NMR (125 
MHz, CDCl3) δ 164.5, 144.5, 134.8, 129.8 (2), 127.8 (2), 87.3, 73.4, 46.7, 35.1, 21.6, 
20.6; HRMS (ESI) Calcd for C13H16NO4S [M+H]: 282.0800. Found: 282.0872. 
N
O
O
Ts
 
(−)-β-Lactone 3-75: To a 10 mL round-bottomed flask containing pyridinium salt 3-19b 
(101 mg, 1.2 equiv, 0.289 mmol), LiCl (5.0 mg, 0.5 equiv, 0.12 mmol) and HBTM (12.8 
mg, 0.2 equiv, 0.048 mmol) was added 1.5 mL CH2Cl2 at 19 oC. Diisopropylethylamine 
(210 µL, 5.0 equiv, 1.20 mmol) was added by syringe, followed by a solution of ketoacid 
3-74 (72 mg, 1.0 equiv, 0.24 mmol) in 2.5 mL CH2Cl2 via syringe pump over 1 h. After 
the addition was complete, the reaction was stirred for an additional 36 h. The volatiles 
were evaporated and the residue was purified by flash chromatography (20%→30% 
EtOAc/hexanes) to afford the (−)-β-lactone 3-75 (26 mg, 39%) as a white solid: [α]17D −
0.65 (c 1.08, CHCl3); Enantiomeric excess was determined to be 80% ee by chiral HPLC 
(Chiral IA, 250 x 4.5 mm (L x I.D.), solvent (isocratic) 70:30 hexanes/2-propanol), flow 
rate 0.5 mL/min,wavelength λ = 254 nm). Retention times: 17.61 min and 21.08 min. 
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Guanidine 3-38: To a mixture of the 2-chloro-imidazolinium 3-44 (912 mg, 3.19 mmol) 
in CH3CN (25 mL) and Et3N (0.9 mL) was added amino pyridine 3-45 (300 mg, 3.19 
mmol) at 22 oC then warmed up 70 oC and stirred for another 5 h. The reaction mixture 
was quenched by saturated NaHCO3 solution. The mixture was extracted with CH2Cl2 
and the combined organic layers were concentrated in vacuo. The residue was purified by 
flash chromatography (CH2Cl2→10% MeOH/CH2Cl2) to afford guanidine 3-38 (749 mg, 
69%) as a colorless oil: Rf = 0.21 (10% MeOH/CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 
8.25 (d, J = 5.0 Hz, 2H), 7.23-7.36 (m, 10H), 6.81 (d, J = 6.0 Hz, 2H), 4.34 (s, 4H), 3.27 
(s, 4H); 13C NMR (125 MHz, CDCl3) δ 157.5, 155.8, 149.8 (2), 136.5(2), 128.6(4), 
128.0(4), 17.6(2), 117.1(2), 50.8(2), 44.9(2); IR (thin film): 3029, 1632 cm-1; HRMS 
(ESI) Calcd. for C22H23N4 [M+H]: 343.19227. Found: 343.1995. 
N
NH2
3
OH
 
Aminopyridine alcohol 3-47: To a solution of pyridine carboxaldehyde 3-46  (825 mg, 
3.7 mmol) in THF (30 mL) at 0 ºC was added n-BuLi (2.2 M in hexane, 5 mL, 11.1 
mmol) dropwise. After stirring for 30 min, the reaction was quenched 1N HCl (ca. 12 
mL). The aqueous layer was made basic (pH = 8-9 pH paper) with saturated NaHCO3 
then extracted with CH2Cl2. The organic layers were dried (MgSO4), concentrated in 
vacuo. The residue was purified by flash chromatography (50% → 70% EtOAc/Hexanes) 
to afford tert-butyl-3-(1-hydroxypentyl)pyridin-4-ylcarbamate (749 mg, 94%) as 
colorless oil. The crude alcohol (178 mg, 0.635 mmol) was dissolved in MeOH (4 mL) 
and 3N HCl (2 mL) was added at 23 oC then warmed up to 40 oC for 18 h. The reaction 
mixture was quenched by saturated NaHCO3 solution. The mixture was extracted with 
CH2Cl2 and the combined organic layers were concentrated in vacuo. The residue was 
purified by flash chromatography chromatography (CH2Cl2→10% MeOH/CH2Cl2) to 
afford aminopyridine alcohol 3-47(82 mg, 72%) as a colorless oil: Rf = 0.21 (10% 
MeOH/CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.83 (d, J = 5.5 Hz, 1H), 7.63 (s, 1H), 
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6.40 (d, J = 5.5 Hz, 1H), 5.09 (s, 2H), missed (OH), 4.52 (t, J = 7.0 Hz, 1H), 1.83-1.90 
(m, 1H), 1.72-1.79 (m, 1H), 1.30-1.40 (m, 1H), 1.30 (q, J = 7.0 Hz, 2H), 1.20-1.23 (m, 
1H), 0.89 (t, J = 2.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 154.0, 148.4, 140.6, 123.5, 
111.1, 73.3, 35.1, 29.0, 23.1, 14.6; IR (thin film): 3349, 1623 cm-1; HRMS (ESI) Calcd. 
for C10H17N2O [M+H]: 181.1341. Found: 181.1314. 
N
N
N
N
Bn
Bn
OH
 
Guanidine 3-48: To a solution of the 2-chloro-imidazolinium 3-44 (1.1 g, 3.84 mmol) in 
CH3CN (20 mL) and Et3N (0.7 mL) was added amino pyridine 3-47 (231 mg, 1.28 mmol) 
at 22 oC then warmed up 50 oC and stirred for 36 h. The reaction mixture was quenched 
by saturated NaHCO3 solution. The mixture was extracted with CH2Cl2 and the combined 
organic layers were concentrated in vacuo. The residue was purified by flash 
chromatography chromatography (CH2Cl2→10% MeOH/CH2Cl2) to afford 3-48 (209 
mg, 38%) as a colorless oil: Rf = 0.21 (10% MeOH/CH2Cl2); 1H NMR (500 MHz, 
CDCl3) δ 8.12 (s, 1H), 7.99 (d, J = 4.0 Hz, 1H), 7.30-7.37 (m, 6H), 7.18 (d, J = 8.5 Hz, 
4H), 6.62 (d, J = 6.0 Hz, 1H), 4.76 (t, J = 7.0 Hz, 1H), 4.35 (s, 4H), 3.52 (s, 4H), 1.75-
1.81 (m, 2H), 1.39-1.47 (m, 1H), 1.26-1.34 (m, 3H), 0.85 (t, J = 6.5 Hz, 3H); 13C NMR 
(125 MHz, CDCl3) δ 157.5, 155.0, 146.3, 146.2, 135.7(4), 130.0, 128.8(4), 127.8(2), 
127.7(2), 115.2, 72.5, 50.7(2), 44.9(2), 36.3, 28.3, 22.6, 14.0; HRMS (ESI) Calcd. for 
C27H33N4O [M+H]: 429.26544. Found: 429.2627. 
N
NH
N
N
Bn
OH
 
Guanidine 3-49: To a solution of the guanidine 3-48 (87 mg, 0.20 mmol) in THF (10 
mL) was added dropwise a solution of Naο/naphthalenide (0.28 M, 1.4 mL) at 22 oC and 
stirred for 6 h. The reaction mixture was quenched by saturated NH4Cl solution and 
extracted with CH2Cl2. The combined organic layers were concentrated in vacuo and the 
residue was purified by flash chromatography (CH2Cl2→10% MeOH/CH2Cl2) to afford 
3-48 (48 mg, 71%) as a yellow oil: Rf = 0.13 (10% MeOH/CH2Cl2); 1H NMR (500 MHz, 
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CDCl3) δ 8.34 (s, 1H), 8.22, (s, 1H), 7.28-7.37 (m, 5H), 6.89 (d, J = 6.0 Hz, 1H), 5.97 
(dd, J = 7.5, 5.5 Hz, 1H), 4.61 (d, J = 15.0 Hz, 1H), 4.50 (d, J = 15.0 Hz, 1H), 3.35-3.48 
(m, 4H), 2.55 (br s, 2H), 1.78-1.83 (m, 2H), 1.27-1.37 (m, 4H), 0.84 (t, J = 6.5 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ 170.81, 155.5, 146.5, 144.6, 137.1, 128.6(2), 128.1(2), 
127.5, 71.3, 48.6, 45.7, 40.5, 34.8, 29.7, 27.7, 22.4, 21.3, 14.0; IR (thin film): 3239, 1735 
cm-1.  
NH
O
OBn
N
O
OBn
3-77b  
Methylallylpyrrolidine 3-78: To a solution of potassium carbonate (290 mg, 2.1 mmol), 
and 3-bromo-2-methyl-1-propene (0.1 mL, 1.05 mmol) in 8 mL of DMF was added a 
solution of pyrrolidine 3-77b (231 mg, 1.05 mmol) in DMF and heated to 40 oC for 24 h.  
After cooling to 21 °C, the mixture was filtrated through a celite pad and concentrated in 
vacuo. Purification of the residue by flash chromatography on SiO2 (10%→20% 
EtOAc/hexanes) afforded 3-78 (135 mg, 47 %) as a colorless oil: Rf 0.20 (20%, 
EtOAc/hexanes); [α]21D –52.2 (c 0.75, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.37-7.40 
(m, 5H), 5.18 (d, J = 12.0 Hz, 1H), 5.12 (d, J = 12.0 Hz, 1H), 4.91 (br s, 1H), 4.81 (br s, 
1H), 3.29 (d, J = 13.0 Hz, 1H), 2.96-3.03 (ddd, J = 9.9, 6.9, 3.6 Hz, 1H), 2.79-2.87 (m, 
1H), 2.74 (d, J = 13.0 Hz, 1H), 2.69 (dd, J = 15.0, 4.5 Hz, 1H ), 2.37 (dd, J = 15.0, 9.0 
Hz, 1H ), 2.14 (d, J = 17.0, 9.0 Hz, 1H), 1.99-2.08 (m, 1H), 1.70-1.80 (m, 2H), 1.57-1.68 
(m, 1H), 1.75 (s,3H); 13C NMR (125 MHz, CDCl3) δ 172.2, 144.1, 136.0, 128.5(2), 
128.11(2), 128.08, 118.8, 66.2, 61.4, 60.9, 53.8, 39.8, 30.9, 22.3, 20.7; IR (thin film): 
3079, 1735 cm-1; HRMS (ESI) Calcd. for C17H24NO2 [M+H]: 274.1807. Found: 
274.1719. 
N
O
OBn
O
 
ketone 3-79 : To a solution of alkene 3-78 ( 82 mg, 0.3 mmol) in diethyl ether (3 mL) 
was added 160 µL of a solution of 4N HCl (1 mL) in dioxane (1 mL) and stirred 30 min 
at 23 oC. After the reaction mixture was concentrated in vacuo, it was taken to the 
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ozonolysis step. An ozone-oxygen mixture was passed through a mixture of alkene salt in 
CH2Cl2/MeOH (9:1, 10 mL) at –78 until a pale-blue color appeared in the solution.  The 
reaction mixture was purged with N2 and dimethyl sulfide (0.5 mL, 6.9 mmol) was 
added. The reaction mixture was warmed to 21 °C and concentrated in vacuo. 
Purification of the residue by flash chromatography on SiO2 (50%→70% 
EtOAc/hexanes) afforded 3-79 (35 mg, 42 %) as a colorless oil: Rf = 0.37 (EtOAc); 
[α]19D –52.9 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.31-7.39 (m, 5H), 5.13 (d, J 
= 12.5 Hz, 1H), 5.10 (d, J = 12.5 Hz, 1H), 3.57 (d, J = 17.5 Hz, 1H), 3.35 (d, J = 17.5 Hz, 
1H), 3.15 (dt, J = 6.0, 1.5 Hz, 1H), 2.95-3.00 (m, 1H), 2.64 (dd, J = 15.0, 5.0 Hz, 1H), 
2.42 (dd, J = 15.0, 6.5 Hz, 1H ), 2.36 (dd, J = 17.0, 8.5 Hz, 1H ), 2.09 (s, 3H), 2.02-2.06 
(m, 1H), 1.72-1.87 (m, 2H), 1.57-1.64 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 210.8, 
166.4, 130.2, 122.9, 122.7, 122.69, 60.69, 58.7, 55.1, 48.8, 34.2, 25.3, 21.9, 17.2. 
O
O
OH
OH
 
Diol 4-8: To a solution of triol 4-10 (2.0 g, 9.08 mmol) in dry MeOH (30 mL) was added 
NaIO4 (3.0 g 14. 04 mmol), and the mixture was stirred at 23 oC for 24 h. The mixture 
was filtered, and the filtrated was concentrated and the resulting residue was passed 
through a short silicagel column eluted with MeOH. The fraction containing the desired 
product was evaporated and dissolved in dry MeOH (20 mL) and the solution was stirred 
at 0 oC while NaBH4 (0.4 g) was slowly added. After 30 min, acetone was added to 
quench the reaction. The reaction mixture was evaporated and the residue was passed 
through a silica gel column eluted with (20% hexanes/EtOAc) to give diol 4-8 (0.81g, 5.0 
mmol) as a yellow viscous oil. Rf 0.28 (20% hexanes/EtOAc). IR (thin film) 3723-3032, 
1665 cm-1; 1H NMR (300 MHz, CDCl3) δ  3.90 (dd, J = 6.6, 3.3 Hz, 1H), 3.78 (d, J = 2.4 
Hz, 2H), 3.75 (dd, J = 5.4, 3.3 Hz, 1H), 3.71-3.62 (m, 2H), 1.48 (s, 3H), 1.39 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ  99.0, 74.1, 64.5, 63.9, 63.1, 28.7, 19.6. 
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Alcohol 4-12: To a solution of diol 4-8 (0.6 g, 3.7 mmol) in CH2Cl2 (40 mL) was added 
TBDPSCl (1.2 g, 4.4 mmol) followed by and Et3N (1.5 mL, 11 mmol) and a crystal of 
DAMP at 22 oC. This solution was stirred for 15 h at which time it was washed with sat. 
aq. NH4Cl (2 x 30 mL), and water (30 mL). The organic layer was dried over MgSO4, 
filtered and concentrated under reduced pressure. Purification by flash column 
chromatography (20% hexanes/EtOAc) to provide silyl ether 4-12 (1.0 g, 2.6 mmol, 
70%) as a yellowish oil. Rf 0.35 (20% hexanes/EtOAc); IR (thin film) 3673-3200, 3076, 
1476, cm-1; 1H NMR (300 MHz, CDCl3) δ 7.72-7.69 (m, 4H), 7.50-7.38 (m, 6H), 3.96-
3.77 (m, 5H), 3.70-3.63 (m, 1H), 1.46 (s, 3H), 1.36 (s, 3H), 1.09 (s, 9H); 13C NMR (75 
MHz, CDCl3) δ 135.6, 132.5, 132.5, 130.0, 127.8, 98.5, 72.4, 66.9, 66.9, 63.8, 28.4, 26.8, 
19.2, 19.1. 
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Cyclic Ketone 4-7.  To stirred solution of oxalyl chloride (0.68 mL, 7.8 mmol) in CH2Cl2 
(20 mL) was added DMSO dropwise (0.73 mL, 10 mmol) at –78oC.  The reaction 
mixture was stirred for 10 min, after which time alcohol 4-12 (1.0 g, 2.6 mmol) was 
added in CH2Cl2 (10 mL) over 30 min.  Triethylamine (2.3 mL, 13 mmol) was added and 
the reaction was stirred for 20 min then allowed to warm to 23 oC then stirred for 20 min. 
Water (30 mL) was added and the aqueous layer was extracted with diethyl ether (2 x 30 
mL). The combined organic layers were dried over (MgSO4), and solvent removed in 
vacuo then the residue was put on silica gel column (hexanes/EtOAc 96:4) to provide the 
ketone 4-7 (720 mg, 70%) as yellow oil. Rf 0.3 (hexanes/EtOAc 9:1); IR (thin film) 3068, 
1747 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.72-7.69 (m, 4H), 7.50-7.38 (m, 6H), 4.36 
(ddd, J = 5.4, 3.0, 1.5 Hz, 1H), 4.29 (dd, J = 16.5, 1.5 Hz, 1H), 4.40 (d, J = 3.0 Hz, 1H), 
4.15 (d, J = 5.4 Hz, 1H), 4.02 (d, J = 16.5 Hz, 1H), 1.49 (s, 3H), 1.49 (s, 3H), 1.09 (s, 
9H); 13C NMR (75 MHz, CDCl3) δ 207.3, 135.5, 133.2, 133.1, 129.6, 127.5, 127.5, 
100.3, 76.5, 66.8, 62.4, 26.6, 24.2, 23.3, 19.1.  
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Ethylene 4-14.  Bis-(cyclopentadienyl)dimethyltitanium (330 mg, 1.6 mmol) was 
prepared by the known procedure. To a solution of Petasis reagent in toluene (5 mL) was 
added ketone 4-7 (250 mg, 0.63 mmol) in toluene (5 mL). The reaction mixture was 
stirred under reflux conditions. After 12 h, the reaction was cooled to 23 oC. The 
precipitates were filtered through Celite and the filtrate was concentrated under reduced 
pressure. Purification by flash column chromatography (2% hexanes/EtOAc) to provide 
the ethylene 4-14 (37 mg, 0.09 mmol, 15%) as a yellow oil. Rf 0.30 (hexanes/EtOAc 
96:4); IR (thin film) 3073, 1475 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.72-7.69 (m, 4H), 
7.50-7.38 (m, 6H), 4.91 (dd, J = 13.2, 1.2 Hz, 2H), 4.45 (m, 1H), 3.93 (dd, J = 10.8, 5.1 
Hz, 1H), 3.83 (dd, J = 10.8, 6.0 Hz, 1H), 1.44 (s, 3H), 1.38 (s, 3H), 1.07 (s, 9H); 13C 
NMR (75 MHz, CDCl3) δ 143.5, 135.7, 135.6, 133.7, 129.6, 127.6, 127.6, 107.5, 99.5, 
71.8, 65.5, 64.2, 27.2, 26.8, 22.3, 19.3.; HRMS (ESI) calcd for C24H32O3SiLi [M+Li]: 
403.2281. Found: 403.2283 
O
O
OTBDPS
Br
 
Vinyl bromide 4-15:  A solution of ethylene 4-14 (37 mg, 0.09 mmol) in CH2Cl2 (4 mL) 
was treat with a solution of Br2 (28 mg, 0.18 mmol) in CH2Cl2 (2 mL) at –78 oC. After 20 
min, the solution was allowed to warm to 23 oC and concentrated under reduced pressure 
to give crude dibromide as a yellow oil. To the solution of the crude dibromide in 
benzene (8 mL) was added DBU 3-23 (55 mg, 0.36 mmol). The mixture was refluxed for 
7 h then allowed to cool to 23 oC. The precipitates were filtered through Celite and the 
filtrate was concentrated under reduced pressure. Purification by flash column 
chromatography (2% hexanes/EtOAc) to provide the vinyl bromide 4-15 (11 mg, 0.02 
mmol, 25%) as a yellow oil. Rf 0.30 (hexanes/EtOAc 96:4); IR (thin film) 3069, 2938, 
2851, 1469, 1425, 1382, 1222, 1105, 822, 785, 705 cm-1; 1H NMR (300 MHz, CDCl3) δ 
7.72-7.69 (m, 4H), 7.50-7.38 (m, 6H), 4.91 (dd, J = 13.2, 1.2 Hz, 2H), 4.45 (m, 1H), 3.93 
(dd, J = 10.8, 5.1 Hz, 1H), 3.83 (dd, J = 10.8, 6.0 Hz, 1H), 1.44 (s, 3H), 1.38 (s, 3H), 1.07 
(s, 9H); 13C NMR (125 MHz, CDCl3) δ 140.9, 135.9, 135.9, 133.8, 130.0, 128.0, 128.0, 
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100.5, 100.2, 72.2, 65.2, 62.5, 27.0, 26.1, 23.7, 19.4; HRMS (ESI) calcd for 
C24H32O3SiLi [M+Li]: 481.1386. Found: 481.1340 
HO
OTBDPS
Br
HO
H  
Butane-1,3-diol 4-6:  BF3·OEt2 (0.82 mg, 0.0058 mmol) was added to a mixture of vinyl 
bromide 4-15 (28 mg, 0.058 mmol) and 1,3-propanedithiol (15.6 mg, 0.143 mmol) in 
CH2Cl2 (3 mL) at 0 oC. The mixture was stirred at 0 oC for 1 h and quenched with 
saturated NaHCO3 (3 drops). The aqueous layer was extracted with CH2Cl2  (2 x 10 mL) 
and the combined organic layers were dried over MgSO4 and concentrated. Purification 
by flash column chromatography (20% hexanes/EtOAc) to provide the diol 4-6 (16 mg, 
0.037 mmol, 63%) as a yellow oil. Rf 0.27 (hexanes/EtOAc 7:3); IR (thin film) 3680-
3127, 3069, 2924, 2851, 1469, 1425, 1113, 822, 698, 705 cm-1; 1H NMR (300 MHz, 
CDCl3) δ 7.67-7.63 (m, 4H), 7.46-7.37 (m, 6H), 6.33 (d, J = 0.8, Hz, 1H), 4.40 (m, 1H), 
4.28 (s, 2H), 3.79 (dd, J = 10.5, 4.5 Hz, 1H), 3.72 (dd, J = 10.5, 6.6 Hz, 1H), 1.07 (s, 9H); 
13C NMR (125 MHz, CDCl3) δ 142.6, 135.8, 132.9, 130.3, 128.1, 108.0, 75.0, 66.9, 61.6, 
27.1, 19.4. 
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Crystal and Molecular Structure Determination 
 
X-ray Diffraction Laboratory 
Department of Chemistry 
Texas A&M University 
Report: April 14, 2008 
Structure: DR67 (3-80b) 
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Table 1.  Crystal data and structure refinement for dr67. 
Identification code  dr67 
Empirical formula  C30 H42 N O6 S 
Formula weight  544.71 
Temperature  110(2) K 
Wavelength  1.54178 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 9.016(3) Å α= 96.61(2)°. 
 b = 12.970(5) Å β= 94.392(19)°. 
 c = 13.568(6) Å γ = 107.975(18)°. 
Volume 1488.5(10) Å3 
Z 2 
Density (calculated) 1.215 Mg/m3 
Absorption coefficient 1.302 mm-1 
F(000) 586 
Crystal size 0.20 x 0.20 x 0.02 mm3 
Theta range for data collection 5.19 to 59.90°. 
Index ranges -9<=h<=10, -14<=k<=14, -15<=l<=15 
Reflections collected 11310 
Independent reflections 4019 [R(int) = 0.2140] 
Completeness to theta = 59.90° 91.3 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9744 and 0.7807 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4019 / 0 / 343 
Goodness-of-fit on F2 1.006 
Final R indices [I>2sigma(I)] R1 = 0.0735, wR2 = 0.1128 
R indices (all data) R1 = 0.2317, wR2 = 0.1473 
Largest diff. peak and hole 0.251 and -0.368 e.Å-3 
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 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for dr67.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
S(1) 261(2) 748(2) 3404(2) 55(1) 
O(1) -5654(6) 674(4) 6512(4) 55(2) 
O(2) -166(5) -290(4) 2755(5) 68(2) 
O(3) 1843(5) 1247(4) 3925(4) 60(2) 
O(4) -6434(5) 4436(4) 9044(4) 49(2) 
O(5) -7362(6) 4131(4) 10505(5) 62(2) 
O(6) -4264(5) 4862(3) 7580(4) 47(2) 
N(1) -965(6) 579(4) 4233(5) 45(2) 
C(1) -3388(7) 2299(5) 6879(6) 42(2) 
C(2) -2937(7) 3068(6) 7902(6) 53(3) 
C(3) -4394(7) 3233(5) 8333(6) 46(2) 
C(4) -5234(8) 3769(6) 7632(7) 49(2) 
C(5) -5653(8) 3084(6) 6567(6) 48(3) 
C(6) -4235(8) 2819(5) 6140(6) 42(2) 
C(7) -4421(9) 1153(6) 7044(7) 52(3) 
C(8) -3852(8) 656(5) 7905(6) 56(3) 
C(9) -4308(8) -553(6) 7788(7) 62(3) 
C(10) -3809(9) -985(6) 8686(8) 81(3) 
C(11) -4212(9) -2239(6) 8568(8) 95(4) 
C(12) -1873(7) 2162(5) 6511(6) 52(3) 
C(13) -2221(7) 1328(5) 5556(6) 49(2) 
C(14) -673(7) 1490(5) 5067(6) 49(2) 
C(15) -99(9) 1668(6) 2693(7) 45(2) 
C(16) -1400(9) 1337(6) 1929(6) 46(2) 
C(17) -1772(8) 2053(6) 1349(6) 47(2) 
C(18) -899(10) 3165(7) 1522(8) 61(3) 
C(19) 384(10) 3507(6) 2281(7) 57(3) 
C(20) 754(7) 2762(6) 2838(6) 45(2) 
C(21) -1253(8) 3966(6) 925(6) 64(3) 
C(22) -6804(8) 3835(6) 8017(7) 57(3) 
C(23) -7379(9) 3800(7) 9626(8) 54(3) 
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C(24) -8357(8) 2704(6) 9029(7) 47(2) 
C(25) -7978(7) 2781(5) 8112(6) 45(2) 
C(26) -9408(8) 1865(5) 9489(6) 60(3) 
C(27) -6428(8) 3605(6) 5795(6) 61(3) 
C(28) -3091(8) 3775(6) 5791(7) 52(2) 
C(29) -2782(9) 3949(7) 4895(8) 62(3) 
C(30) -3547(10) 3184(7) 3908(7) 80(3) 
________________________________________________________________________________ 
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